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Abstract 
The aim of this project was to develop injectable materials to repair damaged 
bone and, to simultaneously release antibacterial drugs and genes in a 
controllable manner.  Fluid poly (propylene glycol -co- lactide) dimethacrylate 
(PGLA-DMA) was first synthesised and then filled with varying levels of β-
tricalcium phosphate (β-TCP) and monocalcium phosphate monohydrate 
(MCPM) to fabricate composite materials.  
 
For all formulations (including polymer and composites), full methacrylate 
conversion was found to occur within 200 s of exposure to blue light.  The 
initial dry polymer modulus was enhanced three-fold by increasing total filler 
content to 70%. After composite immersion in water, β-TCP and MCPM was 
found to react and re-precipitate within the set materials as dicalcium 
phosphate (DCP, i.e. brushite and monetite).  At higher MCPM levels there 
was an increase in DCP formation, composite degradation rate, release of 
both calcium and phosphate ions and buffering of acidic polymer degradation 
products. Additionally, bone-like MG-63 cells were found to attach, spread 
and proliferate on both the polymer and the composite surfaces and, 
composites implanted into chick embryo femurs demonstrated close 
apposition to the host tissue. 
 
To examine the potential value for drug delivery, both the polymer and the 
composites were prepared containing 10% of the antibacterial chlorhexidine 
(CHX).  The drug was found to be released from material via diffusion, which 
increased along with antibacterial activity when the filler content was raised.  
  5 
PGLA-DMA polymer was additionally prepared containing complexes of the 
commercial cationic lipid MetafecteneTM Pro and green fluorescent protein 
plasmid DNA.  Initial studies demonstrated that the components released from 
the materials were capable of gene transfection into human bone-forming 
mesenchymal stem cells in vitro. 
 
These studies thus demonstrate that the injectable, rapidly settable PGLA-
DMA materials produced here might have clinical potential as both bone 
adhesives and drug delivery devices. 
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without CHX respectively; ■ and □ F% = 70%, T/M =4, Md = 
30 µm with and without CHX respectively……………………....  
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Fig. 4.3. Initial mass (A) and volume (B) change with time of polymer 
and composites with CHX after immersion in water. ○ 
polymer; □ and ▫ F% = 50%, T/M = 4, Md = 90 and 30 µm 
respectively; Δ and △ F% = 50%, T/M =1, Md = 90 and 30 
µm; x F% = 60%, T/M = 2, Md = 60 µm; ■ and ▪ F% = 70%, 
T/M =4, Md = 90 and 30 µm;▲and ▲ F% = 70%, T/M =1, Md = 
90 and 30 
µm.…………………………………………………………. 
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Fig. 4.4. Mass (A) and volume (B) change with time of polymer and 
composites with CHX after immersion in water. ○ polymer; □ 
and ▫ F% = 50%, T/M =4, Md = 90 and 30 µm respectively; Δ 
and △ F% = 50%, T/M =1, Md = 90 and 30 µm; x F% = 60%, 
T/M = 2, Md = 60 µm; ■ and ▪ F% = 70%, T/M =4, Md = 90 
and 30 µm;▲and ▲ F% = 70%, T/M =1, Md = 90 and 30 µm. 
Note the fast initial increase (arrows) in mass and volume 
after one day of water immersion and slow slight changes 
afterwards.………………………………………………...……….. 
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Fig. 4.5. A and B: Raman spectra of an example composite with F% = 
70 %, T/M = 1 and Md = 30 μm and an example composite 
with F% = 70 %, T/M = 4 and Md = 30 μm before (0 h) and 
after 24-h and 10-week immersion in water. ◊ polymer, ○ β-
TCP, □ MCPM, Δ CHX, ● dicalcium phosphate (mixture of 
brushite and monetite). C: Raman spectra of standards 
including the set polymer, β-TCP, MCPM, brushite, monetite 
and CHX. Note the absence of MCPM and presence of 
dicalcium phosphate after composite immersion in water for 
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24 h…………………………………………………………………. 165 
Fig. 4.6. A and B: XRD spectra of an example composite with F% = 
70%, T/M = 1 and Md = 30 μm and an example composite 
with F% = 70%, T/M = 4 and Md = 30 μm before (0 h) and 
after 24-h and 10-week immersion in water. ○ β-TCP, □ 
MCPM, ■ brushite, ● monetite. CHX could not be detected in 
all specimen XRD spectra. C: XRD spectra of standards 
including β-TCP, MCPM, brushite, monetite and CHX. Note 
the absence of MCPM and presence of brushite and monetite 
after composite immersion in water for 24 h……...……………. 
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Fig. 4.7. CHX release versus time from polymer (o), composites filled 
with brushite at  50 (Δ), 60 (◊) and 70 wt.% (□) and 
composites filled with reactive β-TCP and MCPM at 50 (▲), 
60 (♦) and 70 wt.% (■). This figure demonstrates the 
enhancement of CHX release with raised filler content and 
with reactive filler of β-TCP and MCPM…………………………  
 
 
 
 
 
172 
Fig. 4.8. CHX release versus square root (SQRT) of time from polymer 
(o), composites filled with brushite at 50 (Δ), 60 (◊) and 70 
wt.% (□) and composites filled with reactive β-TCP and 
MCPM at 50 (▲), 60 (♦) and 70 wt.% (■). Note that the CHX 
release percentage is more linear with SQRT of time than 
that with time (compare Fig. 4.7)………………………….…….. 
 
 
 
 
 
174 
Fig. 4.9. Inhibition zones against bacteria strain SA 8325-4. A: Polymer 
specimen with (+) and without (-) CHX; B: An example 
composite specimen (F% =50%, T/M =1, Md = 30 μm) with (+) 
and without (-) CHX; C: An example composite specimen (F% 
=70%, T/M =1, Md = 30 μm) with (+) and without (-) CHX. 
Note the increase in inhibition zone size with addition of CHX 
and with increase in specimen F%........................................... 
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CHAPTER 5 
Fig. 5.1. Effect of MetafecteneTM Pro : DNA ratios on relative cell 
number and transfection efficiency of hMSC.………………….. 
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Fig. 5.2. Representative fluorescence images of hMSC after 
incubation with 1 µg DNA alone (A) and 1 µg DNA and 2 µl 
MetafecteneTM Pro (LD) (B). In these images, the green 
fluorescent hMSC are successfully transfected whereas the 
hMSC not transfected remain non-fluorescent (background)…  
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Fig. 5.3. A: Representative dot plots of side scatter (SSC) versus 
forward scatter (FSC) of the control hMSC after incubation 
with 1 µg DNA alone (i) and the test hMSC after incubation 
with 1 µg DNA and 2 µl MetafecteneTM Pro (LD) (ii). Each dot 
represents a single cell. 1000 cells are displayed in each 
graph. A region has been drawn around the cells and the 
subsequent data analysis is based on the gated cell 
population……………………………………………………..…....  
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 B: Distribution histogram of the corresponding fluorescence 
data of the gated population of the control hMSc after 
incubation with 1 µg DNA alone (i) and the hMSC after 
incubation with 1 µg DNA and 2 µl MetafecteneTM Pro (LD) 
(ii). The markers M1 and M2 represent the cells with low (< or 
= 30, background fluorescence) and high (>30) fluorescence 
intensity, respectively.……………..………………………………  
 
 
 
 
 
 
200 
Fig. 5.4. Representative SEM images of hMSC incubated for 3 days 
on a ThermanoxTM plastic coverslip (A), a PGLA-DMA film 
with no LD (B), a PLDPBS (C) and a PLDW (D). Note the 
granular surface of PLDPBS ….…..……………………….………  
 
 
 
203 
Fig. 5.5. Representative fluorescence images of hMSC incubated with 
1-day (A) and subsequent 5-day (B) components released 
from the control PGLA-DMA films with no LD (i), PLDPBS (ii) 
and PLDW (iii). Cell nuclei are stained blue and cells 
successfully transfected are green fluorescent......................... 
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Abbreviations 
In alphabetical order 
BMP bone morphogenetic protein 
CDHA calcium-deficient hydroxyapatite 
CHX chlorhexidine 
CPC calcium phosphate cement 
GAM gene activated matrix 
GFP green fluorescent protein 
HA hydroxyapatite 
hMSC human mesenchymal stem cell 
LA lactide 
MA methacrylate 
MCPM monocalcium phosphate monohydrate 
MSC mesenchymal stem cell 
PAH polyanhydride 
PEG poly(ethylene glycol) 
PGLA-DMA poly(propylene glycol -co- lactide) dimethacrylate 
PMMA polymethylmethacrylate 
POE polyorthoester 
PPF 
PPG 
poly(propylene fumarate) 
poly(propylene glycol) 
PPP polyphosphazene 
TCP tricalcium phosphate 
TTCP tetracalcium phosphate 
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The background review first gives a brief introduction in bone structure and 
fracture healing. In addition, a general review and description of bone-repair 
materials and drug delivery is presented. Lastly, the aims and objectives of 
this project are discussed. 
 
1.1.  Bone 
Bone performs several key functions within the body, including provision of 
structural support, protection for many organs and metabolism of minerals 
such as calcium. In addition, it protects the bone marrow which is the primary 
site for the synthesis of blood cells. 
  
1.1.1.  Bone structure and composition 
Bone is covered by a connective tissue membrane called the periosteum. 
Bone itself consists of a smooth, dense, and continuous external layer called 
compact or cortical bone, composing cylindrical units called osteons 
(Haversian systems) (Fig. 1.1) (Silver 2006;Olszta et al. 2007). Each osteon 
is composed of concentric lamellae (layers) of hard, calcified matrix. 
Osteocytes (bone cells) are lodged in lacunae (spaces) between the 
lamellae. By cellular extensions, these bone cells are connected to each 
other and to the central canal (containing blood vessels and nerves). 
Compact bone facilitates bone's main functions: to support the body, to 
protect organs, and to store and release chemical elements such as calcium 
and phosphorous (Silver 2006;Olszta et al.2007). The interior layer of bone, a 
network of interlocking plates and spicules, is called spongy or trabecular 
bone. Like osteons, trabeculae also have osteocytes in lacunae that lie 
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between calcified lamellae. The enclosing cavities or the hollow centre of a 
bone shaft are filled with blood vessels and marrow. Spongy bone protects 
the marrow (Silver 2006; Olszta et al. 2007). 
Lacunae
Osteocyte
Canaliculi
Osteon
Spongy bone
Compact bone
Periosteum
Lamellae
Central 
canal
Nerve
Blood vessel
(Spaces within contain bone marrow)
 
Fig. 1.1. Microscopic organisation of compact and spongy bone. 
 
Bone is a natural composite material. Around 30% of bone is composed of 
organic compounds including collagen type I fibres (approximately 95%), 
proteoglycans and numerous non-collagenous proteins (5%). 70% of bone is 
made up of the inorganic mineral hydroxyapatite (HA). The organic matrix, 
when calcified (strengthened by deposits of HA crystals), embeds osteocytes 
(osteoblasts and osteoclasts) which participate in the maintenance and 
organisation of bone (Olszta et al. 2007;Taton 2001). 
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1.1.2.  Bone healing  
Bone can be fractured due to trauma or damaged by bone diseases such as 
osteoporosis. Osteoporosis can lead to weakening of the bone and increased 
fracture susceptibility. When bone is fractured, fracture healing occurs to 
restore the tissue to its original physical and mechanical properties. Fracture 
healing includes three distinct but overlapping stages: 1) early inflammatory 
stage, 2) repair stage, and 3) late remodeling stage (Fig. 1.2) (Baroli 
2009;Doll et al. 2008;Schindeler et al. 2008). 
 
In the inflammatory stage, a haematoma develops within the fracture site 
during the first few hours and days (Fig. 1.2.A). Inflammatory cells such as 
macrophages, monocytes and lymphocytes and fibroblasts infiltrate the bone, 
resulting in the formation of granulation tissue, ingrowth of vascular tissue and 
migration of mesenchymal stem cells (MSC). The MSC, recruited from the 
bone marrow and the periosteum, will then proliferate and differentiate into 
osteoblasts (Arifin et al. 2006;Doll and Hollinger 2008;Schindeler and Little 
2008). 
 
During the repair stage, fibroblasts lay down a stroma that helps support 
vascular ingrowth. As vascular ingrowth progresses, a collagen matrix is laid 
down when osteoblasts secrete osteoid which is subsequently mineralised by 
calcium phosphate deposited from blood, resulting in the formation of a soft 
callus around the repair site (Fig. 1.2.B.i). The soft callus is usually very weak 
in the first 2 to 3 weeks of the healing process. It then ossifies between 4 and 
16 weeks (formation of hard callus), building a bridge of woven bone between 
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the fracture fragments (Fig. 1.2.B.ii) (Baroli 2009;Doll and Hollinger 
2008;Schindeler and Little 2008).  
 
Remodeling of the bone occurs slowly. The bone can eventually be restored 
to its original shape, structure, and mechanical strength. This is typically 
achieved in six months and beyond (Fig. 1.2.C) (Baroli 2009;Doll and 
Hollinger 2008;Schindeler and Little 2008).  
A Inflammation 
HS
Week 1
Week 2-3
Week 17 & beyond
Week 4-16
C Remodelling
i ii
B Repair 
M
M
MM B
B
B
B
G
V
VV
V
 
Fig. 1.2. Three stages of bone fracture healing including inflammation 
(A), repair (B) and remodelling (C). i and ii represent, respectively, soft 
and hard callus formation during the repair stage. B: bone; M: bone 
marrow; G: granuation tissue; V: blood vessels; S: soft callus; H: hard 
callus.  
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However, natural healing can be problematic in non - union bone defects in 
the long bones or in the case of massive bone loss.  In this context, medical 
intervention aiming to facilitate bone repair is required (Verettas et al. 2002). 
 
1.2. Bone - repair materials 
Currently, the number of people who suffer from bone fracture problems is 
huge and the cost for the treatment of bone fracture is considerable. For 
example, as estimated by the World Health Organisation, osteoporotic 
fracture affects 33% (500,000) of women and 12.5% (140,000) of men over 
the age of 50 in the European Union (Baroli 2009). Moreover, it is expected 
that a cost for the treatment of osteoporosis-related hip fractures will reach € 
31.8 billion by 2025 (Baroli 2009). 
 
Thus, materials able to aid bone repair could be valuable to improve the life of 
patients who suffer from bone fracture and to reduce healthcare expenses 
(Baroli 2009).  
 
1.2.1． Natural bone-repair materials 
In order to induce bone to regenerate itself, growth factors, e.g., bone 
morphogenetic proteins (BMP) have been applied into the fractured or 
diseased site (Vaibhav et al. 2007). These proteins have been shown to 
modulate MSC differentiation and to stimulate bone formation. Genes which 
can express BMP have also been delivered to transfect local cells, stimulate 
BMP expression level and enhance bone regeneration (Kishimoto and 
Watanabe 2009). In addition, gene-modified stem cells have been injected 
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into fractured sites to augment bone growth. This approach exploits the ability 
of adult stem cells to express a transgene that can promote bone formation 
(Hou et al. 2009). None of these therapeutic options, however, provide an 
ideal solution to the problem of massive bone defect repair, especially for load 
bearing sites that require immediate mechanical support.  
 
Massive bone defects can be treated via graft transplantation (autologous or 
allogeneic) (Betz 2002). Autografting is regarded as the ‘gold standard’ as it is 
based on the patient’s own tissue. However, the popularity of this approach 
has been restricted due to the inadequate amount of bone that can be safely 
harvested.  Furthermore, to expand and grow the patients’ tissue takes time 
(approximately three weeks) (Baroli 2009;Barriga et al. 2004;McCann et al. 
2004). Allografting uses material stored within regulated bone banks and may 
circumvent these difficulties. With allograft materials, however, disease 
transfer is of concern (Baroli 2009;Barriga et al. 2004).  
 
Other therapies include the use of natural polymers. Natural polymers can be 
protein based (e.g. collagen, albumin or gelatin) or polysaccharide based 
(alginate, cellulose, or hyaluronate). They can also be synthesised naturally, 
e.g., polyhydroxyalkanoate is generated by micro-organisms under nutrient 
stress (Sabir et al. 2009). These natural polymers are generally biodegradable 
and have excellent biocompatibility (Nuss and von Rechenberg 2008). 
However, they may be immunogenic or suffer from restricted availability and 
their chemical composition is usually difficult to control (Allcock 
2006;Dusseault et al. 2006).  
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1.2.2． Synthetic bone-repair materials 
Synthetic products that can provide structural support and enhance bone 
repair are under increasing demand due to their greater availability, reduced 
concerns of immunogenicity and raw material source reliability (Papisov 
1999). Currently used synthetic bone-repair materials can be divided into 
three major classes: metals, polymers and ceramics. They can be used either 
alone or in combinations. Metals, e.g., titanium, usually have the major 
advantage of high fracture toughness. They may suffer, however, from several 
disadvantages, such as cytotoxicity of any released ions as well as wear 
debris, or high Young's modulus which may lead to stress shielding (Kokubo 
2009). Polymers such as polymethylmethacrylate (PMMA) generally have 
controllable chemical, physical and biological characteristics that depend on 
the repeating units of the polymer chains. Ceramics (e.g., bioactive glasses, 
calcium phosphates, etc) are a large family of inorganic biomaterials with a 
wide range of characteristics (e.g., density, porosity, solubility, etc) that 
strongly depend on the processing method used (Nuss and von Rechenberg 
2008).  
 
1.2.2.1. Required properties  
Current surgical trends are tending towards more minimally invasive surgery.  
These favour materials with injectability and controllable setting. Additional 
requirements to be satisfied include mechanical properties, degradability and 
biocompatibility.
Chapter 1                                                                              Background review 
 30 
A． Injectability 
Injectability (e.g., through needles) enables a material to fill defects of varying 
morphology. Injection of the materials can be achieved either directly 
underneath the skin or via small surgical incisions, thereby avoiding complex 
surgery. After injection, the materials should ideally set forming a solid of 
exactly the required dimensions in situ. This process should also enable 
material adhesion to the surrounding tissue by micromechanical interlocking 
(Temenoff and Mikos 2000).   
 
B． Settability 
The injected material should ideally set from liquid to solid in a few minutes to 
minimise the length of the procedure and enable the material to provide early 
mechanical support to the surrounding tissue, whilst still allowing surgeons 
ample time for placement before hardening (Xu et al. 2007).  
 
C． Mechanical properties 
The materials should provide sufficient mechanical support without causing 
stress shielding (Temenoff and Mikos 2000). To achieve this, their mechanical 
properties should be as close as possible to those of the tissue to be 
regenerated. For compact bone, an implant’s Young’s modulus should be 
around 3 - 30 GPa and strength 20 - 200 MPa (Keller et al. 1990). For 
trabecular bone, the modulus should be around 20 - 500 MPa (Agrawal and 
Athanasiou 1997;Bergsma et al. 1995) and strength 2 - 15 MPa (McCalden et 
al. 1997). 
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Various mechanical properties should be considered for materials used in 
orthopaedics, including under compression, tension and torsion. Tensile 
properties are particularly important upon replacement of compact bone while  
compressive properties are most relevant for trabecular bone (Yaszemski et al. 
1996). 
 
D Degradability 
Degradability enables the new bone to progressively integrate and ultimately 
replace the grafted material, eliminating the need for device removal surgery. 
Gradual degradation of the materials can avoid long-term toxicity problems as 
small amounts of degradation products can be readily disposed of by tissue 
elimination routes. The degradation rate of the material should be coupled to 
that of tissue formation so that slow transfer of mechanical load to the healing 
bone or damage site is facilitated (Temenoff and Mikos 2000). It has been 
suggested that an implant should degrade within 12 weeks as the natural 
bone healing signal appears to disappear about 7 to 12 weeks after injury 
(Ekholm et al. 1995). With longer degradation, a fibrous tissue scar can be the 
result, which may inhibit integration between the implant and the bone.  
 
E  Biocompatibility 
Biocompatibility means that the implanted material itself and its degradation 
products do not cause severe cell death/tissue necrosis, or disrupt the normal  
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biological function of the target cells (Gerhart et al. 1998;Temenoff and Mikos 
2000).  
 
There are a wide variety of procedures used to assess biocompatibility. In 
vitro cell-attachment and cell-proliferation tests are widely used to determine 
whether the materials are deleterious to cells (Teixeira et al. 2008), since 
these aspects have been shown to be closely associated with cell survival, 
cell differentiation, matrix mineralisation and, therefore, new bone formation 
(Garcia and Reyes 2005). In vivo assessment includes examination of the 
tissue response to the implanted materials. Positive short-term indications can 
include the presence of osteoblasts as a marker of bone formation at the 
interface between the material and the bone, along with the absence of 
inflammation or other adverse tissue reaction (Wang et al. 2007). Positive 
long-term results can include osteointegration, i.e., the intimate and direct 
contact of the bone and the implanted material and absence of soft tissue. 
Osteointegration is indicative of a rigid and biologically compatible fixation of 
the implant in the bone during functional loading (Wang et al. 2007). 
 
1.2.2.2. Different synthetic bone-repair materials 
A． Polymers  
I． Polymethylmethacrylate 
PMMA (molecular structure shown in Fig. 1.3) is frequently used in 
orthopaedics (Lewis 2008). It is commonly used as an aid in securing implants 
for total hip or knee replacement. Additionally, PMMA beads have been 
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impregnated with antibiotics before being packed into wound cavities for the 
treatment of chronic bone infections (Nandi et al. 2009).  
 
Fig. 1.3. Molecular structure of polymethylmethacrylate (PMMA). n is the 
number of the repeating monomer units.  
 
PMMA is typically synthesised from methyl methacrylate using benzoyl 
peroxide as initiator. This semi-liquid material can be injected in situ, then 
continues to harden over several minutes, adhering to surrounding tissue via 
micromechanical interlocks. Tissue damage, however, may occur due to the 
high temperature achieved during the curing of PMMA (Lewis 2008). PMMA 
modulus can be varied via adjusting the material porosity and initiator 
concentration. Being non-degradable, PMMA may act as a barrier to bone 
ingrowth and potentially could limit blood flow. Its monomer is considered to 
be cytotoxic, release of which may cause tissue irritation or inflammation 
(Lewis 2008).  
 
II． Polylactide, polyglycolide and poly (lactide-co-glycolide)  
Polylactide, polyglycolide and their copolymers, poly (lactide-co-glycolide) are 
also frequently used in orthopaedics. Polylactide and poly (lactide-co-
glycolide) are generally used as fixation plates and screws while polyglycolide 
is mainly used as biodegradable sutures (Sabir et al. 2009). Their molecular 
structures are shown in Fig. 1.4. They can be synthesised by ring-opening 
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polymerisation of the respective cyclic monomers using antimony or zinc as 
catalysts (Sabir et al. 2009). They are usually viscous liquids or solid materials 
and are not readily injectable unless used as micro- or nano-particles (mainly 
for drug delivery applications) (Herrero-Vanrell and Molina-Martinez 2007). 
Mechanical properties and degradation rates of these polymers can be 
manipulated to some extent by controlling their molecular weight and 
crystallinity. With poly (lactide-co-glycolide), these properties can additionally 
be adjusted by the unit ratio of lactide (LA) to glycolide (Sabir et al. 2009). 
They can be degraded via hydrolytic or enzymatic degradation. Their 
degradation products, lactic acid or glycolic acid, are natural metabolism 
products and can be incorporated in the tri-carboxylic acid cycle and excreted 
by the lungs as carbon dioxide and water (Sabir et al. 2009). Potential 
problems with these polymers may include acid production during degradation. 
The produced acid may reduce the local pH and further induce polymer 
degradation (auto-catalysis). This may eventually cause catastrophic 
degradation leading to sudden loss of structural support and localised acid 
accumulation resulting in tissue damage (Sabir et al. 2009).  
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(c)
(a) (b)
H H
 
Fig. 1.4. Molecular structure of polylactide (a), polyglycolide (b) and poly 
(lactide-co-glycolide) (c). n, x and y are the number of the repeating 
monomer units.  
 
Synthetic polymers with both injectability and degradability include various 
poly (ether-co-ester)s, polyanhydrides (PAH) and poly(propylene fumarate) 
(PPF) (Nair and Laurencin 2007),etc.  
 
IV. Poly (ether- co- ester)s 
Poly (ether-co-ester)s are copolymers of polyether and polyester (molecular 
structure shown in Fig. 1.5). Polyesters are generally not injectable but using 
polyethers as initiator for ring-opening polymerisation of cyclic esters, fluid, 
relatively short chain poly (ether-co-ester)s can be produced (Ho and Young 
2006;Kim et al. 2009). Insertion of ester linkages allows the system to be 
degradable, whereas pure long chain polyethers are not. End-capping of the 
polymer units with acrylate or methacrylate (MA) groups enables crosslinking 
(Ho and Young 2006). 
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n
 
Fig. 1.5. Molecular structure of poly(ether-co-ester)s. R, R’ and R’’ 
represent different functional groups and n is the number of the 
repeating monomer units. 
 
The polyether, poly (ethylene glycol) (PEG) is frequently used to increase 
polyester biocompatibility and to modulate its degradation (Goraltchouk et al. 
2005). Commonly  used polyesters include PLA,  polyglycolide, poly (lactide-
co-glycolide) and poly (ε-caprolactone) (PCL) (Sabir et al. 2009). Photo-
polymerisable ester-PEG-ester hydrogels (e.g., dimethacrylated LA-PEG-LA) 
have been successfully formulated in the last decade (Quick and Anseth 
2004). Setting times of these polymers are variable depending on the 
repeating units of the polymer. Degradation times can vary from days to 
months depending on the crosslinking density, polymer molecular weight and 
the employed ester types (Hubbell 1998). These PEG based materials can 
offer excellent biocompatibility and controllable degradation rates. 
Unfortunately, they often suffer from low mechanical properties due to their 
high water sorption (arising because of the hydrophilicity of PEG) and may 
undergo catastrophic degradation.   
 
Formulations containing less hydrophilic polyethers have therefore been 
developed. For example, fluid poly (propylene glycol-co-lactide) 
dimethacrylates (PGLA-DMA) have been synthesised. Poly (propylene glycol) 
(PPG) (a commonly used excipient in pharmaceutical formulations) has a 
similar molecular structure to PEG but more methyl groups which endow a 
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higher degree of hydrophobicity. These dimethacrylated materials are not only 
injectable and set rapidly, but are also likely to swell to a lesser extent in water 
and degrade and release acid more slowly because of their higher 
hydrophobicity compared with their PEG counterparts. These materials, 
however, are of relatively low modulus and their biological reactivity with 
bone-related cells and tissue is not yet known (Ho and Young 2006).  
 
V. Polyanhydride  
PAH (molecular structure shown in Fig. 1.6) can be synthesised by the 
dehydration of a dicarboxylic acid or a variety of aromatic and aliphatic 
dicarboxylic acids via melt condensation (Sabir et al. 2009). It contains one of 
the most reactive functional groups (-COO-) for hydrolytic degradation, 
ensuring surface-eroding and fast-degrading characteristics. Because these 
polymers are surface-eroding, they are expected to maintain bulk mechanical 
properties while undergoing degradation (Sabir et al. 2009). The fast-
degradation property also allows the material to be used for drug delivery. 
Depending on the monomers (R group in Fig. 1.6) used, the mechanical 
properties as well as degradation time can be varied. For example, PAH can 
be formed from monomers of sebacic acid with addition of monomers of 1,3-
bis(p-carboxyphenoxy) propane or 1,6-bis (p-carboxyphenoxy) hexane. The 
acrylated or methacrylated PAH can be set rapidly, within several minutes. 
These polymers can have mechanical properties similar to those of trabecular 
bone. The degradation rates of these polymers can be controlled, spanning 
from days to months, by changing the ratio of sebacic acid and other 
monomers in the structure (Sabir et al. 2009). Degraded aliphatic monomers 
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such as sebacic acid are likely to participate in the β-oxidation pathway for 
energy production. Degraded aromatic monomers can be eliminated without 
further metabolic transformation (Sabir et al. 2009). Minimal inflammatory 
response to sebacic acid/ 1,3-bis(p-carboxyphenoxy) propane / 1,6-bis (p-
carboxyphenoxy) hexane was also observed (Sabir et al. 2009). One 
drawback of PAH is that most of them have to be stored in a frozen state 
under anhydrous conditions because of the hydrolytic instability of the 
anhydride bond (Park et al. 2005). 
C R C
O O
O
n
 
 
Fig. 1.6. Molecular structure of polyanhydride (PAH). R represents 
different functional groups and n is the number of the repeating 
monomer units.       
 
VI. Poly (propylene fumarate)  
PPF (molecular structure shown in Fig. 1.7) is a synthetic, unsaturated linear 
polyester formed by co-polymerisation of fumaric acid and PPG. PPF can be 
thermal- or photo- crosslinked through its fumarate double bond in 30 minutes. 
Obtaining PPF of high molecular weight is often difficult owing to the side 
reactions due to the presence of the backbone double bond. This may make 
its mechanical properties less than ideal for cortical bone although properties 
within the range of those of trabecular bone have been achieved. The 
degradation of PPF can occur by hydrolytic chain scission of its ester groups 
and is usually of the order of several months. Its degradation products include 
fumaric acid and PPG. These are of relatively low toxicity and can be excreted 
directly or after entry and exit from various metabolic pathways. Degradation 
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rate depends on many factors such as molecular weight, crosslinking density, 
and also other copolymer or constituent ratio in the PPF networks. In vivo 
tests of these polymers have shown no apparent deleterious long-term 
response with only an initial mild inflammatory side effects (Sabir et al. 2009). 
.
O
O
OH
OH
O
O n
 
 
Fig. 1.7. Molecular structure of PPF. n is the number of the repeating 
monomer units.  
 
VII. Other polymers  
Other injectable, degradable polymers under development include 
polyorthoester (POE) and polyphosphazene (PPP). Their molecular structures 
are shown in Fig. 1.8. POE is highly hydrophobic and very stable under 
physiological conditions. They are mainly considered to be potential 
candidates for drug delivery applications. The mechanical properties of POE 
can vary over a wide range by the selection of starting materials with different 
compositions and molecular weights. Their application is limited due to the 
lack of variability in the degradation kinetics (Sabir et al. 2009). POE can 
induce moderate inflammation in bone.  
 
PPP contains alternating nitrogen and phosphorous with no carbon atoms in 
their backbone structure. It is feasible to control the mechanical, degradation 
and biological properties of PPP by precisely controlling the side group’s 
substituents (e.g., R and R’ can be amino acid esters, lactic acid or imidazolyl 
units) (Sabir et al. 2009). 
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Fig. 1.8. Molecular structure of polyorthoester (POE) (a) and 
polyphosphazene (PPP) (b). R and R’ represent different functional 
groups and n is the number of the repeating monomer units.  
 
B． Calcium phosphate cements (CPC) 
Calcium phosphate cements (CPC) are considered as excellent materials for 
maxillofacial and craniofacial applications. In addition, they can be used in 
treating vertebral body compression fractures, femoral neck fractures, distal 
radius fractures, and reinforcement of pedicle screw fixation (Dorozhkin 2008). 
Recently, it has been suggested they might compete with the PMMA bone 
cements and the apatite coatings for fixation of metal endoprostheses in 
orthopaedics and oral implantology (Muller and Stangl 2006) . 
 
CPC can adapt to local defect sites and then harden without elevation of 
temperature, although they may lack sufficient cohesion and tend to 
disintegrate upon early contact with blood or other fluids before they start to 
set. In general, CPC are formed by mixing calcium phosphate powders (one 
or more types), with a liquid (usually water or an aqueous solution). The 
resulting paste will then set and harden after implantation in the body. The 
cement setting and hardening is a result of dissolution and precipitation 
processes. Setting time, porosity and mechanical properties of the CPC can 
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be adjusted by modifying different factors, such as the powder / liquid ratio, 
the chemical composition of reactants (powder and / or liquid) and the particle 
size of calcium phosphates (Ambard and Mueninghoff 2006;Larsson and 
Bauer 2002).  
 
CPC are generally brittle and have low impact resistance and relatively low 
tensile strength. Porosity is considered to be the major reason responsible for 
this weakness as micro- and macro- cracks easily run throughout the mass 
upon loading. CPC are often considered to be degradable, biocompatible and 
osteoconductive. The overall dissolution of CPC is solution-mediated (the 
implant dissolves in physiologic solutions) and cell-mediated (phagocytosis). 
Complete cement resorption and replacement by bone may take months to 
years. Bone substitution depends on sex, age, and general metabolic health 
of the recipient and anatomic site, as well as porosity, crystallinity, chemical 
composition, particle size, and powder / liquid ratio of the cement. The 
degradation products of calcium and phosphate ions are resorbed as part of 
the normal ion pool within the body. The release of phosphate and calcium 
ions is also considered to be biologically beneficial as it stimulates osseous 
tissue development. The dissolved calcium and phosphate ions can re-
precipitate on the surface of the cement as, for example HA, with a high and 
interconnected micro-porosity, chemically and structurally similar to biological 
apatites, starting a bone-cement interaction and bonding process. CPC are 
therefore considered to be more compatible with mineralised tissue and more 
osteoconductive than polymeric materials (Ambard and Mueninghoff 
2006;Larsson and Bauer 2002).  
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Numerous CPC formulations have been proposed in the last 25 years, but 
presently there are two major possible end products for CPC reactions: an 
apatite such as HA (Ca10(PO4)6(OH)2) or calcium-deficient HA (CDHA; 
Ca9(HPO4)(PO4)5OH) and dicalcium phosphate dihydrate (brushite, 
CaHPO4·2H2O) or the anhydrous form, monetite (CaHPO4).  
 
I．Apatite CPC 
HA cements can be produced using the reaction between the basic 
tetracalcium phosphate (TTCP, Ca4 (PO4)2O) and the neutral monetite. TTCP 
and monetite react in water according to the formula below (Bohner 2007): 
2Ca4(PO4)2O + 2CaHPO4 → Ca10(PO4)6(OH)2                                                 1.1
 
 
Most commercial cements are formed using a slightly basic α-tricalcium 
phosphate (α-TCP, α-Ca3(PO4)2), which can be converted via dissolution-
precipitation to a slightly basic CDHA according to (Bohner 2007): 
3α-Ca3(PO4)2 + H2O → Ca9(HPO4)(PO4)5OH                                                1.2 
 
Conventionally, the mixing of apatite CPC powders with aqueous solution 
takes place during surgery and the setting time of the apatite CPC is generally 
too long (Bohner 2007). Recently, puttied premixed CPC pastes were 
therefore prepared (Apelt et al. 2004). For example, Xu et al. have developed 
a premixed CPC whose powder phase consisted of TTCP and monetite and 
liquid phase comprised of PEG with hydroxypropyl methylcellulose as gelling 
agent, and tartaric acid as the hardening accelerator. The CPC can be set in < 
10 min in physiological solution, possesses comparable strength with human 
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cancellous bone and has good osteoblast compatibility (Xu et al. 2007). 
Advantages of these premixed CPC include: (i) avoid powder – liquid mixing 
during surgery thereby shortening the surgical time; (ii) will harden rapidly in 
an aqueous environment or physiological solution and no harden in the 
package or in a syringe. 
 
However, apatite cements are of low solubility at physiological pH and 
therefore would be very slow to resorb in the body. Consequently, the apatite 
cements woud be unlikely to provide sufficient calcium and phosphorous 
required for bone regeneration (Ambard and Mueninghoff 2006;Bohner 2000). 
 
II. Brushite CPC 
Brushite CPC are normally resorbed faster than apatite CPC as brushite is 
more soluble than apatite at physiological pH (Bohner 2001). Brushite CPC 
have been developed using mixtures of monocalcium phosphate 
monohydrate (MCPM, Ca(H2PO4)2.H2O) and -TCP. These two phosphates 
can rapidly react to form lower density brushite according to the equation 
below (Bohner 2007):  
β-Ca3(PO4)2 + Ca(H2PO4)2·H2O + 7H2O → 4CaHPO4·2H2O                         1.3 
 
During this process, the MCPM particles dissolve in water and re-precipitate, 
thereby solidifying the cement and forming brushite crystallites and/or the 
anhydrous dicalcium phosphate, monetite. Previously brushite CPC have also 
been produced using β-TCP or HA with phosphoric acid or using TTCP with 
polyphosphoric acid (Bohner 2007).  
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Setting of brushite CPC can sometimes be too rapid (e.g., within ten seconds) 
(Bohner 2007). In order to increase the setting period and hence provide 
sufficient time to the surgeon for safe CPC placement, use of less soluble 
reagents (e.g. HA instead of β-TCP) has been suggested. This can increase 
the setting period but only to a limited extent (Bohner 2007). Recently, puttied 
premixed CPC pastes were prepared by combining cement liquids comprised 
of glycerol or PEG with CPC powders that consisted of β-TCP and MCPM. 
Setting time of these premixed CPC was raised to between 10 and 30 
minutes. The mechanical properties of these cements, however, were less 
than ideal (Han et al. 2009). 
 
C． Composite materials 
Table 1 summarises different properties of the above mentioned polymers 
and CPC and their main disadvantages. To overcome various problems, 
polymers and CPC may be combined. As mentioned above (section 1.1.1), 
natural bone is made of an organic collagen matrix and HA crystals. Polymer-
ceramic composite materials therefore imitate well natural bone. PMMA, PLA, 
polyglycolide, poly (lactide-co-glycolide), poly (ether-co-ester), PAH and PPF 
can act as the organic phase whereas HA and brushite can act as the mineral 
part in the formulation of composites for bone replacement.  
 
Ceramic particles have been incorporated into injectable polymers as fillers to 
modify their mechanical and degradation properties as well as biocompatibility 
(Cai et al. 2009). The incorporated calcium phosphate fillers can also act in 
degradable polymer systems as internal buffers to neutralise the local pH and 
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inhibit any autocatalytic degradation (Peter et al. 1998). However, there are 
still some limitations in these polymer-calcium phosphate composites. Firstly, 
the filler may not have a strong interaction or bond with the polymer matrix 
and this interface can be a point of material weakness. Secondly, filler 
addition to unsaturated polymer may reduce the light-activated polymerisation 
rate in thicker samples, due to scattering effects (Berthomieu and 
Hienerwadel 2009).  
 
1.3． Delivery of therapeutic agents for bone repair  
Tissue engineering involves the use of materials as structural support for 
regenerating tissue. Incorporation of drugs into these materials can endow 
them with therapeutic properties (e.g., resistance to bacterial infections, 
induction of osteogenesis). Such materials can thus act as local delivery 
devices. Major advantages of using controlled delivery systems include the 
maintenance of a desired drug concentration at a specific site for long period 
of time without reaching a toxic level or dropping below the minimum effective 
level (Arkfeld and Rubenstein 2005). Additionally, such systems may eliminate 
the need for repeated administrations.  
 
Drugs used in bone tissue engineering include antibacterial drugs (to reduce 
infections), anti-inflammatory drugs (to treat inflammatory conditions), anti-
cancer agents (to treat tumors), hormones (to treat osteoporosis) and growth 
factors or their genes (to facilitate wound healing) (Malafaya et al. 2002).  
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Table 1.1. Summary of different properties of polymers and calcium phosphate cements (CPC). 
 Type of 
biomaterial 
Injectability Setting 
rate  
Young’s 
modulus  
Tensile/ 
compressive strength  
Degradation 
rate 
FDA 
approval 
Main disadvantages 
PMMA √ √ √ √ √ √ Non-degradable 
Polylactide - - √ √ √ √ 
Polyglycolide - - √ √ √ √ 
 Poly(lactide-
co-glycolide) 
- - √ √ √ √ 
Non injectable unless in the form of micro- 
or nano-particles;  
Catastrophic degradation 
Poly(ether-co-
ester) 
√ √ √ √ √ - Dependant upon particular formulation 
PAH √ √ √ √ √ √ Low storage stability 
P
o
ly
m
e
rs
 
PPF √ √ √ √ √ - Slow setting and low modulus 
HA √ √ √ √ √ √ Low resorption rate 
C
P
C
 
Brushite √ √ √ √ √ - Low mechanical strength 
PMMA = polymethylmethacrylate; PAH = polyanhydride; PPF = poly (propylene fumarate); CPC = calcium phosphate cements; HA = hydroxyapatite. ‘√’ and 
‘√’ mean that the corresponding material can or cannot meet a desirable criterion respectively; ‘-’ = not applicable.  
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1.3.1． Considerations in drug delivery 
Successful drug delivery requires formulation and sterilisation methods that do 
not damage the pharmacologic actions of the drug. For example, when using 
synthetic degradable polymers for drug delivery, drugs may undergo thermal 
damage due to elevated temperatures during polymer setting (i.e., 
crosslinking) or acid degradation due to acidic breakdown products of the 
crosslinked polymer (del Valle et al. 2009). Other potential problems also 
include initially delayed or burst release (Young and Ho 2008). In addition, 
drugs may interact chemically or physically with the polymer or its degradation 
products, possibly limiting their release (Young and Ho 2008), while 
incorporated drug may affect the degradation rate of the polymer matrix itself 
(Tang and Singh 2008). With CPC, the setting reaction of the CPC itself can 
be significantly modified by drug introduction into either the powder or liquid 
phase. As a result, the physico-chemical and mechanical properties can 
change (Takechi et al. 1998). In other cases, modification of CPC properties 
can result from chemical interactions between the drug and the cement, e.g., 
tetracycline can chelate calcium atoms (Ratier et al. 2001). Drug release rates 
can be too rapid due to the high porosity of CPC (Bohner et al. 1997), or it can 
be inhibited due to the decreasing porosity of the CPC upon formation of a 
dense HA layer on the CPC surface (Otsuka et al. 1997). Moreover, drugs of 
high molecular weight, e.g., proteins, may not be released due to the 
entrapment in nanopores on the CPC surface (Ruhe et al. 2003). 
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1.3.2． Antibacterial drug delivery 
Bacterial infections are a major problem affecting the service life of medical 
implants, and need to be prevented to allow wound healing processes to take 
place. Such implant-associated infections are the result of bacterial adhesion 
and subsequent bio-film formation at the implantation site, so that inhibiting 
adhesion is often regarded as a critical step in preventing infection (Mourino 
and Boccaccini 2009). Antibacterial drugs are therefore incorporated into the 
bone-repair materials to resist bacterial adhesion and infections. 
 
1.3.2.1． Antibacterial drugs to treat bone infections 
Gentamicin and tetraycline (Kim et al. 2004) are commonly employed 
antibiotics in treating trauma, and widely used for the treatment of 
osteomyelitis (bone infection) because of their broad-spectrum characteristics. 
Other antibiotics including vancomycin, polymyxin B, gatifloxacine, 
ciprofloxacin and ampicillin have also been used for this purpose. However, 
bacteria may develop antibiotic resistance (Mourino and Boccaccini 2009). 
Therefore, other antibacterial drugs such as chlorhexidine (CHX) have been 
incorporated into bone fillers or bone cements in order to inhibit bacterial 
growth (Leung et al. 2005;Young et al. 2008;Young and Ho 2008). CHX has 
been chosen as the antibacterial drug due to its broad spectrum of activity 
against both Gram-positive and Gram-negative bacteria and very low 
incidences of resistance development (Harris et al. 2006). 
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1.3.2.2． Antibacterial drug activated matrix 
Biomaterials containing antibacterial drugs are defined as antibacterial drug 
activated matrices. Local drug release profiles should exhibit a high initial 
release rate in order to respond to the elevated risk of infection from bacteria 
introduced during an initial shock. This should then be followed by sustained 
release at an effective level for inhibiting the re-occurrence of latent infection 
(Zilberman and Elsner 2008). 
 
Young et al. have investigated the use of injectable degradable PGLA-DMA 
for CHX delivery (Young and Ho 2008). Early CHX release was consistent 
with diffusion and the drug release rate increased with raised PPG and LA 
unit length. However, interactions between the positively charged CHX ions 
and the large negatively charged bulk acidic degradation products may have 
inhibited sustained drug release. Young et al. have also investigated CHX 
release from brushite CPC using MCPM and β-TCP as reactants (Young et al. 
2008). Most of the CHX was released in one day and the total amount of CHX 
was released within ten days. CHX release in this case is considered to be 
too rapid, possibly due to the high CPC porosity.  
 
1.3.3． Gene delivery 
Growth factors such as BMP have been incorporated into bone-repair 
materials with the aim of improving or increasing the osteoinductive capacity 
of the material (Ohura et al. 1999). An alternative approach for delivering 
growth factors is to deliver their corresponding genes. Since the gene rather 
than a degradable protein is being delivered, this technique may result in 
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more constant levels of protein production (Nussenbaum and Krebsbach 
2006), and, most importantly, an inherently stable DNA which is available and 
potentially active over a prolonged period of time (Bonadio 2000).  
 
1.3.3.1． Genes to enhance bone formation 
Major classes of gene products relevant to bone tissue engineering include 
growth factors (e.g., BMP), transcription factors (e.g., LIM mineralisation 
protein-1, which was shown to induce expression of BMP), cytokines (e.g., 
interleukin 1-receptor antagonist, which was observed to reduce bone 
resorption), and angiogenic factors (e.g., vascular endothelial cell growth 
factor, which was found to induce formation of blood vessels) (Salvay and 
Shea 2006). 
 
1.3.3.2． DNA delivery techniques 
Naked plasmid DNA does not readily enter or express inside cells possibly 
due to its negative charge and susceptibility to nuclease degradation (Liu and 
Huang 2002). A number of techniques to facilitate DNA transfer intracellularly 
and expression by target cells have therefore been developed. These 
techniques can be classified into three general types: 1) mechanical and 
electrical techniques; 2) vector - assisted delivery; and 3) gene activated 
matrix (GAM).  
 
A. Mechanical and electrical techniques  
Mechanical and electrical strategies of introducing naked DNA into cells 
include microinjection, particle bombardment, and electroporation. 
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Microinjection transfers DNA into one cell at a time. This procedure is efficient 
but highly time consuming. Particle bombardment involves transfer of DNA - 
gold micro-particles using equipment such as a gene gun. Its application is 
restricted in the dermis and muscle as direct exposure of target tissues is 
required. Electroporation uses high - voltage electrical current to facilitate 
DNA transfer but it often results in high cell mortality (Luo and Saltzman 
2000).   
 
B. Vector-assisted DNA delivery 
Vector-assisted DNA delivery systems can be classified into two types: 
biological viral DNA delivery systems and chemical non-viral delivery systems.  
 
I. Viral delivery vectors 
Viruses can readily transfer DNA molecules into cells. High transfection 
efficiency can be achieved using this approach in many types of tissues such 
as kidney, heart, etc. Considerable progress for the treatment of a wide range 
of diseases, such as AIDS and cancer has been made using gene therapy 
with viral systems (Luo and Saltzman 2000). However, there are several 
concerns over the use of these vectors. These include 1) the toxicity of the 
viruses, 2) the potential to generate an immune response and 3) the potential 
to inhibit expression of normal cellular genes or to activate oncogenes (Favre 
et al. 2001;Raper et al. 2003).  
 
II. Non-viral delivery vectors 
Commonly used non-viral vectors can be classified into two major types: 1) 
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calcium phosphate precipitation and 2) cationic polymers or lipids. The 
technique of calcium phosphate precipitation for in vitro transfection relies on 
the formation of ionic complexes of divalent metal cations, such as Ca2+, Mg2+, 
Mn2+ and Ba2+ with the phosphate backbones of helical DNA (Truong-Le et al. 
1999), followed by transport across the cell membrane via endocytosis 
(Truong-Le et al. 1999). This technique is usually simple and inexpensive and 
has minimal cellular toxicity. The low level of transgene expression, however, 
has prompted the development of other techniques, e.g., cationic polymers or 
lipids as DNA carriers (Luo and Saltzman 2000).  
 
Cationic polymers or lipids complex with anionic DNA molecules, interact with 
the negatively charged cell surface and deliver DNA into cells (Hwang and 
Davis 2001;Patil et al. 2005). Diversity of physicochemical properties and 
ease of manipulation are also important advantages of polymer or lipid gene 
carriers. Commercially available cationic polymer or lipid based gene 
transfection reagents include LipofectamineTM (Invitrogen), EffecteneTM 
(Qiagen), TranfectamTM (Promega) and MetafecteneTM (Biontex) (Kang et al. 
1999;Oliveira et al. 2009). However, cytotoxicity is the major concern 
regarding these delivery vectors, while, the transfection efficiencies of non-
viral cationic polymers or lipids vectors are not as high as those of viral 
vectors (Hwang and Davis 2001;Patil et al. 2005).  
 
C. Gene activated matrix 
DNA (with or without a chemical non-viral delivery vector) incorporated into 
bone-repair materials, give a gene activated matrix (GAM). Ideally, the GAM 
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should provide a controllable long-term supply of the gene to the target 
tissues, thereby increasing the chance of continuing uptake, intracellular 
function and successful gene therapy. DNA release in this case generally 
occurs through a combination of surface desorption, drug diffusion and 
material degradation (Jang et al. 2004;Quick et al. 2004;Quick and Anseth 
2004). Varying the matrix density, porosity, hydrophilicity and degradation rate 
can control the DNA release rate. 
 
GAM shows improved activity if the genes loaded inside are incorporated 
together with delivery vectors rather than as naked DNA alone (Endo et al. 
2006;Huang et al. 2005;Itaka et al. 2007;Quick et al. 2004;Quick and Anseth 
2004). This increased activity may be due to the vectors protecting the DNA, 
e.g., from polymer degradation and photo-polymerisation (Quick et al. 
2004;Quick and Anseth 2004). For example, Quick et al. produced a surface-
eroding, photo-crosslinkable PAH which was able to deliver DNA plasmids 
into Escherichia coli DH 5α. The DNA coated by alginate could continually 
transform the bacteria for four days whereas the naked DNA was only active 
for one day (Quick et al. 2004). However, the 4-day DNA transformation 
period was still too short for use in bone regeneration. Quick et al. have also 
developed photo-polymerised di-methacrylated LA-PEG-LA macromers as a 
bioerodible hydrogel platform for delivering plasmid DNA (Quick and Anseth 
2004). The DNA, protected by cationic peptide protamine sulfate, could be 
released for 6 - 100 days with high biological activity. The DNA release rate 
can be controlled by varying hydrogel crosslinking density and degradation 
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rates. However, the hydrogel could not provide sufficient mechanical support 
due to its hydrophilicity.  
 
Poly (lactide-co-glycolide) scaffolds have also been used to deliver genes 
encoding BMP-4 (condensed by the cationic polymer, polyethylenimine) in rat 
cranial defects (Huang et al. 2005). Bone formation was observed after 15 
weeks of implantation. Histomorphometric analysis revealed a significant 
increase in total bone formation and bone density within the scaffolds 
incorporating condensed DNA, relative to scaffolds incorporating 
uncondensed DNA. This study has suggested that delivery of condensed 
DNA would be more effective to enhance bone regeneration, compared to 
that of uncondersed DNA. However, these poly(lactide-co-glycolide) scaffolds 
suffered from lack of injectability and therefore required surgical incision.  
 
In summary, the GAM previoiusly investigated suffered from two major 
difficulties: 1) the DNA delivery period was too short (Itaka et al. 2004) and / or 
2) the GAM themselves had low mechanical properties or are not injectable 
(Huang et al. 2005;Quick and Anseth 2004).  
 
1.4. Aim and objectives 
1.4.1. Aim 
Current materials for bone repair with minimally invasive surgery are limited 
by problems such as slow setting rates, poor mechanical properties and slow 
degradation rates. In addition, drug release from such materials, particularly 
DNA, usually occurs as a burst which lasts only for a short period. The aim of 
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this study is therefore to develop novel materials that are injectable, rapid 
setting, of comparable mechanical properties with bone, degradable and 
biocompatible. Moreover, these new materials would be capable of releasing, 
locally and in a controllable manner, therapeutic reagents such as 
antibacterial drugs to treat bone infections and genes to improve osteogenic 
responses.  
 
The materials selected for this study consisted of fluid PGLA-DMA filled with 
MCPM and β -TCP powders (reactants of brushite CPC). The reagents to be 
delivered were CHX and plasmids encoding green fluorescent proteins (GFP), 
a model DNA for gene therapy. The properties considered relevant to this 
study include injectability, polymerisation rate, mechanical properties, 
degradation rate, biocompatibility, CHX release rate, antibacterial activity and 
DNA transfection efficiency.   
 
1.4.2. Objectives 
1. To synthesise and identify PGLA-DMA of defined chemical structure. 
2. To investigate the setting rate, mechanical properties, degradation and 
biocompatibility (in vitro and in vivo) of systematically varying PGLA-DMA 
based composite materials. 
3. To quantify CHX release from the PGLA-DMA based composite materials 
and its subsequent antibacterial activity. 
4. To examine gene transfection in hMSC upon release of condensed GFP 
plasmids from the set PGLA-DMA. 
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Abbreviations 
In alphabetical order 
FTIR Fourier transform infrared 
LA lactide 
MA methacrylate 
MAC methacryloyl chloride 
NMR Nuclear magnetic resonance 
PPG poly (propylene glycol) 
PGLA poly (propylene glycol -co- lactide)  
PGLA-DMA poly (propylene glycol -co- lactide) dimethacrylate 
TEA triethylamine 
TEA·HCl triethylamine∙hydrochloride 
SD standard deviation 
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2.1. Introduction 
This project used fluid degradable poly (propylene glycol -co- lactide) 
dimethacrylate (PGLA-DMA) as the organic component of the composite 
materials (see details in Chapter 3) for bone repair and drug delivery. The 
PGLA-DMA (see molecular structure in Fig. 2.1) consisted of poly (propylene 
glycol) (PPG) of low molecular weight to which degradable lactide (LA) units 
were attached each end.  These were then terminated with polymerisable 
methacrylate (MA) groups. The rationale of using PPG lies in that: (1) It is 
biocompatible. PPG has been evaluated as potential lubricous coatings for 
various medical products (Kim et al. 2000).  PPG of low molecular weight, can 
be eliminated from the body by excretion (He et al. 2001); (2) It is hydrophobic 
and anticipated to produce more hydrophobic backbones to provide a means 
of reducing water sorption rates. LA is used to facilitate degradation and its 
degradation products are natural metabolites in the body (An et al. 
2000;Gunatillake and Adhikari 2003). The MA end groups will enable the 
monomers to polymerise and crosslink using either light or chemical cure 
means.   
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Fig. 2.1. Molecular structure of PGLA-DMA. PPG = poly (propylene 
glycol); LA = lactide; MA = methacrylate. m and n are the unit length of 
PPG and LA respectively.  
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Synthesis of PGLA-DMA with systematically varying the unit length of PPG 
and LA has been reported previously (Ho and Young 2006). The formulation 
with 17 units of PPG and 4 units of LA was selected in this study because of 
its fluidity and stability (Ho and Young 2006).  
 
In previous work, problems in preparation of these monomers included: 1) low 
efficiency of end-capping MA to PGLA (~ 80%); 2) low reaction yield of PGLA-
DMA synthesis (~ 60%) and 3) high level of difficult to remove impurities (i.e., 
crystals of triethylamine∙ hydrochloride (TEA·HCl)) (Ho and Young 2006).  
 
High methacrylation efficiency is desirable as this property of a monomer 
strongely affects crosslinking density after polymerisation. A monomer with 
vinyl groups at both ends will form a densely crosslinked polymer network. 
Those with one vinyl group will however form linear chains, which may make 
the polymer weak and  pliable (Muggli et al. 1998) thereby preventing the 
polymer from matching mechanical properties of any bone tissue it will 
replace. High reaction yield is also advantageous due to improved time and 
cost effectiveness. In addition, TEA·HCl impurities may lower monomer clarity 
and thus light catalysed polymerisation rate. They may also affect the 
physical, chemical or biocompatibility properties of the polymer (e.g., 
accelerate the polymer degradation). As much as possible of the TEA·HCl 
crystals should therefore be removed.   
 
The aim of this study was therefore to increase the MA end-capping efficiency 
and reaction yield of PGLA-DMA synthesis by varying synthesis conditions 
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and to improve the purification level (removal of TEA·HCl) using different 
solvents.  
 
2.2. Materials and methods 
2.2.1. Synthesis of monomer 
PGLA-DMA was synthesised in two steps: 1) LA attachment to PPG to 
produce PGLA and 2) methacrylation of PGLA to produce PGLA-DMA. The 
synthesis procedure primarily used a method described by Ho et al. (Ho and 
Young 2006). As shown by Ho et al., synthesis of PGLA is reproducible with 
high reaction yield (>95%) whereas synthesis of PGLA-DMA is problematical 
(i.e., low methacrylation efficiency and reaction yield and high impurity level). 
In an attempt to improve methacrylation efficiency and reaction yield, in the 
following three reaction conditions were modified or varied.  These include 1) 
change in addition order of methacryloyl chloride (MAC) and triethylamine 
(TEA) to PGLA (as suggested by Shen et al. (Shen et al. 2007)), 2) variation 
in PGLA concentration in dichloromethane and 3) variation in molar ratio of 
MAC to PGLA (see details in section 2.2.1.2.A). Furthermore, additional 
purification steps used by Shen et al. (Shen et al. 2007) have been applied to 
improve TEA.HCl removal (see details in section 2.2.1.2.B).  
 
2.2.1.1. Synthesis of poly (propylene glycol -co- lactide) (PGLA) 
PPG (0.04 mol, information regarding all reagents and their suppliers is 
provided in Appedix A, sic passim) was reacted with 0.16 mol of D,L-LA 
(within a 250 ml one-neck round-bottom flask equipped with a magnetic stirrer) 
at 150 C in a nitrogen atmosphere for 6 h, using stannous octoate (0.05 wt. 
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% of PPG) as a catalyst. Using a Carousel 6 place reaction station (Radleys 
Discovery Technologies, Essex, UK), 6 batches of product could be produced 
at one time.  
 
The resultant products were then cooled to room temperature, 100 ml propan-
2-ol added into each flask and the mixtures vacuum filtered to remove any 
unreacted solid LA. The propan-2-ol was finally removed by rotary 
evaporation at 45 ˚C for 2 h (Rotary evaporator RE200B, Bibby Sterilin Ltd., 
Pontypridd, UK).  
 
2.2.1.2. Synthesis and purification of poly (propylene glycol -co- lactide) 
dimethacrylate (PGLA-DMA) 
A. Synthesis of PGLA-DMA under different reaction conditions 
Purified PGLA was dissolved in 50 ml dichloromethane at concentrations of 
0.1 or 0.2 mol /L. To end-cap both ends with MA units, MAC and TEA (used 
as catalyst) were added whilst maintaining the temperature at 0 C. The molar 
ratio of MAC to TEA was fixed at 1 but MAC to PGLA set as 2 or 4 (for details 
see Table 2.1). Synthesis of PGLA-DMA was repeated six times for each 
reaction condition to address synthesis reproducibility.   
 
All reactions were performed in 250 ml three-neck round-bottom flasks 
equipped with a magnetic stirrer using a cooled Carousel 6 place reaction 
station (Radleys Discovery Technologies, Essex, UK). Two necks of each 
flask were fitted with a dropping funnel: one contained MAC and the other 
TEA (each dissolved in 25 ml dichloromethane). Both solutions were added 
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dropwise and simultanesouly into the PGLA / dichloromethane solution at a 
dripping rate of approximately 15ml/h.  This was contrary to the previous 
report by Ho et al. in which MAC was added after all the TEA (Ho and Young 
2006).  
 
After complete addition of MAC and TEA, the reaction mixture was stirred for 
2 h at 0 °C and then at room temperature (approximately 20 ˚C) for 24 h. A 
simplified synthesis procedure is shown in Fig. 2.2.  
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Fig. 2.2. Two-step synthesis of PGLA-DMA. PPG: poly (propylene glycol); 
LA: lactide; PGLA: poly (propylene glycol -co- lactide); MAC: 
methacryloyl chloride; PGLA-DMA: poly (propylene glycol -co- lactide) 
dimethacrylate.  
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B. Purification of PGLA-DMA 
I. Primary purification using organic solvents 
The mixture of PGLA-DMA and dichloromethane was filtered under vacuum to 
remove any large white crystals of TEA·HCl. Rotary evaporation at 45 ºC 
under vacuum for 15 - 20 min produced further TEA·HCl crystals that were 
removed. The filtrate was dissolved in 100 ml acetone, rotary evaporated at 
45 ºC under vacuum for 15 - 20 min and filtered again. This acetone addition / 
filtration step was repeated three times. After the last wash, the mixture of 
PGLA-DMA with residual acetone was kept in a fume hood overnight to allow 
slow formation of TEA·HCl crystals of larger size for easier filtering. The 
mixture of PGLA-DMA and acetone was finally condensed via rotary 
evaporation under vacuum at 45 ºC for 2 h to remove residual acetone.  
 
II. Further purification using aqueous acid and base 
The following second additional stage was used by other goups (Shen et al. 
2007), but not used in previous studies of PGLA-DMA synthesis (Ho and 
Young 2006).  The resultant PGLA-DMA (40 g) was dissolved in 200 ml 
dichloromethane and then washed with 200 ml dilute HCl (0.1 mol/L). 
Aqueous HCl and PGLA-DMA in dichloromethane were separated using a 
separating funnel: the upper layer consisted of HCl solution with dissolved 
TEA·HCl and the bottom layer was a mixture of PGLA-DMA and 
dichloromethane. The bottom layer was washed several more times using 200 
ml HCl until the pH of the upper layer was close to 7 (TEA·HCl solution was 
alkaline). The bottom layer was then washed using 200 ml NaHCO3 (0.1 
mol/L) two times to remove residual HCl. Finally, the mixture was washed with 
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200 ml double distilled H2O twice to remove traces of NaHCO3. 
Dichloromethane was finally removed by rotary evaporation under vacuum at 
45 °C for 24 h.  
 
2.2.2. Identification of synthesised monomers 
The synthesised PGLA and PGLA-DMA were characterised using Fourier 
transform infrared (FTIR), Raman (see Appedix B for more details) and 1H-
nuclear magnetic resonance (NMR) spectroscopy. Peak assignment was 
aided by comparing spectra of the intermediates (PGLA) and the final 
products (PGLA-DMA) with those of the starting materials PPG, D,L-LA and 
MAC. FTIR, Raman and NMR were used to confirm the presence of different 
chemical groups in the synthesised products. NMR was additionally used to 
gain quantitative information on the chemical structure of PGLA and PGLA-
DMA, i.e., the length of LA segments and the efficiency of MA attachment. 
 
2.2.2.1. Fourier transform infrared (FTIR) spectroscopy  
FTIR spectra were obtained using a Perkin Elmer series 2000 FTIR 
spectrometer with Spectrum software v 5.0.1 (Perkin-Elmer, Beaconsfield, 
UK) using resolution at 4 cm-1, wavenumber between 500 and 4000 cm-1 and 
four scans per spectrum. All spectra were normalised using the PPG ‘C-O’ 
peak at 1088 cm-1. The peak intensities due to other chemical groups then 
provided an indication of the level of that group relative to PPG. 
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2.2.2.2. Raman spectroscopy 
Raman spectra were recorded using a Raman spectrometer fitted with a 633 
nm laser (LabRAM HR, Horiba Jobin Yvon Ltd., Stanmore, UK). The 
instrument filter was set at 100%, hole at 300, slit at 150, grating at 1800 and 
microscope objective ×50. Exposure times for all samples were 10 s and the 
accumulation number set at 6. Background subtraction, normalisation and 
smoothing were performed using the Labspec software. All spectra were 
normalised using the ‘C-H’ peak at 1447 cm
-1. The peak intensities due to 
other chemical groups then provided an indication of the level of that group 
within the molecule. 
 
2.2.2.3. Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were recorded using a 600 MHz Varian Unity INOVA 
spectrometer (Palo Alto, CA, USA) at 25 ºC using WILMAD® NMR tubes of 
diameter of 5 mm with deuterated chloroform (CDCl3) or deuterated water 
(D2O) as solvent. All spectra were normalised using the PPG ‘CH3’ peak at 
1.13 ppm. The peak areas due to other chemical groups then provided an 
indication of the level of that group within the molecule. NMR spectra were 
collected with assistance from Dr. Geoff Kelly. 
 
2.2.3. Determination of methacrylation efficiency of PGLA-DMA 
synthesis 
NMR spectra were used to quantify the methacrylation efficiency of PGLA-
DMA synthesis. Peaks were first assigned to different chemical groups in an 
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NMR spectrum and then relative number of a chemical group R determined 
using:   
n
A
R                                                                                        2.1 
where A is the areas assigned to a chemical group and n is the number of 
hydrogen atoms in that chemical group. For example any peak areas due to 
CH3 groups were divided by 3. 
 
Subsequently the number of LA molecules attached per molecule (m) was 
calculated using:         
PPG
LA
R
R
17m                                                                                                 2.2                                                                     
where LA and PPG represent any peak associated with LA or PPG groups 
respectively.  The number 17 arises because this is the average number of 
propylene glycol units in PPG of 1000 g/mol molecular weight.   
 
The MA end-capping efficiency (EMA, %) was subsequently calculated using:  
100
2R
17R
E
PPG
MA
MA                                                                                           2.3 
2 is the optimal number of MA groups per molecule. Results of methacrylation 
efficiency were presented as the means ± standard deviation (SD), n=6. T-test 
was used to determine if effects of different synthesis conditions on 
methacrylation efficiency were statistically significant (SPSS 14.0 for 
Windows, SPSS, Inc., Chicago, Ill., USA). Statistical evaluation was 
performed with assistance from Ms Aviva Petrie (sic passim).  
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2.2.4. Determination of reaction yield of synthesised monomers 
The reaction yield of PGLA (Y1) and PGLA-DMA (Y2) and overall synthesis 
yield (Y) were calculated using: 
100
M
M
YorY
exp
obt
21                                             2.4 
100
Y×Y
=Y 21                                                                      2.5 
where Mobt  and Mexp are the obtained and expected mass of the product at 
each stage. 
 
2.3. Results 
The obtained intermediate product PGLA and final product PGLA-DMA were 
both colourless and “oil” like. The results of synthesised PGLA-DMA under 
different reaction conditions shown below are products after double 
purification. The difference in purity of products after primary and after further 
purification is presented in section 2.3.3. 
 
2.3.1. Chemical structure of synthesised monomers 
The FTIR spectra of PPG gave absorption peaks at 1447 and 1372 cm-1 due 
to ‘C-H’ groups and at 1088 cm-1 due to ‘C-O’ groups (see example in Fig. 2.3 
and see PPG molecular structure in Fig. 2.2).  
 
In the spectra of PGLA, these peaks remained and additional peaks at 1744 
cm-1 due to LA ‘C=O’ groups and peaks at 1268 and 1184 cm-1 due to LA ‘C-
O’ groups were present (see example in Fig. 2.3 and see PGLA molecular 
structure in Fig. 2.2). In addition, reduction in ‘O-H’ peak height at 3500 cm-1, 
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compared to PPG, was consistent with LA attachment to the PPG. The LA 
attachment to PPG was further confirmed by comparison of the NMR spectra 
of starting D,L-LA with those of PGLA. This is because the linear LA peaks in 
the PGLA NMR spectra are clearly separated from the PPG and are at high 
intensity (see below).  
 
All spectra of PGLA-DMA were similar to those of PGLA with the exception of 
additional small peaks at 1719 and 1678 cm-1 due to MA ‘C=O’ groups, at 
1640 cm-1 attributed to MA ‘C=C’ groups (see example in Fig. 2.3 and see 
PGLA-DMA molecular structure in Fig. 2.2). This was consistent with 
attachment of MA groups to PGLA. 
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Fig. 2.3. FTIR spectra of PPG, PGLA and PGLA-DMA. PPG: poly 
(propylene glycol); PGLA: poly (propylene glycol -co- lactide); PGLA-
DMA: poly (propylene glycol -co- lactide) dimethacrylate. The PGLA-
DMA shown was synthesised under condition ‘F4’ 
(PGLA/dichloromethane of 0.2 mol/L and molar ratio of MAC to PGLA of 
4 mol/mol, see Table 2.1 for details). Note the additional peaks at 1184, 
1268 and 1744 cm-1 of PGLA and peaks at 1640, 1678 and 1719 cm-1 of 
PGLA-DMA indicating respectively attachment of LA to PPG and MA to 
PGLA. 
 
Raman spectra of PPG, PGLA and PGLA-DMA also demonstrated 
attachment of LA to PPG and MA to PGLA (see example in Fig. 2.4). In the 
Raman spectra of PPG, the three main peaks at ~3000 cm-1 (i.e. 2975, 2940 
and 2875 cm-1) and the peak at 1447 cm-1 corresponded to ‘C-H’ groups. The 
spectra of PGLA were similar to those of PPG except for the presence of the 
peak at 1744 cm-1 due to LA ‘C=O’ group.  
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In all spectra of PGLA-DMA, additional peaks were present upon 
methacrylation. These included peaks at 1719 and 1678 cm-1 (both due to MA 
‘C=O’ groups) and at 1640 cm-1 (due to MA ‘C=C’ groups).  
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Fig. 2.4. Raman spectra of PPG, PGLA and PGLA-DMA. PPG: poly 
(propylene glycol); PGLA: poly (propylene glycol -co- lactide); PGLA-
DMA: poly (propylene glycol -co- lactide) dimethacrylate. The PGLA-
DMA shown was synthesised under conditions ‘F4’ 
(PGLA/dichloromethane of 0.2 mol/L and molar ratio of MAC to PGLA of 
4 mol/mol, see Table 2.1 for details).  Note the additional peaks at 1744 
cm-1 of PGLA and peaks at 1640, 1678 and 1719 cm-1 of PGLA-DMA 
indicating respectively attachment of LA to PPG and MA to PGLA. 
 
NMR spectra of PPG, PGLA and PGLA-DMA additionally provided evidence 
for attachment of LA to PPG and MA to PGLA (see example in Fig. 2.5.A).The 
PPG NMR spectra exhibited a broadened peak at 3.54* ppm caused by both 
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‘CH’ and ‘CH2’ protons and a multiple peak at 1.13 ppm due to ‘CH3’ protons. 
Peaks marked with ‘*’ were used for NMR calculations.  
 
In the PGLA spectra, new multiplets at 5.11* ppm (assigned to linear LA ‘CH’ 
protons in the chains) and at 4.35* ppm (assigned to LA ‘CH’ protons adjacent 
to the terminal ‘OH’ groups) appeared (see example in Fig.2.5.A). There are 
also new peaks at 1.54 ppm arising from the presence of linear LA ‘CH3’ 
groups. Unreacted cyclic LA has a quartet at 5.09 ppm due to ‘CH’ protons 
and a doublet at 1.65 ppm due to ‘CH3’ protons (Fig. 2.5.B). The difference in 
the spectra between liner LA and cyclic LA has suggested that the cyclic ring 
of LA has been opened and attached to the PPG.  
 
All final PGLA-DMA spectra showed three additional peaks to those observed 
for the PGLA. Those at 6.21* and 5.64* ppm could be assigned to the protons 
attached to the MA ‘C=C’ bonds and those at 1.95 ppm to MA ‘CH3’ protons. 
The NMR peaks of starting MAC have been slightly shifted, consistent with its 
attachment to LA (compare Fig. 2.5.B and A). 
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Fig. 2.5. A: NMR spectra of PPG, PGLA and PGLA-DMA. The PGLA-DMA shown 
was synthesised under conditions ‘F4’ (PGLA/dichloromethane of 0.2 mol/L and 
molar ratio of MAC to PGLA of 4 mol/mol, see Table 2.1 for details). B: NMR 
spectra of starting reagents D,L-LA and MAC. PPG: poly (propylene glycol); 
PGLA: poly (propylene glycol -co- lactide); PGLA-DMA: poly (propylene glycol -
co- lactide) dimethacrylate; LA: lactide; MAC: methacryloyl chloride. Note the 
additional peaks around 1.54, 4.35 and 5.11 ppm of PGLA and peaks at 1.95, 5.64 
and 6.21 ppm of PGLA-DMA indicating respectively attachment of LA to PPG and 
MA to PGLA. 
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2.3.2. Effect of reaction conditions on PGLA-DMA synthesis 
2.3.2.1. Effect of reaction conditions on methacrylation efficiency 
In order to improve methacrylation efficiency, two reaction variables (i.e., 
PGLA concentration in dichloromethane and molar ratio of MAC to PGLA) 
were investigated. PGLA concentration in dichloromethane had no 
experimentally significant effect on FTIR, Raman or NMR spectra (data not 
shown).  Increase in the molar ratio of MAC to PGLA, however, clearly 
resulted in higher ‘C=C’ content per PGLA-DMA molecule (see example in Fig. 
2.6, comparing F4 and F2 (with MAC/PGLA of 4 and 2 mol/mol respectively). 
FTIR spectra were not highly sensitive to ‘C=C’ group attachment (see 
example in Fig. 2.6.A). Raman spectra, however, were more sensitive in 
detecting ‘C=C’ group, and have demonstrated substantial increase in peak 
intensity at 1640 cm-1 (due to ‘C=C’) when the molar ratio of MAC to PGLA 
was increased from 2 to 4 mol/mol (see example in Fig. 2.6.B). Furthermore, 
NMR spectra of PGLA-DMA synthesised with higher molar ratio of MAC to 
PGLA showed obviously increased peak intensity at 5.64 and 6.21 ppm (due 
to ‘C=C’) (see example in Fig. 2.6.C). 
Chapter 2                                                     Polymer synthesis and preparation 
 74 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
0
0.1
0.2
0.3
0.4
0.5
0.6
5001000150020002500300035004000
Wavenumber (cm-1)
A
b
s
o
rb
a
n
c
e
F4
F2
0
0.1
0.2
0.3
0.4
0.5
0.6
1000125015001750
C=C
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
0.5
40090014001900240029003400
Raman shift (cm-1)
In
te
n
s
it
y
F4
F2
0
0.1
0.2
140016001800
C=C
Chapter 2                                                     Polymer synthesis and preparation 
 75 
 
C 
Fig. 2.6. FTIR (A), Raman (B) and NMR (C) spectra of PGLA-DMA 
synthesised under different reaction conditions. F2 =  
PGLA/dichloromethane of 0.2 mol/L and MAC/PGLA of 2 mol/mol; F4 = 
PGLA/dichloromethane of 0.2 mol/L and MAC/PGLA of 4 mol/mol. This 
figure illustrates how FTIR is less sensitive than Raman and NMR in 
detecting the ‘C=C’ group. Note the increase in the ‘C=C’ peak intensity 
with increase in the molar ratio of MAC/PGLA.  
 
To quantify the effect of different reactions conditions on methacrylation 
efficiency, NMR calculations were used to determine the number of LA and 
MA groups in each PGLA-DMA molecule. It was found that the number of LA 
goups per PGLA-DMA molecule was 3.9, close to the expected value of 4 
(Table 2.1.A). The number of MA groups per PGLA-DMA molecule varied 
depending on the synthesis conditions. The average number of MA groups 
attached to PGLA increased in the order: F1, F2 (1.3) < F3, F4 (1.9) (Table 
2.1.A). There was no significant difference in the methacrylation efficiency 
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when the PGLA concentration in dichloromethane was 0.1 or 0.2 mol/L (Table 
2.1.B). However, the methacrylation efficiency substantially increased when 
the molar ratio of MAC to PGLA increased from 2 to 4 mol/mol (p<0.05) 
(Table 2.1.B).  
 
2.3.2.2. Effect of reaction conditions on reaction yield 
The reaction yield for the synthesis of PGLA was as high as 96 %, as reported 
by Ho and Young (Ho and Young 2006).  The reaction yield for the synthesis 
of PGLA-DMA was lower, between 65 and 78%. The overall yield therefore 
ranged between 63 and 75% (Table 2.1.A). The yield of PGLA-DMA synthesis 
significantly increased when the PGLA concentration in dichloromethane 
increased from 0.1 or 0.2 mol/L (p<0.05) (Table 2.1.B). The molar ratio of 
MAC to PGLA however had no measurable effect on the yield of PGLA-DMA 
(Table 2.1.B). 
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Table 2.1.A. Effect of reaction conditions on methacrylation efficiency and reaction yield of PGLA-DMA synthesis. 
Formulations Synthesis conditions 
 PGLA in dichloromethane 
(mol/L) 
MAC/PGLA 
(mol/mol) 
mLA  mMA  EMA  
(%) 
Observed formula  Y1 
(%) 
Y2 
(%) 
Y  
(%) 
F1 0.1 2 3.9 1.3±0.1 65±5 PPG17 LA3.9 MA1.3 96 70±4 67±4 
F2 0.2 2 3.9 1.2±0.1 60±5 PPG17 LA3.9 MA1.2 96 78±5 75±4 
F3 0.1 4 3.9 1.9±0.1 95±5 PPG17 LA3.9 MA1.9 96 65±5 63±4 
F4 0.2 4 3.9 1.9±0.1 95±5 PPG17 LA3.9 MA1.9 96 75±5 72±4 
mLA and mMA are the number of LA and MA groups per PGLA-DMA molecule (see Eq. 2.2). EMA is the methacrylation efficiency (see Eq. 2.3). The 
expected PGLA-DMA formula was PPG17LA4MA2. Y1 and Y2 are the reaction yield of synthesis of PGLA and PGLA-DMA respectively (see Eq. 2.4). Y 
is the overall reaction yield (see Eq. 2.5). Data are presented as the means ± SD, n=6.  
 
Table 2.1.B. Statistical evaluation in methacrylation efficiency and reaction yield of PGLA-DMA synthesis under different 
reaction conditions. 
 Methacrylation efficiency  Reaction yield 
Reaction conditions F1 F2 F3 F4 Reaction conditions F1 F2 F3 F4 
F1   * * F1  *  * 
F2   * * F2 *  *  
F3 * *   F3  *  * 
F4 * *   F4 *  *  
*significant difference between the values of corresponding formulations. 
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2.3.3. Effect of different solvents on PGLA-DMA purification 
NMR spectra of PGLA-DMA after primary purification using organic solvents 
alone showed a quartet at 3.05 ppm (due to ‘CH2’) and a triplet at 1.24 ppm 
(due to ‘CH3’) attributed to residual TEA∙HCl ((CH3CH2)3N·HCl) crystals (see 
example in Fig. 2.7). These peaks could also be observed in the NMR spectra 
of PGLA-DMA after secondary purification (using aqueous acid and base) but 
at much lower intensity (see example in Fig. 2.5, PGLA-DMA). These results 
have demonstrated that the concentration of TEA∙HCl in further purified 
PGLA-DMA was reduced compared to that in the primary purified PGLA-DMA.  
 
Fig. 2.7. NMR spectrum of an example PGLA-DMA after primary 
purification. TEA·HCl: triethylamine hydrochloride. Note the 
presence of TEA·HCl (impurity).  
0
20
40
60
80
100
120
140
012345678
ppm
In
te
n
s
it
y
0
20
40
60
11.522.533.5
TEA∙HCl
1.24
3.05
Chapter 2                                                     Polymer synthesis and preparation 
 79 
2.4. Discussion 
The synthesis procedure used in this project was found to be successful in 
attaching LA to PPG and MA to PGLA. Effects of different reaction conditions 
on PGLA-DMA synthesis and effects of different solvents on PGLA-DMA 
purification were analysed. 
 
2.4.1. Effect of reaction conditions on PGLA-DMA synthesis 
2.4.1.1. Effect of reaction conditions on methacrylation efficiency 
This study increased the methacrylation efficiency of PGLA from 80 (see 
previous report (Ho and Young 2006)) to >90%. The major difference in the 
synthesis procedure in the current study compared with the previous work 
was the order of addition of MAC and TEA. Previously TEA was added prior to 
MAC whereas in this new study, the two reagents were added at the same 
time. The reason for the increased methacrylation efficiency is unclear but 
might be because of the reduction of some side reactions between MAC and 
TEA (found in other studies, data not shown). If TEA was added first, its high 
concentration might enhance its ability to form by-products with MAC thereby 
lowering the probability of MA attachment to PGLA.  
 
In addition, PGLA concentration in dichloromethane was found to have no 
measurable effect on the methacrylation efficiency. However, increase in the 
molar ratio of MAC to PGLA from 2 to 4 mol/mol markedly improved the 
methacrylation efficiency from 63 to 95%. This indicates that an excess of 
MAC and TEA is required in order to gain good MA attachment efficiency. The 
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high monomer methacrylation efficiency will enable higher crosslinking density 
upon polymerisation and thus potentially improved mechanical properties.  
 
2.4.1.2. Effect of reaction conditions on reaction yield 
This study had also increased the average reaction yield of PGLA-DMA 
synthesis from 60 (see previous report (Ho and Young 2006)) to 75%. The 
higher reaction yield might be a partial consequence of changing the order of 
MAC and TEA addition. The two reagents were added at the same time in the 
present study, which might reduce the probability of side reactions between 
MAC and TEA, thereby increasing the reaction yield (see section 2.4.1.1 for 
more details).  
 
In addition, the reaction yield of PGLA-DMA synthesis increased with the 
increase in PGLA concentration in dichloromethane. The high reaction yield is 
advantageous due to improved time and cost effectiveness. Molar ratio of 
MAC to PGLA however had no effect on the reaction yield. 
 
2.4.2. Effect of different solvents on PGLA-DMA purification  
The primary purification using organic solvents could remove the bulk of the 
produced TEA·HCl crystals, as reported previously (Ho and Young 2006). 
Additional washing with dilute HCl, NaHCO3 solution and double distilled 
water, however, was found to improve removal of small crystals of TEA·HCl.  
 
In summary, the optimal preparation procedure to synthesise and purify 
PGLA-DMA is illustrated below: 
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PPG + LA + stannous octoate (0.05 wt.% of PPG), 
molar ratio of LA/ PPG =4 
Dissolve in propan-
2-ol and filter to 
remove unreacted 
solid LA 
150 ºC N2 atmosphere 
 for 6 h 
Add MAC and TEA dropwise simultaneously in ice bath,  
molar ratio of MAC to PGLA = 4 mol/mol 
PGLA 
Remove propan-2-ol 
Remove 
dichloromethane and 
filter TEA·HCl 
crystals 
Dissolve in acetone 
Remove acetone 
and filter TEA·HCl 
crystals, repeat 
three times 
Recrystallisation overnight, filter TEA·HCl crystals and remove acetone 
 
Cool to 0ºC 
Fluid colourless PGLA-DMA 
Dissolve in 
dichloromethane 
Wash by 0.1 
mol/L NaHCO3 
twice 
Wash by 0.1 mol/L 
HCl, volume ratio of 
dichloromethane to 
HCl = 1, repeat 
several times Remove 
dichloromethane 
Wash by H2O 
twice 
Fig. 2.8. Flow chart of preparation of PGLA-DMA. PPG: poly 
(propylene glycol);  LA: lactide; PGLA: poly (propylene glycol -co- 
lactide); TEA·HCl: triethylamine∙hydrochloride; PGLA-DMA: poly 
(propylene glycol -co- lactide) dimethacrylate.  
Dissolve in 
dichloromethane at 
concentration of 0.2 mol 
PGLA/1L dichloromethane 
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2.5. Conclusion 
The PGLA-DMA synthesised in this study was fluid and colourless with 
chemical structure as expected. Methacrylation efficiency and reaction yield 
were improved via varying synthesis conditions. Purification level was also 
enhanced by using aqueous acid and base in addition to organic solvents.  
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Abbreviations 
In alphabetical order 
CAM chorioallantoic membrane  
CPC calcium phosphate cement  
CQ camphorquinone  
DCP 
DMA 
dicalcium phosphate 
dynamic mechanical analyser  
DMEM Dulbecco’s modified Eagle’s medium  
DMPT N,N-dimethyl-p-toluidine  
EDAX energy dispersive X-ray analysis  
FBS fetal bovine serum  
FTIR Fourier transform infrared  
F% filler content 
HA hydroxyapatite  
HEMA hydroxyethyl methacrylate 
IC ion chromatography 
MCPM 
Md 
monocalcium phosphate monohydrate 
MCPM particle size 
PBS phosphate buffered saline 
PGLA-DMA poly (propylene glycol -co- lactide) dimethacrylate 
SD standard deviation 
SEM scanning electron microscope 
SQRT 
TCP 
square root 
tricalcium phosphate 
T/M 
XRD 
molar ratio of β-TCP/MCPM 
X-ray diffraction 
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3.1. Introduction 
Synthetic poly (propylene glycol -co- lactide) dimethacrylates (PGLA-DMA) are 
fluid and rapidly photo-polymerisable (Ho and Young 2006). The set materials, 
however, have a relatively low modulus as well as a slow degradation rate, and 
produce acid during degradation. These characteristics may, respectively, cause 
concerns of insufficient functional support, impedance of new tissue growth (Rizzi 
et al. 2006) and potential inflammatory response in vivo (Walton and Cotton 
2007), if PGLA-DMA is used as bone adhesives (used to connect fractured bone) 
or fillers (used to fill bone defects).  
 
In the present study, β-tricalcium phosphate (β-TCP) and monocalcium 
phosphate monohydrate (MCPM) particles were incorporated into PGLA-DMA as 
fillers to fabricate composite materials. Although addition of filler particles may 
reduce the rate and level of PGLA-DMA polymerisation (Xia and Cook 2003), it 
was expected that the composite materials could have improved mechanical, 
degradation, acid production and biological properties over the unfilled polymer 
(Cai et al. 2009;Peter et al. 1998).  
 
β-TCP and MCPM are reactants of brushite forming calcium phosphate cement 
(CPC) (Bohner 2007). It was felt that the water-induced setting of β-TCP and 
MCPM directly within the polymer might increase the homogeneous dispersion of 
the particles throughout the polymer and improve the material mechanical 
properties. Reactants that produce brushite rather than hydroxyapatite (HA) were 
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used due to the higher aqueous solubility of brushite at physiological pH (7.2 ~ 
7.4) (Bohner 2001). Brushite therefore dissolves faster than HA providing higher 
phosphate and calcium concentration in solution (Agrawal and Athanasiou 1997). 
These phosphate and calcium ions are essential for bone re-mineralisation 
(Bohner 2000;Bohner et al. 2005;Hofmann et al. 2009), and can also buffer acid 
produced (Linhart et al. 2001).   Furthermore, the much faster setting of brushite 
CPC compared with that of HA CPC is likely to be beneficial in a set polymer 
within which reaction kinetics will be substantially hindered. 
 
The first aim of this study was therefore to examine any possible deleterious 
effect on photo-polymerisation due to the filler addition and to characterise any 
water-sorption induced changes in the filler chemistry. Additionally, the effect of 
filler addition on material modulus, degradation, phosphate and calcium ion 
release as well as acid release (indicative of buffering capacity of filler) were 
investigated. Finally, biocompatibility (in vitro and in vivo) of the PGLA-DMA 
based composite materials was assessed. These results were combined to 
determine whether these composite materials have potential to be used as bone 
adhesives or fillers. Parts of this work were published in Acta Biomaterialia in 
2010 (Zhao et al. 2010).  
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3.2. Materials and methods  
3.2.1. Fabrication of composite materials 
The organic phase of the composite materials consisted of PGLA-DMA (90 wt.%), 
camphorquinone (CQ, 1 wt.%, as photo-initiator), N,N-dimethyl-p-toluidine 
(DMPT, 1 wt.%, as accelerater to enable photo-polymerisation) and hydroxyethyl 
methacrylate (HEMA, 8 wt.%, to aid dispersion of CQ and DMPT). The inorganic 
phase (i.e. filler) was a mixture of β-TCP and MCPM. There were three variables 
in the filler type including filler content (F%, 70, 60 or 50 wt.%), molar ratio of β-
TCP to MCPM (T/M, 4, 2 or 1) and MCPM particle size (Md, 90, 60 or 30 µm) 
(see Table 3.1 for details of different formulations). Variation in F% could have 
influence on the material polymerisation rate (Xia and Cook 2003) and 
mechanical properties (Iisaka 1976;Lee et al. 2007;Witt and Cizek 1954). 
Change in T/M could result in different chemical composition of calcium 
phosphates after reaction and thus degradation, phosphate and calcium ion 
release, pH compensation capability and biocompatibility. Alteration in Md could 
affect the material mechanical properties (Iisaka 1976;Lee et al. 2007;Witt and 
Cizek 1954). Factorial analysis was used in this study to determine the level of 
effect of each of these variables on different material properties including photo-
polymerisation, modulus, degradation, pH compensation ability and 
biocompatibility (see section 3.2.4 for details). This was undertaken to aid 
material optimisation. 
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The organic phase was then mixed with the filler and the resulting composite 
mixtures moulded using steel rings, with top and bottom surfaces covered by 
acetate sheets (3M AF 4301, Manchester, UK). These were then cured in a light 
box (Triad® 2000™ visible light cure system, Dentsply Trubyte, Palo Alto, USA) 
using blue light exposure (100 mW/cm2) for 12 min, to produce solid discs (12 
mm diameter, 2 mm thick, unless otherwise stated). Polymer discs without filler 
were used as control. Raman spectroscopy was then used to confirm full 
polymerisation (i.e. no detectable peak at 1640 cm-1 due to ‘C=C’ in PGLA-DMA) 
(Ho and Young 2006) and the density of the set samples was measured to 
confirm negligible air incorporation (i.e. the practical density was identical to the 
calculated theoretical density within experimental error). Each test was performed 
in triplicate, and the results were expressed as means ± standard deviation (SD).  
 
3.2.2. Characterisation of composite materials 
3.2.2.1. Polymerisation kinetics 
The unset material was placed on a Golden GateTM heated diamond top-plate at 
37 ºC, within a Perkin-Elmer Series 2000 Fourier transform infrared (FTIR) 
spectrometer with Timebase software. The paste was confined within a ring of 5 
mm diameter and 2 mm depth, and sealed with acetate sheet. FTIR spectra of 
the lower few microns of the sample in contact with the diamond were generated 
over the range between 500 and 4000 cm-1 at a resolution of 4 cm-1 every 8 s for 
30 min. At 40 s each mixture was exposed to blue light (400 mW/cm2) for 120 s 
using a dental light curing gun (Coltene®, Sussex, UK). 
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Before and after the 30 min FTIR analysis, all formulations were examined using 
Raman spectroscopy (LabRam HR Raman spectrometer, Horiba Jobin Yvon, 
Stanmore, UK). This instrument was equipped with a 633 nm wavelength laser, x 
50 objective lens and 1800 grating. All spectra were background subtracted and 
normalised by the ‘C-H’ peak at 1447 cm-1. The fraction of the monomer 
remaining, P, was determined as the ratio of the final to the initial height of the 
monomer Raman peaks at 1640 cm-1, attributed to ‘C=C’ stretches of PGLA-
DMA (Ho and Young 2006). 
 
The monomer conversion percentage (Qt) was then quantified using:  
 
 
P)
ΔAΔA
ΔAΔA
Q
0f
0t
t 


 1(                                                                                 3.1 
where ΔAt, ΔA0, ΔAf are the difference in the absorbance at 1716 and 1736 cm
-1, 
respectively, at time t, initially and finally. FTIR spectra exhibited maximum 
spectral change during light curing at 1716 cm-1 (absorbance loss) and at 1736 
cm-1 (absorbance gain) due to the changes in the chemical environment of the 
methacrylate ‘C=O’ bond. Polymerisation rate (%/s) was defined as the slope of 
the linear region of ‘Qt versus light exposure time’ curve (Qt between 20 and 
60%).  
 
3.2.2.2. Water induced chemical changes 
The light cured composite specimens (12 mm diameter, 2 mm thick) were soaked 
statically in 10 ml of deionised water (pH = 7, adjusted by 0.01mol/l NaOH) at 37 
ºC. Specimens after 24 h and 12 weeks of water immersion were collected and 
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air dried at room temperature for chemical characterisation by Raman and X-ray 
diffraction (XRD) spectroscopy. During the 12-week storage period, the solution 
was changed weekly to avoid saturation of degradation products (e.g., Ca2+ and 
PO4
3-) in the storage solution.  
 
A. Raman 
In order to characterise the chemical changes of specimens before and after 24 h 
and 12 weeks of water immersion, Raman maps (×2) of an area (100 × 100 µm) 
of the core (transverse section) of each specimen were obtained at a step size of 
5 µm, using a 633 nm laser, x 50 objective and 1800 grating. Exposure times for 
each single-point spectrum were 10 s and the accumulation number set at 6. 
Each single-point spectrum was recorded and the chemical composition maps 
were generated using LabRam software. The mean Raman spectra were 
obtained following background subtraction and normalisation using the polymer 
‘C-H’ peak at 1447 cm-1. The peak intensities due to other components then 
provide an indication of the level of that component relative to the polymer (Ho 
and Young 2006;Mehdawi et al. 2009). Standard Raman spectra of the polymer, 
β-TCP, MCPM, brushite and monetite were also recorded for comparison.  
 
B. XRD 
XRD was additionally used to identify the presence of different crystalline calcium 
phosphate in the specimen. The specimens were cut transversely and the new 
surfaces generated examined. XRD spectra were obtained using a Brüker D8 
advance diffractometer (Karlsruhe, Germany), with Ni filtered Cu Kα radiation. 
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Data were collected from 10° to 100° 2θ with a step size of 0.02° in a count time 
of 18.9 s using a Bruker Lynx Eye detector. In addition to the International Centre 
for Diffraction Data database volumes 1, spectra of starting chemicals of β-TCP 
and MCPM were used to assign peaks of different calcium phosphates. XRD 
analysis was performed with assistance of Prof. Jonathan Knowles (sic passim). 
 
3.2.2.3. Compressive modulus 
Specimens (5 mm diameter, 2 mm thick) were analysed before and after 
placement in 2.5 ml of neutral deionised water at 37 ºC for 24 h, 1, 4 and 7 days 
and then weekly up to 10 weeks. At each time point, the storage solution was 
replaced with fresh 2.5 ml of deionised water. The variation of polymer and 
composite compressive modulus with time was characterised using a dynamic 
mechanical analyser (DMA 7e, Perkin Elmer Instruments, Bucks, UK, see 
Appendix B for more information).  
 
In this test, a linearly increasing quasi-static stress was applied to the specimen 
on a parallel plate incorporating a 10 mm probe. An increasing static force from 
10 mN to 8000 mN was applied to the sample at a constant rate of 500 mN/min. 
The resultant displacement in strain was plotted against the applied stress, and 
the modulus (E) was calculated as the slope of the initial linear portion (0.1-0.2 
MPa) of the stress-strain curve using Pyris TM version 5 software.  
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3.2.2.4. Hydrolytic degradation 
Each set specimen disc (12 mm diameter, 2 mm thick) was placed upright in the 
conical end of a Sterilin® 30 ml polystyrene container (Sterilin Ltd., Caerphilly, UK) 
in which 10 ml of neutral deionised water was added. Each specimen was then 
incubated in the storage solution at 37 °C for 0, 30 min, 1, 2, 4, 8, 24 h, 2, 4, 7 
days, 2, 3, 4, 5, 7, 9, 10 and 12 weeks. At each time point, the mass and density 
of each disc were measured using an electronic balance with a density kit 
(Mettler Teledo, Osaka, Japan) prior to replacement in fresh storage solution for 
measurement at the next time point. The storage solution at different time points 
was also used for the subsequent ion and acid release study (see section 3.2.2.5 
for details).  
 
The mass change at time t (ΔWt) due to combined water sorption and material 
loss was calculated using:  
100
W
WW
ΔW
a,0
a,0t,a
t 

                                                                                        3.2 
where Wa,t and Wa, 0 are the wet mass (measured in air) of the specimen at time t 
and the initial dry mass (prior to water immersion) respectively.  
 
The specimen density at time t, ρt, was determined using: 
tw,ta,
ta,
wt
WW
W
ρρ

                                                                                          3.3 
where ρw is the density of water at the operating temperature and Ww,t is the wet 
mass (measured in water) of the specimen at time t. 
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The volume change (ΔVt) of the specimen at time t was thus determined using: 
t
ta,
t
ρ
W
V                                                                                                               3.4 
100
V
VV
V
0
0t
t 

                                                                                          3.5 
where Vt and V0 are the wet volume of the specimen at time t and the initial dry 
volume (prior to water immersion) respectively. 
 
Additionally, the water content at 24 h, w, and the final mass loss at 12 weeks, m, 
of the polymer and composites were determined using:  
100
W
WW
w
d,t
d,ts,t 

                                                                                            3.6  
where Ws,t and Wd,t are the swollen and dry mass of the specimen after 24 h of 
immersion in water. The dry specimens were obtained after vacuum drying at 
room temperature to constant mass. 
 
100
W
W-W
m
a,0
fd,a,0                                          3.7 
where Wa,0 is the initial dry mass of the specimen prior to water immersion and 
Wd,f is the final dry mass of the specimen after 12 weeks of immersion in water. 
The dry specimens were obtained after vacuum drying at room temperature to 
constant mass.  
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3.2.2.5. Ion and acid release      
Phosphate and calcium release were monitored using ion chromatography (IC, 
see Appendix B for more information) with Chromeleon® software (Dionex, 
Surrey, UK). To measure PO4
3- concentration, an ICS2500 system equipped with 
an AS50 autosampler and an EG50 eluent generator system was used. The 
mobile phase was a 30 mM KOH solution with a flow rate of 1.5 ml/min and 10 
min running time. An ASRS®-300 (4 mm) column mounted in an AS50 thermal 
compartment and an ASRS suppressor was used. Ca2+ was measured on a 
Dionex ICS1000 system equipped with an AS50 autosampler, using 20 mM 
methylsulphonic acid as the mobile phase at a flow rate of 1 ml/min with a CSRS 
ULTRA (4 mm) column and a CAES suppressor. The running time was also 10 
min. Calibration was obtained with standard solutions containing 1, 10, 25, 50 
and 100 ppm of PO4
3- or Ca2+. An injection loop of 25 μl was used. The pH of the 
collected solutions was determined using a pH meter (Jenway 3340, Essex, UK). 
 
3.2.2.6. Biocompatibility 
A. In vitro biocompatibility 
In vitro biocompatibility was examined using the MG-63 osteosarcoma cell line, 
which has previously been widely employed as an in vitro test model for 
assessing the effects of many types of biomaterials (Lee et al. 2003;Price et al. 
1997). The cells were cultured in polystyrene flasks in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 50 
IU/ml of penicillin and 50 µg/ml of streptomycin (termed ‘full culture medium’) at 
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37 °C in a humidified atmosphere of 5% CO2 in air. Sub-confluent cells (70 - 80% 
confluence) were passaged by using trypsin-EDTA (0.25% (w/v) trypsin, 1 mmol/l 
EDTA).  
       
In this test, the set polymer and composite discs (13 mm diameter, 2 mm thick) 
were sterilised under UV light (254 nm) for 30 min and placed into 15 ml NUNCTM 
centrifuge tubes (Thermo Fisher Scientific, Loughborough, UK) and incubated in 
10 ml of ‘full culture medium (defined in section 3.2.2.6 A)’ at 37 °C for 24 h. This 
was to eliminate the burst acid release due to the dissolution of acidic MCPM and 
to remove any possibly deleterious products initially present in the materials (i.e. 
photo-initiators) (Pagoria et al. 2005). This 24-h pretreatment could also allow full 
reaction of β-TCP and MCPM. The preconditioned discs were then placed into 
individual wells of 24 well tissue culture plates (Thermo Fisher Scientific, 
Loughborough, UK). 1 ml of MG-63 cell suspension (1 x 104 cells/ml) was then 
added to each well and incubated at 37 °C. 
 
To determine cell proliferation, after 3 days of culture, 100 μl of alamarBlueTM dye 
(see Appendix B for more information) was added to each well and incubated for 
a further 4-h period. Fluorescence measurements (excitation wavelength of 530 
nm and emission wavelength of 590 nm) were then made using a Fluroscan 
Ascent plate reader (Labsystems, Helsinki, Finland). Relative cell viability was 
calculated as the ratio of the fluorescence intensity of the reduced alamarBlueTM 
caused by the cells proliferating on the material surface compared with that by 
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the cells growing on the control ThermanoxTM plastic coverslips (NUNCTM, 
Thermo Fisher Scientific, Loughborough, UK), defined as 100%.  
 
In a parallel study, to observe cell and material surface morphology, after 3 days 
of incubation, the specimens were washed with phosphate buffered saline (PBS) 
and fixed using 3% (v/v) gluteraldehyde in 0.1 mol/l sodium cacodylate buffer for 
24 h. The specimens were finally dehydrated in a graded series of ethanol (50, 
70, 95 and 100% x 3) for 10 min each, immersed in hexamethyldisilazane for 2-3 
min, air-dried for 3 h, mounted and coated with gold/palladium (Polaron E5000 
sputter coater, Quorum Technologies, Sussex, UK). Cell and material surface 
morphology was then examined by scanning electron microscopy (SEM, JEOL 
JSM-5410LV, Tokyo, Japan) at an accelerating voltage of 15 kV. Concurrently, 
elemental analysis of the crystal precipitation on different material surfaces was 
determined using energy dispersive X-ray analysis (EDAX, Inca 300, Oxford 
Instruments, UK) combined with SEM. The average P/Ca ratio of the precipitated 
crystals was obtained from 10 readings. 
 
B. In vivo biocompatibility 
The in vivo biocompatibility of the set materials was evaluated using a chick 
embryo chorioallantoic membrane (CAM) model (see Appendix B for more 
information) as previously described (Groessnerschreiber et al. 1992). The 
composite formulation with F = 50%, T/M =1 and Md = 30 μm was selected for 
this test due to its high phosphate and calcium release and buffering capacity 
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(see section 3.3.5). Additionally, its fluidity facilitates the production of thin films 
as required for this test. The fully polymerised composite films (100 μm thick) 
were cut into strips (4 mm long, 1 mm wide) and sterilised using 70% ethanol for 
1 min prior to implantation.  
 
Femurs were isolated from fertilised eggs (J.K. Needle and Co., Herts, UK) after 
14 days of incubation at 39 ºC. Soft tissue was removed from the femur and a 
small defect (up to the bone marrow cavity and 4 mm long) was made manually 
with a tip of a needle (25G, BD Microlance, Benelux, Belgium) in the middle of 
the femur. The periosteum was only disrupted at the defect site. The films were 
implanted sagittally and gently tapped with forceps into the prepared defect so 
that the surface of the film and the femur were level. The femur and film was then 
placed onto the CAM of a 7 day old host egg which had previously been 
‘windowed’ at day 3 (Andacht et al. 2004). The windows were sealed with tape 
and the host eggs incubated at 39 ºC for a further 7 days. Two non-implanted 
femurs (control) and four test femurs with a strip in each were placed in the host 
eggs (two femurs per egg).  
 
After 7 days, the femurs were collected and fixed with 4% paraformaldehyde for 
24 h, washed with PBS prior to dehydration in ascending concentrations of 
ethanol (70 x 2, 95 and 100% x 2, each concentration for 1 h), then cleared in 
xylene for 1 h (x 2) and finally embedded in wax for 80 min. Transverse 8 μm 
sections were cut, placed on a glass slide and heated on a hotplate at 60 ºC for 
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10 min to fix the tissue to the glass slide. The samples were then immersed in 
xylene for 5 min (x 2) to remove wax and rehydrated in descending ethanol 
concentrations (100 x 2 and 50%, each concentration for 1 min) and water (1 min) 
and stained with 1% toluidine blue for 1 min.  
 
The slides were then washed with water, dried with blotting paper, immersed in 
100% ethanol for 10 s, xylene for 10 s and mounted with cover glass using DPX 
mounting medium.  
 
To determine any gross cytotoxicity due to the contact between the implant and 
the CAM, two composite strips were placed directly onto the CAM of a 7 day old 
host egg (one strip per egg), and incubated at 39 ºC for a further 7 days. Images 
were finally captured using a Leica DFC320 digital camera attached to a Leica 
MZ75 binocular microscope (Leica AG, Heerbrugg, Switzerland). 
 
The in vivo study was performed with assistance of Dr. Paul Buxton and was 
approved under the UK Home Office Animals (Scientific Procedures) Act 1986. 
 
3.2.3. Statistical evaluation 
The statistical significance of differences between the polymer and the 
composites in various material properties was evaluated using one-way ANOVA. 
If the values of a property were homogeneously distributed, the Bonferroni post 
hoc test would be used. Data were evaluated using SPSS 14.0 for Windows 
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(SPSS, Inc., Chicago, Ill., USA). The results were expressed as means ± SD, 
and p values <0.05 were considered statistically significant. 
 
3.2.4. Factorial analysis 
Factorial analysis (see details in Appendix C) was used in this study to assess 
the effect of the three variables (F%, T/M and Md) on different material properties 
(P in Eq. 3.8) including photo-polymerisation, compressive modulus, degradation, 
phosphate and calcium release, pH compensation ability and in vitro 
biocompatibility. An appropriate factorial expression in this case would be (Ho 
and Young 2006;Young and Ho 2008): 
dMT/MF%
aaalnPlnP                                                                                3.8                                                  
where <lnP> is the average value of lnP for all 8 possible formulation 
combinations excluding the intermediate formulation (see Table 3.1 for details).  
The intermediate formulation is used to check the validity of Eq. 3.8. When Eq. 
3.8 is valid, the P of intermediate formulation should equal to the geometric mean 
of P of all 8 formulations. ai indicates the level of an effect that a variable (e.g., 
F%) has on a material property (e.g, polymerisation rate). A positive ‘a value’ 
means that the property increases with increasing variable and vice versa for 
negative ai. Higher values of ai
 indicate greater effects of the variable on a 
property. ai for each term was determined using: 
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a                                                                                                        3.9 
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where PH and PL are the geometric means of a property of all samples with the 
variable, e.g., F%, at its high (H) (e.g., 70%) and low level (L) (e.g., 50%) 
respectively. Values of ai were determined in triplicate, and results expressed as 
means ± SD.  
 
3.3. Results  
The unset composites with F% = 50 and 60% were fluid whereas formulations 
with F% = 70% were thicker and ‘paste-like’ (did not spread when placed on a flat 
surface).  
 
3.3.1. Polymerisation kinetics  
In all samples, polymerisation began almost immediately when the curing light 
was turned on (see example in Fig. 3.1). The average polymer polymerisation 
rate was 1.6 %/s (Table 3.1). The average composite polymerisation rate was 1.7 
%/s for composites with F% = 50% (CF50, i.e., formulations 6-9), 1.6 %/s for CF60 
(formulation 5) and 0.9 %/s for CF70 (formulations 1-4), respectively (Table 3.1). 
There was no significant difference in polymerisation rate between the polymer 
and the CF50 or CF60 but high F% (i.e., F% = 70%) resulted in significantly slower 
polymerisation rate (p<0.05). For all samples, over 85% of the monomer could be 
converted after light curing for 120 s and 100% degree of monomer conversion 
(i.e. full polymerisation) could be achieved within 200 s (see example in Fig. 3.1). 
Factorial analysis confirmed that the polymerisation rate was affected strongly 
and only by F%, with higher F% leading to slower polymerisation rate (Table 3.2). 
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Fig. 3.1. Example polymer and composite monomer conversion versus 
time. ○ polymer, Δ F% = 50%, T/M =1, Md = 30 µm, ▲ F% = 70%, T/M =1, Md = 
30 µm.  The results demonstrate the decline in rate (gradient of the linear 
region of the plot between 20 and 60% conversion) with higher filler 
content. 
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Table 3.1. Polymerisation rate, compressive modulus, initial water content and final material loss of 
composites and polymer.  
E0 E24 -∆E24 Ef w m Formulations F% 
(%) 
T/M Md 
(μm) 
q 
(%/s) (MPa) (MPa) (%) (MPa) (%) (%) 
1 70 4 90 0.9±0.2* 27 ± 4* 9 ± 1* 67 ± 3* 7 ± 1* 10±1* 4±1 
2 70 4 30 1.0±0.2* 21 ± 4*  10 ± 1* 52 ± 7* 8 ± 1* 10±1* 4±1 
3 70 1  90 0.9±0.2* 21 ± 4*    7 ± 1 67 ± 9* 6 ± 1* 16±1*    12±1* 
4 70 1 30 0.9±0.2* 27 ± 3*    8 ± 1 70 ± 8* 7 ± 1* 15±1*    12±1* 
5 60 2 60   1.6±0.2 15 ± 1* 9 ± 1* 40 ± 4* 6 ± 1* 11±1*   6±1* 
6 50 4 90   1.7±0.3 12 ± 2* 9 ± 1* 33 ± 4* 5 ± 1*    6±1* 4±1 
7 50 4 30   1.6±0.3 15 ± 1*  10 ± 1* 33 ± 3* 7 ± 1*    6±1* 4±1 
8 50 1 90   1.6±0.3 12 ± 2*    7 ± 1 42 ± 5* 5 ± 1* 10±1*   9±1* 
C
o
m
p
o
s
ite
s 
9 50 1 30   1.7±0.3 14 ± 3*    8 ± 1 43 ± 9* 6 ± 1* 10±1*   10±1* 
Polymer   1.6±0.3     9 ± 4    7 ± 1 9 ± 4  3 ± 1    3±1 3±1 
F% (filler content), T/M (molar ratio of β-TCP to MCPM) and Md (MCPM particle size) are three variables involved in the composite 
filler factorial design. With three variables (F%, T/M and Md), each at two levels, high (e.g. F%=70%) and low (e.g. F%=50%), plus 
one intermediate level (e.g. F%=60%), there are nine formulations. Formulation 5 is defined as intermediate formulation (a 
formulation with all variables (i.e., F%, T/M and Md) at their intermediate level (i.e., 60%, 2 and 30 μm respectively). q = 
polymerisation rate; E0 = initial dry compressive modulus prior to immersion in water; E24 = compressive modulus after 24 h of 
immersion in water; -∆E24 = reduction in modulus after 24 h of water immersion relative to the original dry compressive modulus; Ef 
= final wet compressive modulus after 10 weeks of immersion in water; w = water content of specimens after 24 h of immersion in 
water (see Eq. 3.6); m = final material loss at 12 weeks (see Eq. 3.7). Results = means ± SD (n=3). * significant differences (p<0.05) 
from the control values (i.e. polymer).The best results are marked in bold. 
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Table 3.2. ‘a terms’ demonstrating the effect of filler variables on properties 
of composite materials. 
Filler variable 
Material property  
aF% aT/M aMd 
Polymerisation rate -0.3±0.1 - - 
Initial dry compressive modulus 0.3±0.1 - - 
Reduction in modulus after 24 h of water immersion  0.2±0.1   -0.1±0.04 - 
Initial water content 0.3±0.1 -0.3±0.1 - 
Final material loss   0.1±0.04 -0.5±0.1 - 
PO4
3- release at 24 h 0.3±0.1 -0.6±0.1 0.1±0.05 
Long-term PO4
3- release 0.7±0.1 -0.5±0.1 - 
Ca2+ release at 24 h   0.1±0.02 -0.5±0.1 0.2±0.1 
Long-term Ca2+ release  0.6±0.1 -0.3±0.1 - 
pH of storage solution between 2 and 24 h   -0.1±0.04 0.1±0.05 - 
pH of storage solution between 24 h and 12 weeks 0.1±0.1 -0.1±0.02 - 
Relative cell viability   0.1±0.04   0.3±0.1 - 
F% (filler content), T/M (molar ratio of β-TCP to MCPM) and Md (MCPM particle size) are 
three variables involved in the filler design. The results shown are ‘a values’ calculated using 
Eq. 3.9. Results = means ± SD (n=3). The magnitude of the ‘a’ value and its sign indicate the 
size and direction of the effect of each variable on a material property. A positive ‘a value’ 
means that the property increases with increasing variable and vice versa for negative ‘a’. 
Higher values of ‘a’ indicate greater effects of the variable on a property. ‘-’ means the effect 
of a variable on a property is negligible.  
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3.3.2. Chemical changes before and after water immersion 
3.3.2.1. Raman  
A. Average Raman spectra 
No characteristic ‘C=C’ peak at 1640 cm-1 was observed in any of the polymer 
and composite Raman spectra, consistent with full monomer conversion after 
light exposure. Inorganic Raman peaks were easier to distinguish in composites 
with higher filler content and, due to the relatively small areas (100 x 100 μm) 
examined, more reproducible with smaller MCPM particle size. The major factor 
affecting changes in the average Raman spectra with time was T/M.    
 
I. Formulations with excess β-TCP 
With T/M = 4, β-TCP peaks (main peaks at 945, 970 and 1045 cm-1) dominated 
the average Raman spectra before (0 h) and after specimen immersion in water 
for 24 h and 12 weeks (see example in Fig. 3.2.A). MCPM (main peaks at 903, 
915 and 1108 cm-1) was just observable in the 0-h Raman spectra but not 
detectable in the 24-h and 12-week Raman spectra. Peaks due to dicalcium 
phosphate (DCP, in its hydrated brushite or anhydrous monetite form) were, 
however, difficult to detect in the 24-h and 12-week Raman spectra although 
small regions of DCP could be observed in the Raman maps (see section 
3.3.2.1.B). Raman spectra of polymer, β-TCP, MCPM, brushite and monetite 
standards are shown in Fig. 3.2.C. 
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Fig. 3.2. Raman spectra of an example composite with F% = 70%, T/M = 4 
and Md = 30 μm (A) and an example composite with F% = 70%, T/M = 1 
and Md = 30 μm (B) before (0 h) and after 24-h and 12-week immersion in 
water. ◊ polymer, ○ β-TCP, □ MCPM, ● dicalcium phosphate, i.e., 
hydrated brushite or anhydrous monetite. C: Raman spectra of 
standards including the set polymer, β-TCP, MCPM, brushite and 
monetite.  Note the absence of MCPM and presence of dicalcium 
phosphate after composite (T/M=1) immersion in water for 24 h. 
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ii. Formulations with equimolar β-TCP and MCPM 
Conversely, with equimolar β-TCP and MCPM (T/M=1), peaks in the average 
Raman spectra due to both β-TCP and MCPM could readily be detected in 
dry samples (see example in Fig. 3.2.B). Following 24-h water immersion, the 
β-TCP peak intensity reduced dramatically and MCPM peaks vanished. A 
peak at 980 cm-1 attributed to DCP could be observed. In the following 12 
weeks little change occurred in the level of β-TCP but the level of DCP was 
markedly reduced.  
 
The above results have demonstrated that β-TCP and MCPM had reacted 
and precipitated as DCP, i.e., brushite and monetite in 24 h, with higher initial 
MCPM amount resulting in greater DCP formation. The resultant DCP had 
largely dissolved into the sample storage solution after 12 weeks.     
 
B. Raman maps  
In Raman maps, different colours indicate different chemical components. 
When the components are well separated on the micron scale the area 
occupied by a given colour provides an indication of the amount of the 
component the colour represents. Raman maps also provide information 
regarding the dimensions of each chemical component. 
 
I. Formulations with excess β-TCP 
Before specimen immersion in water, the β-TCP (red) and MCPM (pink) were 
dispersed throughout the fully polymerised polymer (blue) and were readily 
distinguishable in the Raman maps (see example in Fig. 3.3.A.i).  The area 
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occupied by β-TCP was larger than that by MCPM as expected, with the 
particles size of β-TCP smaller than that of MCPM. 
 
After 24-h storage in water, the β-TCP was still clearly distinguished but the 
MCPM was not detectable. Additional small areas representing DCP (green), 
brushite and monetite, were present (see example in Fig. 3.3.A.ii).  
 
After 12-week water immersion, β-TCP was still the major calcium phosphate 
remaining in the samples but the area occupied by DCP was reduced (see 
example in Fig. 3.3.A.iii).  
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Fig. 3.3. Raman maps of representative composite A: F% = 70%, T/M = 4 
and Md = 30 μm and B: F% = 70%, T/M = 1 and Md = 30 μm before (0 h, i) 
and after 24-h (ii) and 12-week (iii) water immersion. Blue stands for 
polymer, red for β-TCP, pink for MCPM, green for dicalcium phosphate, 
i.e., brushite and monetite. Scale bars = 5 μm. Note the absence of 
MCPM and presence of dicalcium phosphate after composite immersion 
in water for 24 h. 
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II. Formulations with equimolar β-TCP and MCPM 
Before the specimen immersion in water, the β-TCP (red) and MCPM (pink) 
were dispersed throughout the fully polymerised polymer (blue) and were 
readily distinguishable in the Raman maps (see example in Fig. 3.3.B.i).  
 
After 24-h immersion in water, the area occupied by β-TCP decreased 
noticeably and the MCPM had vanished (see example in Fig. 3.3.B.ii). 
Instead, large amounts of small particles identified as DCP (green) had 
appeared.  
 
After 12-week water immersion, β-TCP was the major calcium phosphate 
remaining in the samples. The area indicative of DCP was reduced compared 
with that in the 24-h Raman maps (see example in Fig. 3.3.B.iii).  
 
The Raman spectra and Raman maps exhibited consistent results although 
both the average Raman spectra and the Raman maps could not distinguish 
brushite from monetite clearly because of the overlap of their peaks (see Fig. 
3.2.C, compare brushite and monetite peaks). However, brushite and 
monetite could be distinguished by comparison of each of the point spectrum 
in a Raman map with the brushite and monetite standards. 
 
3.3.2.2. X-ray diffraction (XRD) 
XRD studies were consistent with the Raman data but additionally enabled 
brushite and monetite to be more readily quantified and distinguished. 
Moreover, XRD spectra could be more representative as the examination 
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covered the whole specimen surface whereas Raman maps only covered 
small areas (100 x 100 μm). 
 
A. Formulations with excess β-TCP 
As expected, XRD spectra of the dry formulations were dominated by β-TCP 
(main peaks at 27.9, 31.2 and 34.5 º2θ) and MCPM (main peaks at 23 and 
24.3 º2θ) was just detectable (see example in Fig. 3.4.A). After 24-h 
immersion in deionised water, the β-TCP peaks remained but the MCPM 
peaks disappeared. Brushite (main peaks at 12, 21 and 29.4 °2θ) and 
monetite (main peaks at 26.7 and 30.3 º2θ) became visible in the spectra. 
After the specimens were placed in water for 12 weeks, β-TCP and monetite 
peaks remained but brushite peaks vanished. XRD spectra of standards of β-
TCP, MCPM, brushite and monetite are shown in Fig. 3.4.C.  
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Fig. 3.4. XRD spectra of an example composite with F% = 70%, T/M = 4 
and Md = 30 μm (A) and an example composite with F% = 70%, T/M = 1 
and Md = 30 μm (B) before (0 h) and after 24-h and 12-week immersion in 
water. ○ β-TCP, □ MCPM, ■ brushite, ● monetite. C: XRD spectra of 
standards including β-TCP, MCPM, brushite and monetite. Note the 
absence of MCPM and presence of brushite and monetite after 
composite immersion in water for 24 h. 
 
B. Formulations with equimolar β-TCP and MCPM 
β-TCP and MCPM could both be readily detectable in dry samples (see 
example in Fig. 3.4.B). After 24-h sample immersion in water, the MCPM 
peaks had vanished and additional peaks due to brushite and monetite 
became clearly visible. After 12-week specimen immersion in water, β-TCP 
and monetite peaks remained but the brushite peaks declined greatly. 
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Presence of different calcium phosphates in all formulations before and after 
24-h or 12-week water immersion is summarised in Table 3.3. 
 
3.3.3. Compressive modulus 
The average initial dry, 1-day wet and final 70-day wet modulus of the 
polymer was 9, 7 and 3 MPa respectively (Table 3.1). In general, composites 
exhibited significantly higher modulus than the polymer (p<0.05) (Table 3.1, 
Fig. 3.5). The initial dry modulus of CF70, CF60 and CF50 was 21 - 27, 14 - 16 
and 12 - 15 MPa respectively. After 1 day in water, the modulus of all 
composite samples decreased dramatically and was between 6 and 11 MPa. 
By 70 days, the composite modulus was further reduced to 4 - 9 MPa. 
 
Fig. 3.5. Fig. 3.5. Compressive modulus of polymer and composites with 
time after immersion in water. ○polymer, □ F% = 50%, T/M =4, Δ 
F%=50%, T/M =1, ■ F% = 70%, T/M =4, ▲F% = 70%, T/M =1.  Note the 
reduction in modulus (arrows) after 1 day of water immersion. 
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Table 3.3. Summary of filler components before (0 h) and after 24-h and 12-week water immersion. 
Composites 0h 24 h 12 weeks 
F% (%) T/M Md (μm) β-TCP MCPM β-TCP brushite monetite β-TCP brushite monetite 
70 4 90 S W S W W S - W 
70 4 30 S W S W W S - W 
70 1 90 S S S S S S W S 
70 1 30 S S S S S S W S 
60 2 60 S W S W W S - W 
50 4 90 S W S W W S - W 
50 4 30 S W S W W S - W 
50 1 90 S S S S S S W S 
50 1 30 S S S S S S W S 
F% (filler content), T/M (molar ratio of β-TCP to MCPM) and Md (MCPM particle size) are three variables involved in the composite filler 
factorial design. S/W means respectively strong and weak peak intensity of a calcium phosphate component in XRD spectra; ‘-’= not 
detectable. 
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Factorial analysis showed that the initial dry compressive modulus was 
dependant primarily on F%, with higher F% leading to greater modulus (Table 
3.2). Additionally, reduction in modulus after immersion in water for 24 h was 
affected mostly by F% but additionally by T/M (Table 3.2). Increase in F% and 
decrease in T/M (i.e., higher MCPM content in fillers) resulted in greater 
reduction in modulus after water immersion.  
 
3.3.4. Hydrolytic degradation 
Polymer exhibited small and comparable mass (3%) and volume (3%) 
increase during the initial 24 h of water immersion (Fig. 3.6). All composite 
discs increased rapidly in mass during the initial 24 h of water submersion, but 
more so in volume (compare Fig. 3.6.A and B). Composites with F% = 50% 
and T/M = 4 (■) exhibited least mass (approximately 6%) and volume 
(approximately 13%) change whereas those with F% = 70% and T/M =1 (▲) 
showed greatest mass (approximately 18%) and volume (approximately 35%) 
increase (Fig. 3.6).  
 
Regarding the initial water content (see Eq. 3.6), factorial analysis showed 
that this property was affected strongly by F% and T/M (Table 3.2). Increase 
in F% and decrease in T/M (i.e. increase in hydrophilic MCPM content in the 
specimens) encouraged greater water sorption. Composites with F% = 70%, 
T/M=1 (formulations 3 and 4) exhibited maximum initial water content, ~ 16%, 
followed by F% = 50%, T/M=1 (formulations 8 and 9), F% = 60%, T/M=2 
(formulation 5) and F% = 70%, T/M=4 (formulations 1 and 2), ~ 10%, and last 
came F% = 50%, T/M=4 (formulations 6 and 7), ~ 6% (Table 3.1). All 
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composites exhibited significantly higher initial water content compared to 
polymer (p<0.05). 
 
Between 24 h and 10 weeks, a slight decrease in polymer and composite 
mass and a lesser reduction in volume (compared to mass decrease) were 
generally observed (Fig. 3.7, compare A and B), indicative of combined bulk 
and surface erosion during hydrolytic degradation.  
 
Regarding the final material loss (see Eq. 3.7), factorial analysis established 
that this property was affected mostly by T/M but additionally by F% (Table 
3.2). Decrease in T/M and increase in F% (i.e., higher MCPM content in fillers) 
resulted in greater final material loss. Composites with T/M=1 (CT/M1, i.e., 
formulations 3, 4, 8 and 9) exhibited maximum final mass loss, ~ 12%, 
followed by CT/M2 (formulation 5), ~ 6%, and CT/M4 (formulations 1, 2, 6 and 7), 
~ 4% (Table 3.1). CT/M1 or CT/M2 exhibited significantly higher final material loss 
than that of polymer (p<0.05).  
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Fig. 3.6. Initial mass (A) and volume (B) change with time of polymer and 
composites after immersion in water. ○ polymer, □ F% = 50%, T/M =4, Δ 
F%=50%, T/M =1, X F% = 60%, T/M =2, ■ F% = 70%, T/M =4, ▲F% = 70%, 
T/M =1. 
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Fig. 3.7. Mass (A) and volume (B) change with time of polymer and 
composites after immersion in water. ○ polymer, □ F% = 50%, T/M =4, Δ 
F%=50%, T/M =1, X F% = 60%, T/M =2, ■ F% = 70%, T/M =4, ▲F% = 70%, 
T/M =1. Note the fast initial increase in mass and volume after one day 
(arrows) of water immersion and slow slight changes afterwards. 
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3.3.5. Ion and acid release      
3.3.5.1. Phosphate and calcium ion release 
The phosphate release profiles exhibited burst release in the first 24 h and 
then the release rate declined with time (Fig. 3.8.A). The phosphate release 
rate of different formulations increased in the order: F% = 50%, T/M =4 (□) < 
F% = 70%, T/M =4 (■) < F% = 60%, T/M = 2 (x) < F% = 50%, T/M =1 (Δ) < 
F% = 70%, T/M =1 (▲). At 24 h, the cumulative phosphate release was 
between 1 and 7% (Table 3.4). At 12 weeks, the cumulative phosphate 
release was between 7 and 23%. The phosphate release after 24 h was linear 
with square root (SQRT) of time (R2 > 0.95, Fig. 3.8.B), indicating a diffusion-
controlled release mechanism.  
 
Factorial analysis has demonstrated that the initial 24-h phosphate release 
was affected mostly by F% and T/M, with Md having much smaller effects 
(Table 3.2). Increase in F% and decrease in T/M, led to an increase in initial 
phosphate release. Moreover, with larger MCPM particle size more phosphate 
was found to be released. The long-term ion release (see release constant K 
in Table 3.4) was also enhanced upon increase in F% and decrease in T/M 
(i.e. upon raising the level of MCPM in the composite formulations) (Table 
3.2). 
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Fig. 3.8. Cumulative phosphate release from different composite 
formulations as a function of time (A) and square root (SQRT) of time 
(B). □ F% = 50%, T/M =4, ■ F% = 70%, T/M =4, X F% = 60%, T/M =2, Δ 
F%=50%, T/M =1, ▲F% = 70%, T/M =1. Note that the phosphate release 
after 1 day is more linear with SQRT of time than that with time.  
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Table 3.4. PO4
3- and Ca2+ release; pH of storage solution; viability of cells proliferating on composite and polymer 
surfaces. 
        Formulations PO4
3- release Ca2+ release Average pH 
 F% 
(%) 
T/M 
 
Md 
(μm) 
24 h  
(%) 
12 weeks 
(%) 
KPO4 
(%/day0.5) 
24 h  
(%) 
12 weeks 
(%) 
KCa 
(%/day0.5) 
2 – 
24 h 
24 h – 12 
weeks 
Relative cell 
viability 
 (%) 
70 4 90 1.8 ± 0.1 10.5 ± 0.1 1.1 ± 0.1 0.9 ± 0.0 3.6 ± 0.8 0.3 ± 0.1 4.3* 5.4* 87±10* 
70 4 30 1.6 ± 0.1 10.3 ± 0.3 1.1 ± 0.1 0.8 ± 0.1 3.9 ± 0.4 0.4 ± 0.1 4.2* 5.5* 85±10* 
70 1 90 5.9 ± 0.0 21.7 ± 0.7 1.9 ± 0.1 2.6 ± 0.0 7.8 ± 0.6 0.6 ± 0.2 3.5* 5.7*        44±4* 
70 1 30 6.3 ± 0.2 19.4 ± 0.5 1.6 ±0. 3 2.4 ±0.2 7.3± 0.4 0.6 ± 0.1 3.5* 5.7*        46±7* 
60 2 60 2.5 ± 0.2 11.9 ± 0.3 1.1 ± 0.1 1.2 ± 0.0  5.8 ± 0.1 0.6 ± 0.1 4.0* 5.3*        50±7* 
50 4 90 1.1 ± 0.2  8.2 ± 0.8 0.9 ± 0.1 1.2 ± 0.1 3.7 ± 0.2 0.3 ± 0.1 4.2* 4.6*        69±3 
50 4 30 1.1 ± 0.0  8.0 ± 0.5 0.8 ± 0.1 0.6 ± 0.0 3.6 ± 0.8 0.4 ± 0.1 4.3* 4.6*        70±4 
50 1 90 3.4 ± 0.2 16.5 ± 0.2 1.4 ± 0.1 3.2 ± 0.1 8.5 ± 0.6 0.6 ± 0.1 3.7* 5.4*        44±4* 
C
o
m
p
o
si
te
s 
50 1 30 2.5 ± 0.3 14.0 ± 0.0 1.4 ± 0.1 1.8 ± 0.1 6.4 ± 0.1 0.6 ± 0.1 4.0* 5.5*        42±4* 
Polymer N/A N/A N/A N/A N/A N/A 5.5 4.0        66±5 
F% = filler content; T/M = molar ratio of β-TCP to MCPM; Md = MCPM particle size. KPO4 and KCa are the gradient of the curve of ‘cumulative 
percentage of phosphate or calcium release versus SQRT of time’ between 24 h (1 day0.5) and 12 weeks (9.2 day0.5). Relative cell viability was 
determined as the ratio of the fluorescence intensity of the reduced alamarBlueTM caused by the cells proliferating on the material surfaces 
with that by the cells growing on ThermanoxTM plastic coverslips. * significant differences (p<0.05) from control values (i.e., polymer). The best 
results are marked in bold. 
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The calcium release with time showed a similar profile to that of phosphate 
release (i.e. burst release in the initial 24 h and reduced release afterwards) 
and the release rate of different formulations increased with decrease in T/M 
(Fig. 3.9.A). Cumulative calcium release at 24 h and 12 weeks was 
respectively 0.6 ~ 3.3 and 3 ~ 9%, between one third and half of percentage 
phosphate release (Table 3.4). The calcium release after 24 h was linear with 
SQRT of time (R2 > 0.95, Fig. 3.9.B), suggesting a diffusion-controlled release 
mechanism.  
 
Factorial analysis has demonstrated that the initial 24-h calcium release was 
affected mostly by T/M, with F% and Md having much smaller effects (Table 
3.2). Decrease in T/M led to an increase in intial calcium ion release. 
Moreover, with higher filler content and larger MCPM particle size more 
calcium was found to be released. In addition, the long-term calcium release 
(see release constant K in Table 3.4) was enhanced upon increase in F% and 
decrease in T/M (i.e. upon raising the level of MCPM in the composite 
formulations) (Table 3.2). 
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Fig. 3.9. Cumulative calcium release from different composite formulations 
as a function of time (A) and SQRT of time (B). □ F% = 50%, T/M =4, ■ F% = 
70%, T/M =4, X F% = 60%, T/M =2, Δ F%=50%, T/M =1, ▲F% = 70%, T/M =1. 
Note that the calcium release after 1 day is more linear with SQRT of time 
than that with time.  
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3.3.5.2. Acid release 
The pH of the polymer storage solution decreased to an average value of 5.5 in 
the first 2 - 24 h and then remained at approximately 4.0 for the following 12 
weeks (Table 3.4). The polymer storage solution in the initial 2 – 24 h exhibited 
higher pH than that of all composites (p<0.05). However, for the following 12 
weeks, the pH of the polymer storage solution was significantly lower than that of 
all composites (p<0.05).   
 
The average pH of the first 2 - 24 h storage solutions for composites was lowest 
for formulations with the highest amount of MCPM (i.e. high F% and low T/M), 
being 3.5 with F% = 70% and T/M = 1 but between 3.7 and 4.3 for all other 
formulations (Table 3.4). Conversely, the average pH in the remaining 12-week 
period, was lowest for the formulations with least MCPM (i.e. low F% and high 
T/M) being 4.6 with F% =50% and T/M =4 but between 5.3 and 5.7 for all other 
formulations.  
 
Factorial analysis demonstrated that initial storage solution pH was significantly 
affected by both F% and T/M. Decrease in F% and increase in T/M (i.e. reduction 
in MCPM amount of each specimen) resulted in higher early pH (Table 3.2). 
Conversely, the long-term storage solution pH was increased upon increase in 
F% and decrease in T/M (i.e. increase in MCPM amount of each specimen) 
(Table 3.2). 
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These above findings have suggested that, in the long term, less acid was 
released from the composites than polymer, although more acid was released 
from the composites in the initial 2 – 24 h. In addition, in the long term, 
formulations with higher levels of MCPM were more effective at buffering acid 
produced during polymer degradation, compared to the formulations with lower 
levels of MCPM.  
  
3.3.6. Biocompatibility 
3.3.6.1. In vitro biocompatibility   
After 3 days of incubation, the MG-63 cells were found to be spread on the 
surfaces of the control ThermanoxTM plastic coverslips (flat surface) as well as all 
other material surfaces although those attached to the ThermanoxTM appeared to 
have the most pronounced cytoplasmic processes (Fig. 3.10.A-D). The polymer 
had a flat smooth surface appearance whereas that of the composites was 
granular.  Moreover, needle-like crystal precipitation was observed on some 
areas of the surfaces of the composites with T/M =1.  The MG-63 cells appeared 
able to spread over both these crystals and the underlying composite (Fig. 
3.10.E). Elemental analysis has shown that the average atomic ratio of P/Ca of 
these precipitated crystals was 0.97:1, being close to 1.0. This suggests that the 
crystals were DCP (i.e., brushite and/or monetite). 
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Fig. 3.10. SEM images of 3-day MG-63 cell proliferation on different material 
surfaces. A: a ThermanoxTM plastic coverslip; B: a polymer; C: a composite 
with F% = 70%, T/M = 4 and Md = 30 μm; D: a composite with F% = 70%, T/M 
= 1 and Md = 30 μm; E: crystal precipitation (arrows) on the surface of a 
composite with F% = 70%, T/M = 1 and Md = 30 μm.  
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The viability of cells after 3 days of incubation on the polymer and composite 
surfaces were found to be between approximately 40 and 90% of that on the 
control ThermanoxTM plastic coverslips (Table 3.4). Cell viability on the sample 
surfaces increased in the order: F% = 70% and T/M =1, F% = 50% and T/M =1, 
F% = 60% and T/M =2 < F% = 50% and T/M =4, polymer < F% = 70% and T/M = 
4 (Table 3.4).  
 
Factorial analysis showed that the cell viability was affected most by T/M but 
additionally by F% (Table 3.2). Increase in T/M and F% (i.e., higher β-TCP 
content of composites) resulted in greater number of cells proliferating on the 
composite surfaces.  
 
3.3.6.2. In vivo biocompatibility 
After 7 days of incubation, all chick femurs implanted with or without a composite 
film were found to be embedded in the CAM, with blood vessels surrounding the 
femur. The sample femurs with the implants appeared to have comparable cross-
sectional diameter and anatomic structure with the control samples with no 
implant (compare Fig. 3.11.B and A). The bone marrow, trabecular bone, 
periosteal tissue and the implant could all be readily identified. The implants 
appeared to be in close proximity to the bone, with no indication of immunological 
reaction, e.g., no noticeable accumulation of leucocytes, as shown by higher 
magnification in Fig. 3.11.C. Bone adjacent to the implant site appeared 
histologically normal. 
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Fig. 3.11. Histology of toluidine blue stained cross-sections of chick 
embryo femurs without (A) and with (B) implantation with a composite film 
with F% = 50%, T/M = 1 and Md = 30 μm. CAM: chorioallantoic membrane; B:  
bone marrow; T: trabecular bone; PS: periosteal tissue; F: implant. Note 
that the implant appeared to be in close proximity (arrows) to the bone (C). 
Scale bars: 100 µm.  
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In addition, the CAM response to the composite material, as shown in Fig. 3.12, 
has indicated that blood vessels appeared to be passing in close proximity to the 
implant, with no evidence of vessel haemorrhage in the region of the grafted 
material.  
 
Fig. 3.12. CAM response to the implanted composite material. CAM: 
chorioallantoic membrane; F: composite implant. Note the absence of 
negative reaction (e.g., vessel haemorrhage) in the region of the grafted 
material and the presence of blood vessels (arrows) passing in close 
proximity to the implant. Scale bars: 1mm. 
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3.4. Discussion  
In this study, the effect of calcium phosphate filler addition on material 
polymerisation, water-induced chemical changes, compressive modulus, 
hydrolytic degradation, ion release, acid release, and in vitro biocompatibility was 
quantified using factorial analysis. Additionally, in vivo biocompatibility, i.e., bone 
tissue response of a chick embryonic femur to a set composite implant was 
assessed.  
 
3.4.1. Effect of filler addition on polymerisation  
For all formulations, over 85% monomer conversion could be obtained with 120 s 
of blue light irradiation, although higher F% (i.e., 70%) led to slower 
polymerisation rate.  This is likely due to the increased scattering of the initiating 
blue light by the high level of filler particles. Nevertheless, Raman confirmed that 
the adhesive monomer could be fully polymerised in the presence of calcium 
phosphate fillers. The level of monomer conversion is greater than normally 
observed in acrylates or methacrylates under comparable conditions (Sideridou 
et al. 2002), possibly because of the low glass transition temperature of the initial 
monomer, which would prevent the vitrification that limits final polymerisation 
(Bohner et al. 2005;Ho and Young 2006). Such rapid and complete photo-
polymerisation is highly desirable as this may allow immediate material bonding 
to the surrounding tissues after injection and limit the release of reactive and 
potentially toxic double bond-containing components during degradation (Ho and 
Young 2006). 
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3.4.2. Effect of filler addition on water induced chemical changes  
Raman with XRD proved that water sorption could catalyse conversion of β-TCP 
and MCPM to DCP, i.e., brushite and monetite within 24 h inside the crosslinked 
polymer. The primary chemical composition of the calcium phosphates after 24-h 
water immersion, DCP or β-TCP, was dependant on T/M. The ratio of produced 
DCP to β-TCP decreased in the order T/M = 1 > T/M = 2 > T/M = 4 as expected. 
In addition, the remaining β-TCP at T/M =1 after 24 h of water immersion has 
suggested that MCPM was partially reacted and partially dissolved into the 
surrounding storage solution prior to reaction, leading to the reduction of pH of 
the storage solution (see section 3.4.6 for details). In future study, to allow full 
reaction of β-TCP, higher molar ratio of MCPM to β-TCP (i.e., > 1) could be 
employed. 
 
Additionally, the relative amount of DCP (particularly brushite) to polymer 
decreased whereas the amount of β-TCP to polymer kept almost constant during 
long-term water immersion. This was probably due to the higher solubility of DCP 
than β-TCP (solubility product constant (Ksp) at 25 ˚C of brushite, monetite and 
β-TCP = 2.59 x 10-7, 1 x 10-7 and 2.07 x 10-33 respectively (Elliott 1994)). This 
result was consistent with the higher phosphate and calcium release from 
specimens with T/M =1 (high DCP formation) compared to specimens with T/M = 
2 or 4 (low DCP formation). The formation of DCP may be beneficial since the 
resultant DCP fillers generated higher phosphate and calcium release associated 
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with higher pH compensation ability (see section 3.4.5 and 3.4.6 for more 
details).  
 
3.4.3. Effect of filler addition on material modulus 
The addition of calcium phosphate particles enhanced the dry compressive 
modulus of the polymer by up to three fold. The level of mechanical 
reinforcement depended mainly on the amount of added filler. During the first 24 
h of water immersion, composite modulus decreased far more than that of 
polymer. This was consistent with higher initial MCPM amount and thus higher 
water content after 24 h water immersion of the composites. The water present in 
the composites could act as a plasticiser, leading to swelling of the material and 
reduction in the material modulus (Sideridou et al. 2003).  
 
The modulus of the composites declined continuously but only very slightly over 
the remaining 10 weeks. The maintenance of modulus suggests the potential for 
long-term functional support. The dissolution of calcium phosphates within the 
polymer may contribute to the modulus maintenance via ‘salt-bridge’ or ionic 
bond formation within the composite during the course of degradation. When the 
polymer degrades, carboxylic acid groups are produced and the salt-bridges start 
to form between the carboxyl groups on polymer fragments and calcium cations 
from the calcium phosphate (this may explain the result of slower release of Ca2+ 
than PO4
3-). This could produce ‘an ionomer’ whose ionic crosslinks combined 
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with partially degraded polymer networks, result in maintenance of compressive 
modulus (Chung et al. 2003;Peter et al. 1999;Xie et al. 2007).  
 
The modulus of the composites obtained (10 ~ 30 MPa) was lower than that of 
human trabecular bone (20 ~ 500 MPa) (Agrawal and Athanasiou 1997;Bergsma 
et al. 1995). Such materials with low modulus could, however, be used as 
temporary bone adhesives for infiltration or stabilisation of, for example, 
osteoporotic bone that has become brittle due to the loss of collagen (Yaszemski 
et al. 1995). As new bone grows progressively against the receding surface of 
the degrading material, and eventually integrates and replaces the material, the 
temporarily formed ‘bone-material’ might be expected to have increased modulus 
compared with the implant material alone.  
 
3.4.4. Effect of filler addition on hydrolytic degradation 
It was found that adjustment of material degradation rate can be achieved by 
manipulating the composition of added calcium phosphates. Specimens with T/M 
=1 showed higher degradation rate compared to those with T/M = 4, probably 
due to the formation of more DCP whose solubility is higher than β-TCP (see 
section 3.4.2). In order to accelerate further the material degradation, higher 
molar ratio of MCPM to β-TCP (i.e., > 1) could be employed due to the higher 
solubility of MCPM and their reaction products (i.e., brushite and monetite). 
Moreover, dissolved MCPM is slightly acidic.  This acidity might catalyse the 
polymer hydrolytic degradation (Walton and Cotton 2007).  
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In addition, generally, composites exhibited faster degradation rates than the 
polymer. This is considered to be an improvement over the polymer (only 3% 
material loss in 12 weeks) although the maximum degradation of composites 
(12% in 12 weeks) may not be fast enough for use as bone adhesives. However, 
the actual material degradation rate in vivo may be faster than in vitro  because 
of possible additional enzymatic cleavage which may occur in vivo (Hou et al. 
2004).  Further studies of the in vivo degradation of these materials are required 
to determine whether the materials meet the previously suggested optimal in vivo 
degradation rate (complete degradation in 12 weeks) (Walton and Cotton 2007). 
 
Degradation products of the composite materials are presumably, calcium and 
phosphate ions or particles (from the inorganic phase) and, polyethers, 
monomeric and oligomeric lactic acid, and oligo (methacylic acid) (from the 
organic phase). These degradation fragments are considereded to be of low 
toxicity and can be excreted directly or after entry and exit from various metabolic 
pathways  (Sawhney et al. 1993). 
 
3.4.5. Effect of filler addition on ion release 
Composites with T/M =1 generated higher phosphate and calcium release than 
those with excess β-TCP. This may be because the formulations with T/M =1 had 
more resultant soluble DCP in the specimens whereas the formulations with T/M 
= 2 or 4 had more less soluble β-TCP in the specimens (see section 3.4.2 for 
details). The ability to release phosphate and calcium ions may be beneficial in 
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aiding bone re-mineralisation and regeneration, as these ions have shown to 
stimulate osteogenic differentiation (Ripamonti 1996). In addition, through a 
dissolution–precipitation process, a bone-like mineral layer could develop, 
leading to new bone formation initiated by the presence of osteogenic 
compounds in body fluids (e.g., bone morphogenetic proteins). Furthermore, the 
released ions could nucleate in the pores of bone collagen fibrils, resulting in 
increased mineralisation along the fibrils (Glimcher 1989). 
 
The composites provided burst release of PO4
3- and Ca2+ in the initial 24-h 
immersion in deionised water. This could be explained by largely dissolution of 
the fillers, particularly the MCPM, which has a higher solubility than β-TCP (Ksp at 
25˚C of MCPM and β-TCP is 7.18 x 10-2 and 2.07 x 10-33 respectively (Elliott 
1994).  
 
The burst PO4
3- and Ca2+ release was then followed by a substantial decline in 
the release rate for the remaining experimental period. The ratio of PO4
3- to Ca2+ 
release (KPO4/KCa = 2 ~ 3, see Table 3.4) suggested that the phosphate and 
calcium elements might be released in the form of Ca(H2PO4)2 with possibly 
some phosphoric acid (H3PO4). In the presence of water, ion exchange with the 
produced brushite or monetite could neutralise the acidic polymeric fragments 
forming monocalcium phosphate via the following reaction: 
2 RCOOH + 2 CaHPO4(s) → (RCOO
-)2Ca
2+(aq) + Ca2+(H2PO4
-)2(aq)             3.10     
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The CaHPO4  ‘mops up’ acidic protons (from degraded polymer) upon forming 
Ca(H2PO4)2 and as a result, the solution would be buffered (Korrenhof and 
Timmer 1992). When there is excessive acid, CaHPO4 will not be sufficient to 
‘mop up’ the acidic protons and thus phosphoric acid will be formed. This 
neutralisation of polymer degradation products, i.e., control of pH, may be 
beneficial in reducing irritation to any tissues surrounding the implanted material. 
It could also reduce the possibility of sudden catastrophic core degradation of the 
material caused by acid build-up (Sabir et al. 2009).  
 
3.4.6. Effect of filler addition on acid release 
The initial pH drop with the composite specimens in the first 24 h might be 
attributed to the release of acidic MCPM. The initial burst acid release may not 
present a serious problem in vivo, because of the rapid and continuous 
circulation of body fluid as well as the high buffering capacity of serum (Mabilleau 
et al. 2004). The higher pH of the composite storage solution than polymer at 
later times indicated a buffering effect by the calcium phosphates (see Eq. 3.10 in 
section 3.4.5). This buffering effect was more pronounced for the formulations 
with T/M =1, compared to those with T/M = 2 or 4. This may be because the 
specimens with T/M =1 had higher amount of more soluble DCP and thus 
released more PO4
3- to buffer the acidic polymer degradation products. However, 
the specimens with T/M = 2 or 4 had more β-TCP with lower solubility, and had 
released less PO4
3- and thus provided less sufficient pH compensation.  
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The results of ion release as well as pH of the storage solution found above have 
suggested that the fillers (particularly when T/M = 1) could provide release of 
phosphate and calcium ions that may both aid bone regeneration and 
simultaneously, at least partly, buffer the released acidic polymer degradation 
products. Additionally, the overall final amount of released acids and organic 
degradation products would be reduced by raising the filler level, as the fraction 
of polymer is lower.  
 
3.4.7. Effect of filler addition on in vitro biocompatibility 
The in vitro biocompatibility test indicated that bone-like MG-63 cells could attach 
and spread on both the polymer and composite surfaces, with an apparently 
normal morphology despite the different surface nature of the polymer (smooth) 
and composites (granular). Composites with higher β-TCP content resulted in 
greater number of cells proliferating on their surfaces compared to those with 
higher MCPM content. This may be because the surfaces of the formulations with 
higher β-TCP content are more stable due to the less soluble β-TCP. Those with 
higher MCPM may be more dynamic.   
 
In addition, precipitation of DCP crystals was observed on the surfaces of the 
formulations with T/M =1. MG-63 cells were found to be able to adhere to these 
crystals. Phosphate and calcium ion release from the material surface may cause 
over saturation in the culture medium, inducing the nucleation and growth of DCP 
crystals at the material-medium interface. This dissolution and reprecipitation of 
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calcium phosphate crystals might have superior properties for the stimulation of 
bone formation and bone bonding, by development of a bone-like mineral layer 
on the material surface (Barrere et al. 2006).  
 
3.4.8. In vivo biocompatibility 
The formulation of F% = 50%, T/M =1 and Md = 30 µm was selected for the in 
vivo test due to its fluidity (spread when placed on a flat surface), high phosphate 
and calcium release and buffering capacity. When composite films of this 
formulation were implanted into the chick embryo femurs, they exhibited close 
contact with the adjacent bone, with no indication of adverse immunological 
reaction. In addition, the response of the CAM to the implant itself did not indicate 
any detectable vessel hemorrhage in the region of the grafted material, and 
apparently normal blood vessels could be seen passing under the implant and in 
close proximity to it. These observations have indicated that the implanted 
composite material was unlikely to have been toxic to normal bone in vivo, and 
suggested that such materials could have potential for clinical application as 
bone adhesives.  
 
3.5. Conclusion 
The injectable degradable composite materials investigated in this study are 
elastic, release phosphate and calcium ions, buffer acid production and appear to 
be biocompatible. Increase in the amount of calcium phosphate fillers 
(irrespective of β-TCP or MCPM) resulted in enhanced compressive modulus of 
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the dry materials although all composites exhibited a comparable modulus after 
water immersion. Composites with an equal molar ratio of β-TCP and MCPM 
(T/M =1) formed relatively more dicalcium phosphate, i.e., brushite and monetite 
after 24 h of water immersion, released higher levels of phosphate and calcium 
ions and were thus more capable of buffering acid production than those with 
excess β-TCP. All formulations tested were found to be biocompatible by the 
procedure used here.  
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Abbreviations 
In alphabetical order 
CHX chlorhexidine 
CQ camphorquinone 
DCP 
DMPT 
dicalcium phosphate 
N,N-dimethyl-p-toluidine 
F% 
FTIR 
filler content 
Fourier transform infrared 
HEMA hydroxyethyl methacrylate 
MCPM 
Md  
monocalcium phosphate monohydrate 
MCPM particle size 
MRSA-16 methicillin-resistant Staphylococcus aureus -16  
PGLA-DMA poly (propylene glycol -co- lactide) dimethacrylate 
S. aureus Staphylococcus aureus 
SA 8325-4 S. aureus 8325-4 
SD standard deviation 
SQRT 
TCP 
T/M 
square root 
tricalcium phosphate 
molar ratio of β-TCP/MCPM 
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4.1. Introduction 
In Chapter 3, reactive calcium phosphate particles of β-tricalcium phosphate (β-
TCP) and monocalcium phosphate monohydrate (MCPM) (powder components 
of brushite – forming bone cements (Bohner 2007)) have been added to the 
synthetic poly (propylene glycol-co-lactide) dimethacrylate (PGLA-DMA) to 
produce composite bone adhesives (used to connect fractured bone) (Zhao et al. 
2010). The filler of β-TCP and MCPM has been found to react and re-precipitate 
as dicalcium phosphate (DCP, brushite and monetite) upon water sorption. 
Modulus of the polymer was found to be enhaced upon addition of calcium 
phosphate fillers. Additionally, dissolution of the resultant DCP was found to 
generate phosphate and calcium ions that may aid bone re-mineralisation, with 
concomitant neutralisation of acidic degradation products. Importantly, these 
composite materials have been shown to be biocompatiblie with bone cells. 
Furthermore, after implantation into chick embryo femurs, the composite 
adhesives have been shown to be in close contact with the adjacent bone, with 
no indication of adverse immunological reaction. 
 
The above findings have suggested that the composite materials developed in 
this project have potential clinical value as bone adhesives. Nevertheless, when 
such medical implants are used in bone fractures or as external fixation devices, 
bacterial infection caused by Staphylococcus aureus (S. aureus) are commonly 
associated (Mandal et al. 2002;Nair et al. 2000). As a result, the service life of 
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such medical implants would be reduced, which may prevent effective wound 
healing processes to take place (Mourino and Boccaccini 2009).  
 
Thus controlled release of an antibacterial drug from these medical implants 
would be of substantial clinical value in limiting bacterial infection (Young and Ho 
2008). As previously reported, S. aureus bacteria are generally highly susceptible 
to the antibacterial chlorhexidine (CHX, see molecular structure in Fig. 4.1) 
(Nascimento et al. 2008). This drug has been found to have very low incidence of 
resistance development (Harris et al. 2006) and minimal toxicity to host cells (Lee 
et al. 2005;Leung et al. 2005;Nerurkar et al. 1995;Riggs et al. 2000). Extensive 
testing has been performed with both topical application of CHX over prolonged 
periods and internal use of CHX (Dejong et al. 2001). For example, it has been 
incorporated into bone adhesives and has been shown to successfully prevent 
bacterial adhesion to the implants, without significant toxicity (Dejong et al.  
2001;Harris et al. 2006). Moreover, CHX has Food and Drug Administration 
approval for human use when applied to internally placed medical devices, 
including intravenous catheters (Maki et al. 1997) and an implanted antimicrobial 
surgical mesh (Choe et al. 2000).   
 
Fig. 4.1. Molecular structure of CHX. 
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In this study, adhesives were prepared consisting of fluid PGLA-DMA filled with 
calcium phosphate fillers (a reactive mixture of β-TCP and MCPM) and loaded 
with the antibacterial CHX. The effect of the addition of CHX and filler was 
measured on several material properties, including polymerisation rate and 
degree of monomer conversion, water sorption and material degradation, water 
accelerated chemistry changes, CHX release kinetics and antibacterial activity. 
Parts of this work have been submitted to Journal of Materials Science: Materials 
in Medicine in Nov. 2010.  
 
4.2. Materials and methods 
4.2.1. Sample fabrication 
Fabrication of samples was described in Chapter 3, section 3.2.1. Briefly, the 
PGLA-DMA was mixed with camphorquinone (CQ), N,N-dimethyl-p-toluidine 
(DMPT) and hydroxyethyl methacrylate (HEMA). Varying levels of β-TCP and 
MCPM particles were then added in the monomer mixture. CHX (10 wt.% of the 
total mixture) was finally added to each formulation. Detailed composite 
formulations are listed in Table 4.1. Polymer and composite formulations without 
CHX were used as controls.  
 
Polymerised discs of 5 mm (for agar diffusion tests) or 12 mm diameter (for all 
other studies) and 2 mm thickness were obtained by placing the polymer and 
composite pastes into steel rings with top and bottom surfaces covered by 
acetate sheets, and curing using blue light in a light box. Raman spectroscopy 
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was used to confirm full polymerisation and the density of the set samples was 
measured using an electronic balance with a density kit to confirm negligible air 
incorporation. Each test was performed in triplicate, and results were expressed 
as means ± standard deviation (SD). Results shown were samples with CHX 
unless otherwise stated.  
 
4.2.2. Polymerisation kinetics  
Determination of the polymerisation rate and degree of monomer conversion of 
the CHX loaded polymer and composite discs was determined using the same 
method as previously described for non-CHX loaded discs (detailed in Chapter 3, 
section 3.2.2.1).  
 
Briefly, the unset materials were placed on a diamond top-plate within a Fourier 
transform infrared (FTIR) spectrometer, confined within a ring of 5 mm diameter 
and 2 mm depth and sealed with an acetate sheet. FTIR spectra were then 
generated continuously for 30 min after sample exposure to intensive blue light.  
 
The difference in FTIR absorbance at 1716 and 1736 cm-1 was recorded and the 
change between time t=0 and t calculated. This was divided by the maximum 
change between the beginning and end of the experiment to calculate the extent 
of the reaction at time t. Multiplication by the final percentage reaction then gave 
monomer conversion percentage at time t. This was determined using the height 
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of the Raman ‘C=C’ peak at 1640 cm-1 of each sample after light cure divided by 
that of the uncured pastes. 
 
Monomer conversion percentage (see Eq. 3.1 in Chapter 3) was then plotted 
versus light exposure time and the polymerisation rate (the gradient of the linear 
region of the plot between 20 and 60% conversion), was subsequently calculated 
and reported. 
 
4.2.3. Mass and volume change upon water sorption 
Determination of mass and volume change of specimens after immersion in 
water was described in Chapter 3, section 3.2.2.4.   
 
Briefly, the specimen discs were placed upright in the conical end of a Sterilin 
tube, containing 10 ml of neutral deionised water. After 0, 15 min, 2, 8, 24 h, 2, 7 
and 10 days and 3, 5, 6, 7, 8, 9 and 10 weeks at 37 °C, the specimen mass and 
density were measured prior to placement of samples in fresh storage solution.  
 
Percentage wet mass and volume change were calculated using the difference in 
results at time t compared with initial values then divided by the initial values 
times 100 (see Eq. 3.2– 5 in Chapter 3).  
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At the end of the study period, specimens were dried under vacuum to constant 
mass. The final water content (ΔMw) and the material mass loss (ΔM) were 
calculated using: 
100
W
MW
ΔMw
f
ff 

                                                                                           4.1 
where Wf and Mf are respectively the final wet and dry mass of the specimen. 
 
100
y)M-(1
MM-M
ΔM
0
df0 


                                                                                      4.2 
where M0 and Md are respectively the intitial dry mass of the specimen and mass 
of the released drug from that specimen. y is the initial mass fraction of CHX 
(i.e.10 wt.%). 
 
Specimens before and after 24 - h and 10 - week storage in water were used for 
Raman and XRD examination (detailed in section 4.2.5). The storage solution at 
each time point was used to determine the CHX concentration (detailed in 
section 4.2.6). The frequency of water change was selected to ensure the 
solubility limit of CHX (20 mg/ml) was not reached but that sufficient CHX was 
present for accurate determination by UV spectrometry (> 5 μg/ml) (Young and 
Ho 2008). To gain evidence for any anomalous effect arising due to MCPM/TCP 
reaction within the formulations, composite discs filled with 50, 60 and 70 wt.% 
brushite particles were used as additional controls in the CHX release studies. 
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4.2.4. Water sorption induced chemical changes 
Samples stored as above for 0, 24 h and 10 weeks in water were analysed using 
Raman and XRD to assess any chemical changes in the filler upon water 
sorption. The specimens were air dried at room temperature for 24 h prior to 
Raman and XRD examination.   
 
4.2.4.1. Raman 
Each specimen was cut vertically with a razor blade prior to analysis. Surfaces 
produced were then examined using a LabRam spectrometer (Horiba Jobin 
Yvon, Stanmore, UK) equipped with a 633 nm wavelength laser, x 50 objective 
lens and 1800 grating. Mean sample spectra were generated by averaging 15 
line Raman spectra. Each line spectrum was an average of 31 point spectra 
along a 150 µm line with step size of 5 µm. Exposure times for each single-point 
spectrum were 10 s and the accumulation number set at 6. The line spectrum 
was recorded every 100 µm from the top surface to the center of the specimen. 
Background subtraction was performed using Labspec software for each single 
point spectrum. The mean spectra were eventually normalised using the polymer 
‘CH’ peak at 1447 cm-1. The peak intensities due to other components then 
provide an indication of the level of that component relative to the polymer 
(Young et al. 2009; Mehdawi et al. 2009). 
 
In the following only those spectra of formulations with CHX are provided. 
Corresponding spectra of formulations without the drug are reported earlier (see 
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Chapter 3, section 3.3.2.1). Standard Raman spectra of the polymer, β-TCP, 
MCPM, brushite, monetite and CHX were also recorded for comparison. 
 
4.2.4.2. X-ray diffraction (XRD) spectroscopy 
XRD was additionally used to identify the presence of different chemical 
components in each specimen. XRD spectra of the 0-h, 24-h and 10-week 
specimens (transverse sections of specimen core) of different formulations were 
recorded as previously described (see details in Chapter 3, section 3.2.2.2.B). 
Peak assignment of different chemical components was performed using the 
International Centre for Diffraction Data database volumes 1 and spectra of 
starting chemicals of β-TCP, MCPM and CHX.  
 
4.2.5. In vitro chlorhexidine (CHX) release 
4.2.5.1. Quantification of drug release rate 
To quantify the rate of CHX release, UV absorbance spectra of the above sample 
storage solutions were measured between 200 and 350 nm at a scan speed of 
120 nm/min with spectral bandwidth of 2 nm and data interval of 1 nm using a 
Unicam UV 500 Thermospectronic® Spectrometer (Thermo Spectronic, 
Cambridge, UK). These were compared with solution spectra of pure CHX at 
concentrations of 5 to 50 μg/ml to obtain the CHX concentration in each sample 
(see Eq. 4.3). The CHX concentration was then converted to cumulative mass of 
CHX released from each specimen (see Eq. 4.4). The percentage of the released 
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CHX at time t was finally calculated as the ratio of the amount of released CHX at 
that time to the total amount of CHX in the original specimen, defined as 100%. 
'mu
k
A
m 





                                                                                                   4.3 

t
0
tmM
                                                                                                             4.4 
where m is the amount of released CHX at a given time t, A is the absorbance 
due to CHX at the wavelength of 254 nm, k is the gradient calculated from the 
calibration curve of ‘the CHX absorbance versus concentration’, u is a dilution 
factor, m’ is the mass of storage solution (i.e. 10 g), and M is the cumulative 
mass of the released CHX at anytime t.  
                                                                                            
One assumption of using these equations was that the absorbance at 254 nm 
due to impurities (e.g., degraded polymer) was negligible. This could be 
confirmed by the fact that the full UV spectrum matched that of the pure CHX 
(data not shown). The full UV spectrum could also provide some evidence for 
maintenance of the chemical structure of CHX after release.          
 
4.2.5.2. Evaluation of drug release mechanism 
To evaluate the CHX release mechanism, an empirical equation, proposed by 
Ritger and Peppas was used (see Eq. 4.5). This equation is popular for analysis 
of drug release from swelling/degradable tablets (Ritger et al. 1987a).  
nt kt
M
M

                                                                                                              4.5 
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where Mt is the amount of drug released at time t, and M∞ is the amount of drug 
released after infinite time; k is a constant incorporating structural and geometric 
characteristics of the discs, t is the release period and n is a diffusion exponent, 
indicative of the release mechanism. A ‘n’ value between 0.45 and 0.89 suggests 
anomalous transport (a coupling of diffusion and macromolecular relaxation 
mechanisms) in which there may be some influence of swelling and/or erosion 
(Ritger et al. 1987b).  
 
The release data from these systems are also often analysed as a function of the 
square root (SQRT) of time if drug release is governed by pure diffusion. 
However, the use of this relationship in swelling/degradable systems is not 
completely justified (Colombo et al. 2000). To quantify the contribution of 
diffusion and swelling/degradation mechanism, drug release data was also fitted 
in a binomial equation (see Eq. 4. 6), proposed by Young et al (Young and Ho 
2008): 
tktk
M
M
1
0.5
0.5
t 

                                                                                                 4.6 
where Mt again is the amount of drug released at time t, and M∞ is the amount of 
drug released after infinite time; k0.5 is the diffusion constant and k1 is the 
swelling/degradation constant respectively. A higher value of k1 / k0.5 indicates 
drug release versus time is more linear. 
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4.2.6. Antibacterial susceptibility assessment 
The antibacterial activity of the polymer and composites containing CHX was 
assessed by an agar diffusion assay (British Society for Antimicrobial 
Chemotherapy standardised disc susceptibility testing method (Andrews 2008)), 
using bacterial strains of S. aureus 8325-4 (SA 8325-4) and methicillin-resistant 
S. aureus -16 (MRSA-16). Briefly, the test bacterium was spread onto the surface 
of blood agar plates (Oxoid, Basingstoke, UK). Sample discs (5 mm diameter, 2 
mm thick) were then placed on top and the plates incubated at 37 ºC in a 5% 
CO2 atmosphere for 24 h. Diameters of inhibition zones (including specimens) 
were measured in three different directions using calipers.  
 
4.2.7. Statistical evaluation 
The statistical significance of differences between the formulations with and 
without CHX on various material properties including polymerisation rate, initial 
mass and volume change, final water content and material loss, was evaluated 
using one-way ANOVA with the Bonferroni post hoc test. Data were evaluated 
using SPSS 14.0 for Windows (SPSS, Inc., Chicago, Ill., USA). The results were 
expressed as means ± SD, and p values <0.05 were considered statistically 
significant. 
 
4.2.8. Factorial analysis 
Factorial analysis was used in this study to assess the effect of three variables 
(F%, T/M and Md) on different material properties of formulations containing CHX 
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(Ho and Young 2006;Mehdawi et al. 2009;Young and Ho 2008;Zhao et al. 2010). 
These material properties included polymerisation rate, initial mass and volume 
change, final water content, final material mass, CHX release at 10 day and 10 
weeks and antibacterial activity. 
 
The effect of each variable on a material property was expressed using ‘a values’ 
(see Eqs. 3.8 - 9 in Chapter 3). If error bars on ‘a’ values (means ± SD) do not 
cross zero, the variable has on average a significant effect on the property. A 
positive ‘a value’ means that the property increases with increasing variable and 
vice versa for a negative ‘a’. Higher values of ‘a’ indicate greater effects of the 
variable on a property. 
 
4.3. Results 
4.3.1. Effect of CHX and filler addition on polymerisation rate and degree of 
monomer conversion 
Polymerisation on the FTIR diamond began immediately upon turning on the high 
intensity curing light irrespective of formulation. For formulations with the same 
level of filler (see example in Fig. 4.2, circle or square), the curves of monomer 
conversion percentage versus light exposure time of formulations with CHX (filled 
symbols) overlapped with those without CHX (non-filled symbols). There was no 
significant difference in the polymerisation rate between the samples with and 
without CHX (Table 4.1).  
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Additionally, increasing the filler content from 50 wt.% to 70 wt.% resulted in 
slower polymerisation (see example in Fig. 4.2, compare circle and square) 
although adding filler to the polymer at a level of 50 or 60 wt.% had no 
measurable effect (Table 4.1). The average polymerisation rate was found to be 
1.7 %/s for polymer, 1.6 %/s for composites with F% = 50 % (i.e. composite 
formulations 6-9 in Table 4.1), 1.5 %/s for composites with F% = 60 % (i.e. 
composite formulation 5 in Table 4.1), and 0.9 %/s for composites with F% = 70% 
(i.e. composite formulations 1-4 in Table 4.1) (Table 4.1). According to factorial 
analysis, the only variable which significantly affected the polymerisation rate was 
the filler content, F%, and the polymerisation rate was reduced with increase in 
F% (Table 4.2). 
 
For all samples, over 85% of the monomer was polymerised following 120 s of 
blue light exposure and 100% monomer conversion was observed by 200 s (see 
example in Fig. 4.2). This result established that the final degree of monomer 
conversion was not affected by CHX and filler addition.  
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Fig. 4.2. Percentage monomer conversion with time of representative 
composite formulations. The results demonstrate the lack of effect of CHX 
but decline in rate (gradient of the linear region of the plot between 20 and 
60% conversion) with higher filler content. ● and ○ F% = 50%, T/M =4, Md = 
30 µm with and without CHX respectively; ■ and □ F% = 70%, T/M =4, Md = 
30 µm with and without CHX respectively. 
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Table 4.1. Polymerisation rate, initial mass and volume change, final water content and material loss of composites 
and polymer. 
Polymerisation rate 
(%/s) 
Initial mass change 
at 24 h (%) 
Initial volume 
change at 24 h (%) 
Final water content 
at 10 weeks (%) 
Final material loss 
at 10 weeks (%) 
 
 
F% 
(%) 
T/
M 
Md 
(µm) 
- CHX  + CHX - CHX  + CHX - CHX  + CHX - CHX  + CHX - CHX  + CHX 
1 70 4 90 0.9±0.2 0.9±0.2     12±1 13±1* 20±1 24±1* 11±1 20±1* 4±1 4±1 
2 70 4 30 1.0±0.2 0.9±0.2     11±1 12±1* 20±1 22±1* 11±1 19±1* 4±1 4±1 
3 70 1 90 0.9±0.2 1.0±0.2  19±1 20±1* 35±1 39±1* 20±1 40±2* 10±1   10±1 
4 70 1 30 0.9±0.2 0.9±0.2  18±1     21±1* 34±1 37±1* 21±1 33±2* 10±1 9±1 
5 60 2 60 1.5±0.3 1.5±0.3  10±1 12±1* 18±1 21±1* 13±1 19±2* 6±1 6±1 
6 50 4 90 1.7±0.3 1.6±0.3     6±1 8±1* 8±1 14±1* 8±1 15±1* 4±1 4±1 
7 50 4 30 1.6±0.3 1.5±0.3   6±1 7±1* 10±1 12±1* 9±1 12±1* 4±1 4±1 
8 50 1 90 1.6±0.3 1.6±0.3 8±1 12±1* 15±2 18±1* 14±1 23±1* 8±1 10±1 
C
o
m
p
o
s
ite
s 
9 50 1 30 1.7±0.3 1.6±0.3 10±1 10±1 13±1 14±1 15±1 20±2* 9±1 10±1 
Polymer 1.6±0.3 1.6±0.3 2±1 5±1*     3±1 5±1*     3±1    8±1*     3±1 4+1 
F% (filler content), T/M (molar ratio of β-TCP to MCPM) and Md (MCPM particle size) are three variables involved in the composite filler factorial 
design. With three variables (F%, T/M and Md), each at two levels, high (e.g. F%=70%) and low (e.g. F%=50%), plus one intermediate level (e.g. 
F%=60%), there are nine formulations. Formulation 5 is defined as intermediate formulation in this study. ‘-’ and ‘+’ stand for formulations without 
and with CHX respectively. Results = means ± SD (n=3). * significant differences (p<0.05) from control values (formulations without CHX). The 
best results are marked in bold.  
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Table 4.2. ‘a terms’ demonstrating the effect of filler variables on properties of CHX – containing materials 
Inhibition zone sizes   Polymerisation 
rate 
Initial mass 
change 
Initial volume 
change 
Final water 
content 
Final 
material loss 
CHX release 
at 10 days 
CHX release 
at 10 weeks SA 8325-4 MRSA-16 
aF%  -0.3±0.02 0.3±0.1 0.4±0.1 0.2±0.1 - 0.3±0.01 0.2±0.01 0.1±0.04 0.1±0.1 
aT/M -  -0.2±0.01   -0.2±0.01 -0.3±0.1 -0.4±0.1 - - - - 
aMd - 0.1±0.01  0.1±0.02  0.1±0.04 - - - - - 
F% (filler content), T/M (molar ratio of β-TCP to MCPM) and Md (MCPM particle size) are three variables involved in the filler design. The results 
shown are ‘a values’ calculated using Eq 3.8 – 9 (see Chapter 3, section 3.2.4). Results = means ± SD (n=3). The magnitude of the ‘a’ value and 
its sign indicate the size and direction of the effect of each variable on a material property. A positive ‘a value’ means that the property increases 
with increasing variable and vice versa for a negative ‘a’. Higher values of ‘a’ indicate greater effects of the variable on a property. ‘-‘ means the 
effect of a variable on a property is negligible.  
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4.3.2. Effect of CHX and filler addition on water induced mass and volume 
change 
Polymer and composites with CHX showed higher initial mass and volume change 
compared to the control formulations without CHX (p<0.05, see Table 4.1). This 
result demonstrated that addition of CHX significantly raised the initial mass and 
volume change of polymer and composites. The drug addition also significantly 
raised the final water content (p<0.05, see Table 4.1), but had no measurable 
effect on the final material loss of either the polymer or the composites (Table 4.1).  
 
Polymer exhibited small and comparable mass (5±1%) and volume (5±1%) 
increase during the initial 24 h of water immersion (Table 4.1). All composite discs 
increased rapidly in mass (see example in Fig. 4.3.A) during the initial 24 h of 
water submersion, but more so in volume (see example in Fig. 4.3.B). 
Formulations with F% = 50% and T/M = 4 (i.e. composite formulations 6 and 7 in 
Table 4.1) exhibited minimum mass (approximately 7%) and volume 
(approximately 13%) change whereas those with F% = 70% and T/M =1 (i.e. 
composite formulations 3 and 4 in Table 4.1) showed maximum mass 
(approximately 20%) and volume (approximately 38%) increase (Table 4.1). 
Factorial analysis showed that the initial mass and volume change was affected 
strongly by F% and T/M, but less so by Md (Table 4.2). Increase in F% and 
decrease in T/M (i.e. increase in MCPM content in the specimens), as well as 
increase in Md, encouraged greater water sorption and thus mass and volume 
increase.  
Chapter 4                                                                                            Drug delivery 
 160 
-2
3
8
13
18
23
0 0.2 0.4 0.6 0.8 1
Time (days)
M
a
s
s
 c
h
a
n
g
e
 (
%
)
 
A 
-5
0
5
10
15
20
25
30
35
40
45
0 0.2 0.4 0.6 0.8 1
Time (days)
V
o
lu
m
e
 c
h
a
n
g
e
 (
%
)
 
B 
Fig. 4.3. Initial mass (A) and volume (B) change with time of polymer and 
composites with CHX after immersion in water. ○ polymer; □ and ▫ F% = 50%, 
T/M = 4, Md = 90 and 30 µm respectively; Δ and △ F% = 50%, T/M =1, Md = 90 
and 30 µm; x F% = 60%, T/M = 2, Md = 60 µm; ■ and ▪ F% = 70%, T/M =4, Md = 
90 and 30 µm;▲and ▲ F% = 70%, T/M =1, Md = 90 and 30 µm. 
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Between 24 h and 10 weeks, a slight decrease in polymer and composite mass 
and less reduction in volume (compared to mass decrease) were generally 
observed (Fig. 4.4, compare A and B), indicative of combined bulk and surface 
erosion during the hydrolytic degradation.  
 
Factorial analysis has shown that the final water content was affected strongly by 
F% and T/M, but less so by Md (Table 4.2). Increase in F%, decrease in T/M and 
increase in Md, resulted in higher final water content.  
 
Regarding the final material loss, factorial analysis established that varying the 
F% or the Md had no substantial effect on this property (Table 4.2). However, a 
decrease in T/M significantly enhanced final material loss. Composites with 
T/M=1 (i.e. composite formulations 3, 4, 8 and 9 in Table 4.1) exhibited maximum 
final mass loss ~ 10%, followed by composites with T/M=2 (composite 
formulation 5 in Table 4.1, ~ 6%) and composites with T/M=4 (composite 
formulations 1, 2, 6 and 7, ~ 4%). Composites with T/M=4 exhibited comparable 
mass loss to the polymer (Table 4.1).  
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Fig. 4.4. Mass (A) and volume (B) change with time of polymer and composites with 
CHX after immersion in water. ○ polymer; □ and ▫ F% = 50%, T/M =4, Md = 90 and 30 
µm respectively; Δ and △ F% = 50%, T/M =1, Md = 90 and 30 µm; x F% = 60%, T/M = 
2, Md = 60 µm; ■ and ▪ F% = 70%, T/M =4, Md = 90 and 30 µm;▲and ▲ F% = 70%, T/M 
=1, Md = 90 and 30 µm. Note the fast initial increase (arrows) in mass and volume 
after one day of water immersion and slow slight changes afterwards. 
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4.3.3. Effect of CHX and filler addition on water accelerated chemical 
changes 
4.3.3.1. Raman 
In general, no characteristic ‘C=C’ peak at 1640 cm-1 was observed in any of the 
polymer and composite Raman spectra (see example in Fig. 4.5), consistent with 
full monomer conversion during light exposure. By comparison with the standard 
CHX spectrum, no shift of characteristic CHX peaks were observed before and 
after photo-polymerisation and upon 24 - h or 10 - week storage in water (data 
not shown), indicative of maintenance of CHX chemical structure after light 
exposure and water storage respectively.  
 
The major factor affecting changes in the average Raman spectra with time was 
CHX and T/M.  
 
With T/M=1 (see for example Fig. 4.5.A), β-TCP (main peaks at 945, 970 and 
1045 cm-1), MCPM (main peaks at 903, 915 and 1108 cm-1) and CHX (main 
peaks at 1093, 1298 and 1600 cm-1) were readily detectable (see Raman spectra 
of standards of single element in Fig. 4.5.C). Following 24-h water immersion, the 
MCPM peaks vanished. The peaks of β-TCP and CHX were substantially 
reduced, and a peak at 980 cm-1, assigned to DCP (mixture of brushite and 
monetite) appeared. The brushite peak was more intense for those formulations 
containing CHX. In the absence of CHX, spectra were consistent with greater 
monetite formation (see Chapter 3, section 3.3.2.1). In the 10-week specimens, 
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little change occurred in the level of β-TCP whereas DCP and CHX peak 
intensity were both markedly reduced. 
 
Conversely, with excess β-TCP (particularly T/M=4, see for example Fig, 4.4.B), 
peaks due to β-TCP dominated the average Raman spectra at all times. The 
MCPM peaks vanished after 24-h water immersion. A small shoulder at 980 cm-1 
attributed to DCP could be observed in both 24-h and 10-week spectra. CHX 
peaks were easily detectable in the 0 and 24-h specimens but less obvious in the 
10-week specimen. In summary, excluding any peaks associated with CHX, 
Raman spectra with and without drug were comparable when β-TCP was in 
excess. 
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Fig. 4.5. A and B: Raman spectra of an example composite with F% = 70 %, 
T/M = 1 and Md = 30 μm and an example composite with F% = 70 %, T/M = 4 
and Md = 30 μm before (0 h) and after 24-h and 10-week immersion in water. 
◊ polymer, ○ β-TCP, □ MCPM, Δ CHX, ● dicalcium phosphate (mixture of 
brushite and monetite). C: Raman spectra of standards including the set 
polymer, β-TCP, MCPM, brushite, monetite and CHX. Note the absence of 
MCPM and presence of dicalcium phosphate after composite immersion in 
water for 24 h. 
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4.3.3.2. XRD 
In all specimen XRD spectra, CHX was not detectable at the concentration of 10 
wt.%. Before water immersion, β-TCP (peaks at 27.9, 31.2 and 34.5 º2θ) and 
MCPM (peaks at 23 and 24.3 º2θ) were clearly observed with formulations with 
T/M = 1 or 2 (see for example Fig.4.5.A) but less pronounced with T/M = 4 (see 
for example Fig.4.5.B). XRD spectra of standards are shown in Fig. 4.6.C.  
 
After 24-h water immersion, the β-TCP peak intensity was reduced with T/M =1 
or 2 (see for example Fig.4.5.A) but remained intense when β-TCP was in 
excess (particularly T/M =4) (see for example Fig. 4.6.B). MCPM was not 
detectable in any 24-h XRD spectra. Intense peaks at 12, 21 and 29.4 º2θ 
indicating brushite and peaks at 26.7 and 30.3 º2θ, identified as monetite, were 
apparent if T/M =1 or 2 but just detectable with T/M = 4. With T/M =1 or 2, the 
brushite peak was more intense for the formulations containing CHX. In the 
absence of CHX, spectra were instead consistent with greater monetite formation 
(see Chapter 3, section 3.3.2.2). With T/M = 4, brushite peak intensity was not 
significantly affected by CHX addition.  
 
After 10-week water immersion, β-TCP was readily detectable in all specimen 
XRD spectra, particularly with T/M = 4. Brushite vanished in any specimen XRD 
spectra. Monetite was readily visible with T/M=1 or 2 (see for example Fig. 4.6.A) 
but less clear with T/M = 4 (see for example Fig. 4.6.B).  
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The above Raman and XRD analysis are consistent with the formation of 
brushite and monetite in 24 h as a result of the reaction of β-TCP and MCPM. It 
was also found that the CHX addition raised the formation of brushite over 
monetite particularly when composites had T/M =1 or 2. In the formulations with 
T/M = 4, the effect of CHX addition was not measurable. During long-term water 
immersion, any produced brushite has largely dissolved into the storage solution. 
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Fig. 4.6. A and B: XRD spectra of an example composite with F% = 70%, 
T/M = 1 and Md = 30 μm and an example composite with F% = 70%, T/M = 4 
and Md = 30 μm before (0 h) and after 24-h and 10-week immersion in water. 
○ β-TCP, □ MCPM, ■ brushite, ● monetite. CHX could not be detected in all 
specimen XRD spectra. C: XRD spectra of standards including β-TCP, 
MCPM, brushite, monetite and CHX. Note the absence of MCPM and 
presence of brushite and monetite after composite immersion in water for 
24 h. 
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4.3.4. Effect of filler addition on CHX release  
UV spectra of sample storage solutions exhibited identical profiles to those of 
pure CHX solutions, indicating that the CHX was released without any obvious 
change in chemical structure (data not shown). CHX was released faster in the 
initial 10 days and then the release rate declined with time (Fig. 4.7). CHX 
release rate increased in the order: polymer < composites with F% = 50% (CF50) 
< CF60 < CF70 (Fig. 4.7). At 10 days, the average cumulative CHX release was 14, 
26, 42, and 52% of the original CHX when the filler content increased from 0, 50, 
60 to 70 wt.%, respectively. At 10 weeks, the average cumulative CHX release 
from polymer, CF50, CF60, and CF70 was 43, 57, 66 and 77%, respectively (Table 
4.3). Factorial analysis demonstrated that F% was the only factor having a 
significant effect on CHX release rate (at 10 days or 10 weeks, Table 4.2), with 
CHX release enhanced by raising F%.  
 
For control formulations with brushite fillers, the released CHX at 10 days and 10 
weeks, respectively, was 23 and 51% for CF50, 26 and 59% for CF60, and 35 and 
66% for CF70 (Table 4.3). Like composites with β-TCP and MCPM fillers, CHX 
release rate from control formulations with brushite fillers increased in the order: 
polymer < CF50 < CF60 < CF70 (Fig. 4.7). In addition, in general, composites filled 
with β-TCP and MCPM exhibited significantly higher CHX release than the 
composites filled with brushite (p<0.05) at corresponding F% (Fig. 4.7). 
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The above results have demonstrated that CHX release was enhanced with 
raised F% (regardless of filler composition of β-TCP and MCPM or brushite) and 
with reactive filler of β-TCP and MCPM (compared to brushite filler).  
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Fig. 4.7. CHX release versus time from polymer (o), composites filled with 
brushite at  50 (Δ), 60 (◊) and 70 wt.% (□) and composites filled with reactive 
β-TCP and MCPM at 50 (▲), 60 (♦) and 70 wt.% (■). This figure demonstrates 
the enhancement of CHX release with raised filler content and with reactive 
filler of β-TCP and MCPM.  
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Table 4.3. CHX release at 10 days and 10 weeks; results of fitting the CHX release data to Eq s 4.5 and 6; inhibition 
zone sizes against SA 8325-4 and MRSA-16.  
Formulations Inhibition zone diameter 
(mm)  F% 
(%) 
T/M 
 
Md 
(µm) 
10 day CHX 
release (%) 
10 week CHX 
release (%) 
k n k0.5 
(%/day0.5) 
k1 
(%/day) 
k1/ k0.5 
(day-0.5) 
SA 8325-4 MRSA-16 
70 4 90 54 ± 1 75 ± 1 16 0.52 23 -1.8 -0.08 141 131 
70 4 30 50 ± 5 81 ± 5 16 0.51 23 -2.0 -0.09 141 131 
70 1 90 53 ± 2 74 ± 1 18 0.49 23 -1.9 -0.08 131 111 
70 1 30 50 ± 5 77± 5 17 0.46 21 -1.6 -0.08 151 131 
60 2 60 42 ± 1 66 ±3  13  0.51 16  -1.0 -0.06  121 111 
50 4 90 27 ± 1 59 ± 2 7 0.53  10    -0.39 -0.04 121 111 
50 4 30 24 ± 1 58 ± 1 6 0.54 8  -0.28 -0.03 121 111 
50 1 90 28 ± 1 58 ± 1 8 0.50 10    -0.44 -0.04 121 111 R
e
a
c
tiv
e
 β
-T
C
P
 a
n
d
 
50 1 30 26 ± 3 54 ± 1 7 0.51 9    -0.34 -0.04 121 101 
70 N/A N/A 35 ± 2 66 ± 2 9 0.49 11    -0.37 -0.03 N/A N/A 
60 N/A N/A 26 ± 2 59 ± 2 7 0.53 8    -0.09 -0.01 N/A N/A 
B
ru
sh
ite
50 N/A N/A 23 ± 2 51 ± 2 6 0.52 7    -0.14 -0.02 N/A N/A 
Polymer 14 ± 2 43 ± 2 4     0.53 3     0.26 0.87     111 101 
F% (filler content), T/M (molar ratio of β-TCP to MCPM) and Md (MCPM particle size) are three variables involved in the factorial design. k is a 
drug release rate constant incorporating structural and geometric characteristics of the specimen and n is a diffusion exponent; k and n were 
obtained by fitting the CHX release data to Eq. 4.5 (fitting range corresponded to release% < 60%); n value between 0.45 and 0.89 suggests a 
release mechanism by diffusion and macromolecular relaxation. k0.5 is a diffusion constant and k1 is a swelling/degradation constant, both of 
which were determined by fitting the CHX release data to Eq. 4.6 (fitting range corresponded to release% < 60%); A higher value of k1 / k0.5 
indicates more linear drug release. Inhibition zone diameter was measured including the specimen (5 mm diameter). Results = means ± SD (n=3). 
The best results are marked in bold 
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To evaluate the CHX release mechanism, the CHX release data was plotted 
versus SQRT of time. The plot of CHX release versus SQRT of time was more 
linear than that versus time (compare Fig. 4.8 and 4.7), as expected for a 
diffusion-controlled process. For all formulations, the gradients of the curves 
(CHX release percentage versus SQRT of time) were almost constant at any 
time points when the release percentage was less than 60% but these gradients 
decreased when the release percentage was larger than 60%.  
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Fig. 4.8. CHX release versus square root (SQRT) of time from polymer (o), 
composites filled with brushite at 50 (Δ), 60 (◊) and 70 wt.% (□) and 
composites filled with reactive β-TCP and MCPM at 50 (▲), 60 (♦) and 70 
wt.% (■). Note that the CHX release percentage is more linear with SQRT of 
time than that with time (compare Fig. 4.7). 
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The release data were then fitted in Eqs. 4.5 and 6 to further investigate the 
release mechanism. Eq. 4.5 could fit drug release data up to 60% with all R2 
values greater than 0.99. Composites with reactive β-TCP and MCPM or brushite 
fillers, with higher F% generated faster CHX release (higher k value, Table 4.3). 
The diffusion exponent n ranged between 0.46 – 0.54 for all formulations, 
indicative of a coupling of diffusion and swelling/erosion mechanism according to 
Peppas (Ritger et al.1987b).  
 
Eq. 4.6 could also fit drug release data up to 60% with all R2 values greater than 
0.99. The result that k0.5 is greater than k1 has indicated that the release mainly 
followed a diffusion mechanism although swelling/erosion had some effect on 
CHX release. k0.5 increased in the order: polymer < composites with F% = 50% 
(CF50) < CF60 < CF70 (Table 4.3). Composites with reactive filler had larger k0.5 than 
those with brushite filler at the same F%.  
 
4.3.5. Effect of CHX and filler addition on adhesive antibacterial activity 
Although a small thin halo of growth inhibition around some of the control 
formulations with no CHX was occasionally observed, all the CHX – containing 
formulations (both polymer and composites) had very much larger and clearer 
inhibition zones (see example in Fig. 4.9). Inhibition zone sizes increased when 
the F% was increased, with average diameters for the SA 8325-4 strain of 11, 12, 
12 and 14 mm for 0, 50, 60 and 70 wt.% filler, respectively. With the MRSA-16 
strain, the zone diameters were on average 10, 11, 11 and 13 mm for 0, 50, 60 
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and 70 wt.% filler, respectively (Table 4.3). Factorial analysis showed that F% 
was the only factor having a significant effect on the sizes of the inhibition zone, 
with zone diameters enlarged by raising the F% (Table 4.2).  
A 
 
 
B 
 
C 
 
 
 
 
 
 
 
Fig. 4.9. Inhibition zones against bacteria strain SA 8325-4. A: Polymer 
specimen with (+) and without (-) CHX; B: An example composite specimen 
(F% =50%, T/M =1, Md = 30 μm) with (+) and without (-) CHX; C: An example 
composite specimen (F% =70%, T/M =1, Md = 30 μm) with (+) and without (-) 
CHX. Note the increase in inhibition zone size with addition of CHX and 
with increase in specimen F%.  
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4.4. Discussion  
In this chapter, the effect of CHX addition on polymerisation rate and degree of 
monomer conversion, water sorption and material degradation in addition to 
water accelerated chemical changes of the composite materials discussed in 
Chapter 3 were reported.  Effect of filler variables on CHX release kinetics and 
adhesive antibacterial activity were then investigated. 
 
4.4.1. Effect of CHX and filler addition on polymerisation rate and degree of 
monomer conversion 
The lack of effect of CHX addition on the monomer polymerisation rate found 
here is similar to a previous study of photo-polymerisation kinetics of non-
degradable methacrylate composites, although CHX was found to increase 
subsequent dark cure in that study (Mehdawi et al. 2009). This enhanced dark 
cure effect was not detected in the present study possibly because the monomer 
conversion percentage was already more than 85% when the light was turned 
off. However, a high level of filler addition (i.e. 70 wt.%) was found to lower the 
polymerisation rate, which may have been due to the increased scattering of the 
initiating blue light because of the high level of filler particles.  
 
All formulations were found to set rapidly and completely on light exposure, with 
full monomer conversion being achieved regardless of CHX and filler addition. 
Such fast and full cure as shown here could allow rapid material bonding to 
surrounding tissues after injection and would, additionally, limit the release of 
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reactive and potentially toxic double bond-containing monomers (PGLA-DMA) 
during placement (Ho and Young 2006). 
 
4.4.2. Effect of CHX and filler addition on water sorption and hydrolytic 
degradation 
The initial increase in mass and volume could be ascribed to water sorption 
which exceeded material degradation and drug release. The addition of CHX 
raised the early water sorption of both the polymer and the composites. This may 
be attributed to the water soluble nature of CHX: the dissolved CHX increasing 
the adhesive internal osmotic pressure, attracting water sorption (Young and Ho 
2008). The increase in the amount of MCPM present per specimen was also 
found to substantially enhance early water sorption. With molar ratios of β–TCP 
(Ca3 (PO4)2)/MCPM (Ca (H2PO4)2
.H2O) of 4, 2 or 1, the MCPM amount was 
found to determine the water needed for brushite (CaHPO4
.2H2O) formation, 
according to the following equation, with 0.5 g of water being required to convert 
1 g of MCPM into brushite (Bohner 2007):  
Ca3 (PO4)2 + Ca (H2PO4)2
.H2O + 7H2O → 4CaHPO4
.2H2O                               4.7 
 
The water sorption levels found in this study (data not shown) was just sufficient 
for this reaction to occur. This may explain the formation of monetite (Ca 
(H2PO4)2) in addition to brushite, as shown by the Raman and XRD analysis (see 
details in section 4.4.3).  
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In addition, larger MCPM particles were also found to enhance early water 
sorption. MCPM with large particle sizes would be expected to dissolve and react 
more slowly, thereby increasing the time over which MCPM was present in the 
formulations and thus enhancing the early water sorption.  
 
The incorporation of CHX into the material was also found to raise the final water 
content, possibly due to the replacement of the released CHX with water. In 
addition, CHX addition did not affect the material degradation. Based on factorial 
analysis, final material loss was only enhanced by reducing T/M which could 
have resulted in the formation of higher levels of more soluble brushite and 
monetite (relative to β-TCP).  
 
As mass reduction was greater than that of volume between 24 - h and 10 - week 
hydrolytic degradation of these bone adhesives was likely to be a combination of 
bulk and surface erosion. With bulk filler loss decrease in mass and maintenance 
in volume is expected (Abou Neel et al. 2010).  This is because higher density 
filler is replaced by lower density water.  Bulk loss of lower density drug and 
polymer and their replacement by water would have less effect on overall mass. 
Additionally, during water immersion, chemical reactions causing changes in 
component solubility may alter the osmotic pressure within the material matrix.  
This may result in extra water sorption and material expansion and thus mass 
and volume increase. With surface erosion alone (i.e. materials are eroded from 
the surface of the matrix), decrease in mass and volume at a comparable rate 
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would have been seen (Abou Neel et al. 2010). The results found in this study 
(the mass reduction was greater than the volume reduction) thus indicated the 
co-occurrence of the two types of degradation but the proportion of either 
degradation type is uncertain.  
 
4.4.3. Effect of CHX and filler addition on water accelerated chemical 
changes 
Raman and XRD results were consistent with the reaction of β-TCP and MCPM 
to form brushite and monetite upon water sorption in 24 h in absence or 
presence of CHX. Higher ratios of brushite/monetite in formulations containing 
CHX was observed in 24-h Raman and XRD spectra, particularly with T/M =1 
(Zhao et al. 2010). This might be due to the basic nature of CHX which may help 
stabilise brushite and prevent its conversion to monetite in presence of water 
(Grover et al. 2005). Additionally, as shown in this study, CHX addition raised the 
initial water sorption which may promote more brushite (hydrous DCP) formation.  
 
The major factor affecting the composite chemical composition after immersion in 
water was T/M. With T/M =1, brushite and monetite were the major calcium 
phosphates after placement in water whereas with T/M = 2 and 4, β-TCP was the 
major calcium phosphate. Composites with T/M = 1 would thus degrade faster 
than composites with T/M = 2 and 4 as brushite and monetite have higher 
solubility than β-TCP (Elliott 1994; Zhao et al. 2010). This may explain the 
observation that the final material loss was enhanced by reducing T/M. The faster 
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degradation rate may be clinically beneficial in that faster degradation would 
result in higher calcium and phosphate ion release, possibly providing greater 
potential for bone regeneration (Ripamonti et al. 1996;Zhao et al. 2010). In 
addition, too slow or insufficient degradation of an implant may influence body 
fluid invasion and cell migration, possibly preventing proper healing of bone 
defects and impeding tissue remodelling, as suggested by other studies (Rizzi et 
al. 2006).  
 
4.4.4. Effect of filler addition on CHX release 
The CHX release was governed mainly by diffusion although swelling/erosion of 
the composite matrix had also some effect. With diffusion – controlled processes 
gradient of drug release versus time decreases with time due to increasing 
distance that the drug must diffuse through the matrix.  
 
It was expected that faster CHX release might couple with higher MCPM amount 
as the resultant increase in water content of the vehicle may plasticise the 
polymer phase. Enhanced mobility of polymeric chains could then favour 
transport of entrapped drug and raise drug release rate (Carr et al. 1997). 
Surprisingly, as shown by factorial analysis, faster CHX release was only 
associated with increased amount of fillers but not water sorption. This may be 
because the absorbed water was ‘bound in’ brushite crystals (particularly when 
T/M =1) and not ‘free’ to facilitate drug release. Raising F% did, however, 
substantially increase drug diffusion. Higher filler addition may create more 
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interface between the calcium phosphate particles and the polymer, which could 
provide “channels” for small molecules to diffuse through (Lin et al. 2007). In 
addition, increase in the amount of the released drug with progressively 
increasing filler content may be due to the reduced amount of polymer in the 
corresponding formulations. The presence of degradable polymer may generate 
insoluble acidic polymer degradation fragments to bind basic CHX and thus limit 
the drug release (Young and Ho 2008). 
 
In addition, composites with reactive filler (β-TCP and MCPM) yielded faster CHX 
release than those filled with brushite. This may be due to the more soluble 
MCPM in the reactive system allowing faster water sorption to facilitate drug 
release compared to the less soluble brushite. Moreover, both the brushite and 
the reactive system showed the same trend: drug release was raised with 
increased F%. These findings further support the “channel” hypothesis as 
mentioned above: higher filler addition may create more interface between the 
filler particles and the polymer as the “channel” for small molecules to diffuse out 
(Lin et al. 2007). These results have suggested a simple approach to control 
polymeric drug delivery systems via incorporation of different levels of inorganic 
soluble or insoluble filler particles.  
 
The CHX release slowed down at later time points possibly due to the interaction 
between the basic CHX (due to the amine groups in the CHX molecular 
structure) and the acidic polymer degradation fragments. High F% may have 
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allowed more complete CHX release at later times since less polymer was 
present to interact with CHX as explained below. The acid / base equilibrium can 
be described by the following Bronsted-Lowery expression (Atkins 1994) : 
C22H29Cl2N9NH (aq) + H3O
+ (aq) <---> C22H29Cl2N9NH2
+ (aq) + H2O (l)             4.8 
C22H29Cl2N9NH2
+  (aq) + RCOO-  (s)<---> C22H29Cl2N9NH2 OOCR (s)                 4.9 
 
The acidic degradation products could possibly drive the equilibrium to the right. 
During the polymer degradation, the RCOO- groups could ‘mop’ up the dissolved 
CHX molecules and hence inhibit further release of CHX into the storage 
solution. The drug trapped within the polymer structure may not be released until 
the polymer fully degrades.  
 
4.4.5. Effect of CHX and filler addition on adhesive antibacterial activity  
Addition of CHX to the bone adhesives was found to endow them with 
antibacterial activity.  The bacterial assays confirmed that the CHX released from 
the polymer and the composites in the first few hours could effectively inhibit the 
growth of S. aureus (methicillin-resistant or not). Higher filler content was found 
to generate larger bacterial inhibition zones on agar plates, indicative of higher 
antibacterial activity. The ability to inhibit bacterial growth is often regarded as a 
critical step in infection prevention, thereby improving the service life of medical 
implants (Mourino and Boccaccini 2009). 
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4.5. Conclusion 
The PGLA-DMA based bone adhesives containing CHX have been found to be 
rapid setting, degradable and with controllable drug release properties, making 
them potentially suitable as antibacterial bone adhesives. The addition of CHX 
had no effect on either the material polymerisation or subsequent degradation 
kinetics, although it enhanced initial water sorption and the ratio of resultant 
brushite to monetite. Increasing the total filler percentage above 60 wt.% 
decreased the adhesive polymerisation rate. Early water sorption of the set 
adhesive discs increased with total MCPM level, while decreasing T/M from 4 to 
1 substantially enhanced total mass loss at 10 weeks. Drug release was found to 
occur by diffusion and was enhanced by raising the total filler percentage and 
reducing polymer content. Growth inhibition of S. aureus (methicillin susceptible 
or resistant) was found to increase at higher total filler content.  
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Abbreviations 
In alphabetical order 
CQ camphorquinone 
DMPT N,N-dimethyl-p-toluidine  
FBS fetal bovine serum 
FCM flow cytometry 
FSC forward scatter 
GFP green fluorescent protein 
hMSC human mesenchymal stem cell 
HEMA hydroxyethyl methacrylate 
LD lipid-DNA complex 
LDPBS LD generated in phosphate buffered saline 
LDW LD produced in deionised Water 
MEM modified Eagle’s medium 
PBS phosphate buffered saline 
PGLA-DMA poly (propylene glycol -co- lactide) dimethacrylate 
PLD PGLA-DMA film containing LD  
SD standard deviation 
SEM scanning electron microscopy 
SSC side scatter 
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5.1. Introduction  
The continuing and prolonged presence of growth factors such as bone 
morphogenic proteins at wound sites has previously been demonstrated to be 
of biomedical value (Woo et al. 2003). DNA plasmids that encode growth 
factors have therefore been incorporated into bone-repair materials in order to 
improve or increase bone regeneration efficacy (Huang et al. 2005). The 
advantages of delivering DNA plasmids rather than proteins lies in the greater 
DNA stability and the ability of DNA, after being taken up by cells, to provide 
protein production (Nussenbaum and Krebsbach 2006) over a prolonged 
period of time (Bonadio 2000).  
 
Ideally, DNA loaded bone - repair materials should provide not only structural 
support for the diseased or damaged bone to be replaced, but also a 
controllable long-term supply of a therapeutic gene to the surrounding bone 
tissue. The purpose of localised and long-term gene delivery is ultimately to 
expose cells to DNA for a prolonged period of time in order to increase the 
possibility of DNA uptake and expression in the target cells and to achieve 
successful tissue regeneration (Betz et al. 2008). 
 
A number of different DNA - releasing materials are currently under 
investigation, e.g., poly (lactide-co-glycolide) scaffolds (Huang et al. 2005), 
photo-polymerisable di-methacrylated lactide - poly (ethylene glycol) - lactide 
hydrogels (Quick and Anseth 2004), surface-eroding polyanhydrides (Quick et 
al. 2004) and calcium phosphate cements (Itaka et al. 2007). These particular 
materials, however, have several fundamental problems. For example, they 
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are either not injectable or have limited mechanical strength (Huang et al. 
2005;Quick and Anseth 2004). Moreover, the released DNA is often 
ineffectual or the delivery period is short (Itaka et al. 2007;Quick et al. 2004). 
Injectable materials that could provide structural support and simultaneously 
release effective therapeutic DNA for a long term would therefore constitute a 
significant advance.  
 
The fluid poly (propylene glycol -co- lactide) dimethacrylate (PGLA-DMA) 
studied in this project has previously been shown to be capable of 
solidification within seconds of intense blue light exposure (Ho and Young 
2006), and the set PGLA-DMA found to have readily controllable mechanical 
and degradation properties (Ho and Young 2006). Moreover, the set polymer 
was highly compatible with bone cells (Zhao et al. 2010). Furthermore, an 
antibacterial drug, chlorhexidine was found to be released from the set 
polymer in a controllable manner (Young and Ho 2008). Consequently, it 
would be advantageous if the adhesive could also release a therapeutic gene 
to facilitate bone healing. However, release of DNA from this polymeric 
adhesive has not previously been investigated. 
 
In this study, DNA plasmids containing a gene encoding green fluorescent 
protein (GFP) was first condensed with a nonviral gene delivery vector, 
MetafecteneTM Pro, to produce a lipid-DNA complex (LD). The GFP gene was 
used as a marker for gene transfection (gene transfer and expression) as the 
target cells (i.e., human mesenchymal stem cells (hMSC)) have little 
background green fluorescence and the cells become highly green 
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fluorescent after successful transfection (Soboleski et al. 2005). This enables 
accurate measurement of transfection efficiency (the proportion of the cells 
which take up and express the gene relative to the total cell population being 
transfected). MetafecteneTM Pro, formulated with cationic lipids with colipids in 
water, is a transfection reagent that facilitates gene transfection at a high 
efficiency with low cytotoxicity (Iczhowski et al. 2004). hMSC were selected 
because such cells occur in the periosteum and bone marrow and are 
capable of proliferation and differentiation into bone cells in vitro (Heyde et al. 
2007).  
 
In order to obtain maximum transfection efficiency in hMSC with minimal 
cytotoxicity, the ratio of MetafecteneTM Pro: GFP plasmid was first optimised. 
The optimal LD was then dispersed in the PGLA-DMA monomer and light 
cured to fabricate polymer films containing LD (PLD). Thin films rather than 
the thicker discs used in earlier chapters were produced as these would 
require less GFP plasmids and MetafecteneTM Pro, which are expensive. 
Additionally, the greater surface area to volume ratio of the thin films should 
increase the LD release rates.  
 
Relative cell number and gene transfection efficiency was quantified after 
hMSC were incubated in direct contact with PLD or after the cells were 
incubated with components released from PLD (termed ‘PLD extracts’). 
Relative cell number (%) was determined as the number of cells present in 
‘test’ samples relative to that in ‘control’ samples (PLD with no LD). Gene 
transfection efficiency was defined as the number of cells which express  
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GFP relative to the total number of cells present in ‘test’ samples, also 
expressed as a percentage. The aim of the approach ‘hMSC in direct contact 
with PLD’ was to investigate whether DNA could effectively be transferred 
directly from the surfaces of the films into the cells (Woo et al. 2003). The 
rationale of this approach is that if the cells could take up the LD directly from 
the PLD then delivery might be better controlled, localised and protected in 
any subsequent in vivo application (Bonadio et al. 1999). The method utilising 
‘PLD extracts’ was performed in order to examine whether the PLD enables 
non-localised gene expression, i.e., whether GFP expression can be 
observed in hMSC incubated in culture media containing DNA released from 
the PLD as a model of long-term DNA transfection in adjacent and 
surrounding cells during tissue regeneration (Woo et al. 2003). 
 
5.2. Materials and methods  
5.2.1. Optimisation of lipid-DNA complexes (LD) 
An optimisation procedure recommended by the MetafecteneTM Pro 
manufacturer (Biontex Laboratories GmbH, Martinsried, Germany) was used 
to determine the optimal ratio of MetafecteneTM Pro solution to DNA for 
highest relative cell number and transfection efficiency. Briefly, a DNA solution 
containing 1 µg of GFP plasmids in 50 µl of phosphate buffered saline (PBS) 
was added to 50 µl of PBS containing 0 (used as control), 2, 4, 6, 8 or 10 µl of 
MetafecteneTM Pro. The mixture was incubated at room temperature for 15 
min before dropwise addition to a hMSC suspension (containing 1 x 105 cells) 
in 500 μl of α-modified Eagle’s medium (α-MEM) supplemented with 15% fetal 
bovine serum (FBS) (termed ‘full culture medium’) in a 24 well plate 
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(KrystalTM, Flowgen Bioscience Ltd, Nottingham, UK). The wells had black 
walls and clear bottoms to enable direct imaging using a fluorescence 
microscope. After 24 h of incubation at 37 ºC in 5% CO2 in air, the culture 
medium was removed and replaced with 1 ml of fresh full medium 
supplemented with 50 IU/ml of penicillin and 50 µg/ml of streptomycin. Each 
MetafecteneTM Pro:DNA ratio had 4 replicates.   
 
After 48 h, relative cell number was measured to determine the effect of 
increasing ratios of MetafecteneTM Pro: DNA on it. Relative cell number was 
defined as the number of cells present in each ‘test’ well relative to that in the 
‘control’ wells, i.e., cells present in a well containing only GFP plasmids but no 
MetafecteneTM Pro. The number of cells in each well was counted in four 
random fields of view under a light microscope (20x objective, Olympus BH-2, 
Tokyo, Japan).  
 
To investigate the effect of increasing ratios of MetafecteneTM Pro: DNA on 
gene transfection efficiency, GFP plasmid transfection of hMSC (i.e. presence 
of green fluorescent cells) was examined using a Leica DM IRB fluorescence 
microscope (Leica Microsystems Ltd., Milton Keynes, UK). Images were 
produced using Leica FW4000 software. Flow cytometry (FCM, see Appendix 
B for more details) was then used to quantify gene transfection efficiency as 
follows. The cells were detached using trypsin-EDTA (0.25% (w/v) trypsin, 1 
mmol/l EDTA) for 5 min at room temperature, washed with PBS, centrifuged 
at 1000 rpm for 5 min, and suspended and fixed in 500 μl/well of 4% formalin 
for 30 min. FCM was carried out using a FACScan (Becton Dickinson, Oxford, 
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UK) and data analysis performed using CellQuest software upon collection of 
10, 000 cells. Instrument settings were adjusted using normal hMSC 
(incubated with neither DNA nor MetafecteneTM Pro) to optimise the 
parameters of forward scatter (FSC, indicative of cell size) and side scatter 
(SSC, indicative of cell granularity). Dot plots of SSC versus FSC were 
obtained to identify the cell population. This was then plotted versus 
fluorescence intensity (FL1, green channel) as a histogram to identify and 
quantify the GFP-positive cells in the cell population (see details in section 
5.3.1). Transfection efficiency was calculated as the percentage of GFP 
positive cells (cells with increased fluorescence intensity) relative to the total 
number of cells in each examined sample.  
  
5.2.2. Preparation of polymer films containing LD (PLD)  
5.2.2.1. Preparation of freeze-dried LD 
0.5 mg of GFP plasmid in 50 ml aqueous solution and 1 ml of MetafecteneTM 
Pro in 50 ml aqueous solution was combined to produce LD. Two types of 
solution was used, PBS and deionised water. PBS use is recommended by 
the MetafecteneTM Pro manufacturer. Precipitation of salts after lyophilisation 
of the PBS solution (NaCl, KCl, Na2HPO4 and KH2PO4), however, might affect 
the PLD structure and thus DNA release. Deionised water was therefore used 
as an alternative to avoid the potential problem. 
 
After incubation as above (see section 5.2.1), the solution mixtures were 
frozen using liquid nitrogen and lyophilised to solid powders in a Heto 
Drywinner freeze drier (Heto-Holten, Allerod, Denmark), operating at 0.5 Pa 
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with a condenser temperature of −90 °C for 48 h. LDPBS and LDW  indicate 
dried LD produced using PBS and deionised water, respectively.  
 
5.2.2.2. Fabrication of PLD 
The resultant freeze-dried LD powders (0.5 g of LDPBS or 2 mg of LDW) were 
mixed with 0.2 g of PGLA-DMA monomer mixture (PGLA-DMA (90 wt.%), 
hydroxyethyl methacrylate (HEMA, 8 wt.%), camphorquinone (CQ, 1 wt.%) 
and N,N-dimethyl-p-toluidine (DMPT, 1 wt.%)) and each powder-monomer 
mixture placed onto 4 ThermanoxTM plastic coverslips (13 mm diameter, 
NUNCTM, Thermo Fisher Scientific, Loughborough, UK), giving 4 samples of 
PLDPBS and 4 samples of PLDw. Thermanox
TM plastic coverslips were used to 
limit the diameter of the resultant PLD to 13 mm so that they would fit into a 
24 well plate. The coverslips were removed after the polymer films were 
photo-polymerised (see below). Details of components and their mass in each 
film are summarised in Table 5.1. 
Table 5.1. Components and their theoretical mass in each PLD film. 
Components 
 
PLD formulations 
PGLA
-DMA 
(mg) 
Metafectene
TM 
Pro 
(mg) 
GFP 
plasmid 
(mg) 
NaCl 
(mg) 
KCl 
(mg) 
Na2HPO4 
(mg) 
KH2PO4 
(mg) 
         PLDPBS 50 0.5 0.125 100 2.5 1.8 3 
PLDW 50 0.5 0.125 - - - - 
‘-’= not applicable. 
 
After covering with an acetate sheet the resultant monomer films were cured 
in a light box (Triad® 2000™ visible light cure system, Dentsply Trubyte, Palo 
Alto, USA) for 2 min. Full monomer conversion (i.e., no presence of the peak 
at 1640 cm-1 due to ‘C=C’ in PGLA-DMA) was confirmed using a Raman 
spectrometer (LabRAM HR, Horiba Jobin Yvon Ltd., Stanmore, UK, see 
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details in Chapter 3. section 3.2.1). The set films were subsequently sterilised 
by immersion in 50 ml of 70% ethanol for 5 min and air-dried at room 
temperature for 24 h prior to use in the transfection experiments.  
 
5.2.3. Relative cell number and gene transfection efficiency using PLD 
Each film of both PLD formulations (PLDPBS and PLDW) was placed in the 
bottom of a 24 well plate. Each PLD formulation had 4 replicate films. 1 ml of 
hMSC suspension (1 x 104 cells/ml) in full culture medium (defined in section 
5.2.1) was added and then incubated at 37 °C for 3 days.  
 
To investigate the effect of ‘direct contact with PLD’ on cell morphology, after 
3 days of incubation, the cells on 4 of the 8 films (2 from each PLD 
formulation) were washed with PBS and fixed using 3% (v/v) gluteraldehyde in 
0.1 mol/l sodium cacodylate buffer for 24 h. The specimens were finally 
dehydrated in a graded series of ethanol (50, 70, 95 and 3 x 100%) for 10 min 
each, immersed in hexamethyldisilazane for 2-3 min, air-dried for 3 h, 
mounted and coated with gold/palladium (Polaron E5000 sputter coater, 
Quorum Technologies, Sussex, UK). Cell morphology was then examined by 
scanning electron microscope (SEM, JEOL JSM-5410LV, Tokyo, Japan) at an 
accelerating voltage of 15 kV. 
 
Relative cell number (%) was calculated as the number of cells on each SEM 
image of ‘test’ PLD divided by that on the SEM image of control PGLA-DMA 
films without LD. Two films of each PLD formulation were used and four SEM 
images were produced for each film. There were two controls in this test. 
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PGLA-DMA films without LD were used as a control to determine the effect of 
the LD on relative cell number; ThermanoxTM plastic coverslips were also 
used as a control to determine the effect of PGLA-DMA films alone, without 
LD, on relative cell number. 
 
In a parallel study, the remaining 4 films were used to determine the effect of 
‘direct contact with PLD’ on gene transfection efficiency of hMSC.  In this 
case, cells after 3 days of incubation on the remaining 2 replicate films of 
PLDPBS, PLDW and control PGLA-DMA films without LD, were washed with 
PBS and fixed using 4% formalin for 10 min. The fixed cells were then washed 
with PBS, permeabilised with 0.1% Triton X-100 for 10 min and washed again 
with PBS. Nuclei were then stained using 0.1 μg/ml Hoechst 33258 dye (a 
fluorescent stain for labelling DNA) for 3 min and after further washing by 
PBS, viewed under the Leica DM IRB fluorescence microscope (20 x 
objective). Transfection efficiency (%) was calculated as the percentage of 
GFP positive cells (green fluorescent cells) relative to the total number of cells 
in an examined area (i.e., the number of blue nuclei present). 
 
5.2.4. Relative cell number and gene transfection efficiency using ‘PLD 
extracts’ 
hMSC suspension (1 ml, 1 x 104 cells/ml) in full culture medium (defined in 
section 5.2.1) was seeded into a 24 well plate and incubated for 4 h to allow 
cell attachment. Each of the PGLA-DMA films with no LD (control), PLDPBS 
and PLDw were then suspended in the culture medium above the cell 
monolayer. After incubation for 1 day, each film was removed from the first 
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well and suspended above a fresh second cell monolayer in a new well for a 
further 5 days of incubation. At the end of each time point (1 and 5 days), the 
film was removed and the culture medium renewed.  
 
After 48 h of film removal and culture medium renewal, the cells were washed 
with PBS and fixed using 4% formalin for 10 min, washed with PBS, 
permeabilised with 0.1% Triton X-100 for 10 min and washed again with PBS. 
Nuclei were then stained using 0.1 μg/ml Hoechst 33258 dye for 3 min and, 
after further washing with PBS, visualised under the Leica DM IRB 
fluorescence microscope (20 x objective).  
 
Relative cell number was then determined as the percentage of the number of 
cells (i.e., blue nuclei) present in the well incubated with PLD relative to that of 
cells incubated in parallel with control PGLA-DMA films with no LD, defined as 
100%. Transfection efficiency was calculated as the percentage of GFP 
positive cells (green fluorescent cells) relative to the total number of cells (i.e., 
the number of blue nuclei present) in each examined area. Each experiment 
had 4 replicates. 
 
5.2.5. Statistical evaluation 
The statistical significance of differences in relative cell number and gene 
transfection efficiency under different circumstances was evaluated using 
one-way ANOVA. If the values of a property were uniformly distributed, the 
Bonferroni post hoc test was used. Data were evaluated using SPSS 14.0 for 
Windows (SPSS, Inc., Chicago, Ill., USA). The results are expressed as mean 
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± Standard Deviation (SD), and p values <0.05 were considered statistically 
significant. 
 
5.3. Results  
5.3.1. Optimal MetafecteneTM Pro:DNA ratio for relative cell number and 
gene transfection efficiency 
As the ratio of MetafecteneTM Pro:DNA was increased from 2 to 10 (µl/µg), 
there was a linear decrease in relative cell number (R2=0.95; Fig. 5.1), from 
approximately 80 to down 40% (Table 5.2). However, although the difference 
in relative cell number between the ratios of MetafecteneTM Pro:DNA at 2, 4 
and 6 μl/μg was not statistically significant, at the ratio of MetafecteneTM 
Pro:DNA of 8 and 10 μl/μg, the relative cell number was substantially lower 
than that at 2 μl/μg (p<0.05). This finding has suggested that high 
concentrations of MetafecteneTM Pro to DNA or cells may result in cell death. 
Table 5.2. Effect of MetafecteneTM Pro:DNA ratios on relative cell number 
and gene transfection efficiency of human mesenchymal stem cells 
(hMSC). 
MetafecteneTM Pro: DNA (μl/μg)  
2 4 6 8 10 
 Relative cell number (%) 83±8 80±9 67±7 57±5* 39±4* 
Transfection efficiency (%) 53±9 56±8 49±8    47±7 37±7* 
Relative cell number (%) was determined as the ratio of the number of cells present in 
each well after transfection at MetafecteneTM Pro:DNA ratios between 2 and 10 μl/μg 
relative to that of ‘control’ cells incubated with DNA alone but no MetafecteneTM Pro. 
Transfection efficiency (%) was quantified using FCM as the proportion of the cells with 
increased fluorescence intensity (> background fluorescence intensity compared with the 
control cells incubated with DNA alone but no MetafecteneTM Pro) relative to the total cell 
population being examined after transfection (see below). Results are expressed as 
means ± SD, n= 4. * indicates significant differences (p<0.05) from values of 
MetafecteneTM Pro:DNA ratio at 2 μl/μg. 
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Fig. 5.1. Effect of MetafecteneTM Pro : DNA ratios on relative cell number 
and transfection efficiency of hMSC. 
 
Normal hMSC without any transfection had undetectable background green 
fluorescence using fluorescence microscope (data not shown). Control hMSC 
after incubation with GFP plasmids alone also showed little green 
fluorescence (see example in Fig. 5.2.A). In contrast, cells incubated with both 
DNA and MetafecteneTM Pro, i.e., LD, became highly fluorescent, indicating 
successful transfection (see example in Fig. 5.2.B). 
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Fig. 5.2. Representative fluorescence images of hMSC after incubation 
with 1 µg DNA alone (A) and 1 µg DNA and 2 µl MetafecteneTM Pro (LD) (B). 
In these images, the green fluorescent hMSC are successfully transfected 
whereas the hMSC not transfected remain non-fluorescent ( background). 
 
FCM was additionally used to quantify the transfection efficiency. First, FCM 
was used to compare the changes of the cell population due to different 
MetafecteneTM Pro:DNA ratios by measuring changes in cell size (FSC) and 
granularity (SSC). Dot plots showing SSC versus FSC exhibited an oval-shaped 
region (see example in Fig. 5.3.A). A comparison of the normal hMSC and the 
control hMSC incubated with DNA alone showed very similar FSC and SSC 
data distribution (data not shown). A comparison of the control hMSC incubated 
with DNA alone and the hMSC incubated with DNA and MetafecteneTM Pro (i.e., 
LD), however, showed a slight reduction in cell size distribution, as indicated by 
the left-shifted FSC data and no apparent change in cell granularity as indicated 
by the similar SSC data (see example in Fig. 5.3.A, compare i and ii). However, 
at high MetafecteneTM Pro:DNA ratio (i.e. MetafecteneTM Pro:DNA = 10 μl/μg), 
an additional population of particles near the lower left corner (indicative of cell 
debris or fragments) appeared (data not shown). These results suggested that 
the transfection procedures did not induce apparent cell death when the 
MetafecteneTM Pro:DNA ratio was less than 10 μl/μg. 
A 
100 μm 
B 
100 μm 
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Fig. 5.3.A. Representative dot plots of side scatter (SSC) versus forward 
scatter (FSC) of the control hMSC after incubation with 1 µg DNA alone 
(i) and the test hMSC after incubation with 1 µg DNA and 2 µl 
MetafecteneTM Pro (LD) (ii). Each dot represents a single cell. 1000 cells 
are displayed in each graph. A region has been drawn around the cells 
and the subsequent data analysis is based on the gated cell population.  
 
    
Fig. 5.3.B. Distribution histogram of the corresponding fluorescence data 
of the gated population of the control hMSc after incubation with 1 µg 
DNA alone (i) and the hMSC after incubation with 1 µg DNA and 2 µl 
MetafecteneTM Pro (LD) (ii). The markers M1 and M2 represent the cells 
with low (< or = 30, background fluorescence) and high (>30) 
fluorescence intensity, respectively.  
 
i ii 
i ii 
M1 
M1                     M2 
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In order to quantify the percentage of cells with successful transfection in the 
examined cell population, a region has also been drawn around the hMSC cell 
cluster to include the population with the highest cell density for subsequent 
fluorescence data analysis. This selected region was found to contain more 
than 70% of the total cell population. 
 
The histogram of fluorescence data of control hMSC incubated with DNA 
alone showed a distribution with a slight negative skew, with the fluorescence 
intensity ranging from 1 to 30, peak intensity approximately around 9 (see 
example in Fig. 5.3.B.i). In contrast, histograms of the tranfected hMSC using 
LD showed a distribution with a significant positive skew, with the 
fluorescence intensity ranging from 5 to 104 (see example in Fig. 5.3.B.ii), 
indicating that the population contained many cells which had been 
transfected, i.e. expressing GFP. The distribution had two peaks, the first 
located at a fluorescence intensity of 15 and the second 35. Markers M1 and 
M2 were arbitrarily set to represent the cells with low fluorescence intensity (< 
or = 30, background fluorescence intensity) and high fluorescence intensity (> 
30). The transfection efficiency was then calculated as the percentage of cells 
in M2 relative to the total number of cells (i.e., total cells in M1 + M2).  
 
The calculated transfection efficiency at different MetafecteneTM Pro:DNA 
ratios was between 40% (MetafecteneTM Pro:DNA = 10 µl/µg) and 55% 
(MetafecteneTM Pro:DNA = 2 µl/µg) (Table 5.2). There was no significant 
difference in transfection efficiency between the MetafecteneTM Pro:DNA 
ratios at 2, 4, 6 and 8 μl/μg. At the MetafecteneTM Pro: DNA ratio of 10 μl/μg, 
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the transfection efficiency was significantly lower than that at 2 μl/μg (p<0.05). 
From the results of relative cell number and transfection efficiency 
experiments reported above, the ratio of MetafecteneTM Pro:DNA of 2 μl/μg 
was chosen as optimum and used for further studies. 
 
5.3.2. Relative cell number and gene transfection efficiency using PLD 
After 3 days of incubation, the hMSC were found to be spread on the surfaces 
of control ThermanoxTM plastic coverslips (smooth surface), control PGLA-
DMA films (which were observed to have smooth surface) and PLDPBS (which 
had a granular surface) (Fig. 5.4.A-C). The size and morphology of the cells 
cultured on control PGLA-DMA films and on PLDPBS (see example in Fig. 
5.4.B and C) appeared comparable with that of the cells on control 
ThermanoxTM plastic coverslips (see example in Fig. 5.4.A). However, no 
hMSC could be observed on the surface of PLDw (see example in Fig. 5.4.D).
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Fig. 5.4. Representative SEM images of hMSC incubated for 3 days on a 
ThermanoxTM plastic coverslip (A), a PGLA-DMA film with no LD (B), a 
PLDPBS (C) and a PLDW (D). Note the granular surface of PLDPBS. 
 
There was no significant difference between the number of cells in each 
examined area on ThermanoxTM plastic coverslips (30±10 cells/0.36 mm2) and 
that of cells on PGLA-DMA films containing no LD (30±10 cells/0.36 mm2). The 
number of cells on PLDPBS (25±5 cells/0.36 mm
2) and PLDW (0 cells/0.36 mm
2) 
was 66±17% and 0% of that of cells on plain PGLA-DMA films, respectively.  
A 
B 
100 μm 100 μm 
C 
 
100 μm 
D 
 
100 μm 
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Moreover, no GFP expression in hMSC (green fluorescent cells) on any of 
these material surfaces could be observed using a fluorescence microscope 
(data not shown).  
 
5.3.3. Relative cell number and gene transfection efficiency using ‘PLD 
extracts’ 
The percentage number of hMSC incubated with components released from 
PLDPBS compared with that of hMSC incubated with control PGLA-DMA films 
with no LD after the first day and after a subsequent period of 5 days were 
found to be 72±8 and 95±8%, respectively. In contrast, the percentage of cells 
after incubation with components released from PLDW was only 33±4% for the 
initial 1 day (p<0.05), although this was increased to 90±9% for the subsequent 
5 days. These results suggested that components released from PLDPBS and 
PLDW (particularly PLDW) on the first day had a detrimental effect on the cells. 
Thereafter, however, the hMSC appeared to grow well in the presence of the 
components released from PLDPBS and PLDW at least for the subsequent 5 
days. 
 
GFP expression (the presence of green fluorescent cells) was not detected in 
hMSC transfected by the initial 1-day (see example in Fig. 5.5.A.ii) and 
subsequent 5-day (see example in Fig. 5.5.B.ii) components released from 
PLDPBS. However, GFP expression was clearly observed in hMSC transfected 
by the initial 1-day components released from PLDW (see example in Fig. 
5.5.A.iii). This system exhibited transfection efficiency of 80±15%. GFP 
expression was also observed in the hMSC transfected by components 
released from PLDW after 5 days (see example in Fig. 5.5.B.iii), although the 
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percentage of transfected cells was found to be less than 5%. These results 
suggested that only the components released from PLDW on the first day were 
able to effectively transfect hMSC, whereas the components released thereafter 
(5 days) had only limited transfection activity. 
A 
 
B 
 
  
  
Fig. 5.5. Representative fluorescence images of hMSC incubated with 1-day 
(A) and subsequent 5-day (B) components released from the control PGLA-
DMA films with no LD (i), PLDPBS (ii) and PLDW (iii). Cell nuclei are stained 
blue and cells successfully transfected are green fluorescent. 
100 μm 
i i 
 
100 μm 
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5.4. Discussion 
5.4.1. Effect of MetafecteneTM Pro:DNA ratio on relative cell number and 
gene transfection efficiency  
Relative cell number decreased with progressively increasing MetafecteneTM 
Pro:DNA ratios between 2 and 10 μl/μg, while the transfection efficiency 
varied little at MetafecteneTM Pro:DNA ratios between 2 and 8 μl/μg but was 
significantly reduced when the ratio was increased to 10 μl/μg. In view of low 
cytotoxicity (i.e. high relative cell number) and high transfection efficiency, the 
ratio of MetafecteneTM Pro:DNA of 2 μl/μg was chosen as optimum. 
 
The reduced relative cell number and transfection efficiency of hMSC at high 
MetafecteneTM Pro:DNA ratios may be due to the toxicity of cationic lipids in 
MetafecteneTM Pro solution. As reported previously, cytotoxicity is normally 
closely associated with the charge ratio between the cationic lipid species and 
the nucleic acids (e.g. the ratio of MetafecteneTM Pro:DNA in the present 
study), as well as the concentration of LD used for a certain number of cells 
(e.g. the amount of MetafecteneTM Pro per cell in the present study) (Lv et al. 
2006). Higher charge ratios have been found to cause higher cell death to a 
variety of cell types although they sometimes produce higher transfection 
efficiency (Lv et al. 2006). In addition, the toxic effect of cationic lipids can 
include cell shrinking and reduced number of mitoses, possibly resulting from 
the large size of the LD, and the high positive zeta potential required for their 
uptake (Lv et al. 2006).  
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5.4.2. Relative cell number and gene transfection efficiency using PLD 
5.4.2.1. PLDPBS 
hMSC were found to be able to adhere to and spread on PLDPBS although the 
number of cells on the PLDPBS was lower compared with that on the control 
PGLA-DMA films after 3 days of culture. This may be due to the presence of 
salts (NaCl, KCl, Na2HPO4, KH2PO4, see Table 5.1) precipitated from PBS 
after lyophilisation for production of LD powders. The presence of these salts 
might have changed the film surface structure for cell attachment and also 
altered the salt concentration of the culture medium in the direct vicinity of the 
attached cells.  
 
Regarding gene transfection using PLDPBS, no GFP expression of hMSC was 
observed on the PLDPBS. This may be due to the dissolution of the highly 
soluble salts (NaCl, KCl, Na2HPO4, KH2PO4) with LD from the PLDPBS in the 
sterilising solution prior to hMSC seeding on these films. It is also possible 
that the physical structure (e.g., particle size) of LD may have been destroyed 
during the freeze-drying process in the presence of PBS, resulting in loss of 
tansfection activity (Yadava et al. 2008), as this process can sometimes cause 
fracture of the liposomal bilayers leading to liposomal fusion and phase 
separation (Crowe and Crowe 1988). However, this is uncertain until further 
study to investigate the effect of lyophilisation on LD structure in presence of 
PBS. 
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5.4.2.2. PLDW 
hMSC were found not be able to adhere to or spread on PLDW, possibly due 
to the high concentration of cationic lipids on the surface of the PLDW. As 
indicated in section 5.4.1, this high concentration of cationic lipids (i.e. high 
cationic lipids/DNA and high cationic lipids/cell) may cause cell death, thereby 
reducing the number of attached cells as shown in this study. As no hMSC 
were attached to the PLDW, no GPF transfection of hMSC was observed on 
these films.  
 
5.4.3. Relative cell number and gene transfection efficiency using ‘PLD 
extracts’ 
5.4.3.1. PLDPBS extracts 
The number of hMSC incubated in the ‘PLDPBS extracts’ for the initial 1 day 
and for the subsequent 5 day was higher than 70% and 90%, respectively, of 
that in the ‘extracts’ of the control PGLA-DMA films. Although hMSC were 
found to proliferate relatively well in these systems, no hMSC transfection by 
the ‘PLDPBS extracts’ at any time was detected. This may be due to the 
dissolution of the highly soluble salts (precipitated from PBS with LD) from the 
PLDPBS in the sterilising solution prior to film incubation with hMSC in culture 
medium. In addition, the LD shape, size and structure may be partially 
destroyed during lyophilisation in PBS.  
 
5.4.3.2. PLDW extracts 
The number of hMSC incubated in the ‘PLDW extracts’ for the initial 1 day was 
less than 40% of that in the ‘extracts’ of the control PGLA-DMA films whereas 
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the percentage of hMSC was as high as 90% when the cells were incubated 
in the ‘PLDw extracts’ for the subsequent 5 days. The initial lower cell number 
of day-1 ‘PLDW extracts’ may be due to the large amount of LDW released 
from the surface of the PLDW. As indicated in section 5.4.1, this high 
concentration of LD may cause cell death, thereby reducing the number of 
cells in the ‘PLDW extracts’.  
 
GFP expression could be clearly observed in hMSC exposed to the day-1 
‘PLDW extracts’ but not in the subsequent 5-day extracts. The initial short-term 
transfection activity of ‘PLDW extracts’ might be due to the LDW released from 
the surface of the PLDW. However, the LDW within the bulk of the PLDW would 
not have been readily released (prior to polymer degradation), reducing the 
gene expression at later time points.  
 
In order to allow long term DNA release for sustained transfection, it would be 
beneficial to increase the polymer degradation rate. This is because it was 
found that release of particles with large size (e.g. LD) from the poly (ether-co-
ester) networks usually depends on the rate of hydrolysis of the polymer 
crosslinks (Quick and Anseth 2004). Nevertheless, more sustained 
transfection in vivo than found here in vitro may occur as polymer degradation 
might be accelerated by the presence of enzymes (Hou et al. 2004) and cells 
(Mabilleau et al. 2004). 
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5.5. Conclusion 
The present work is an initial study of DNA delivery using PGLA-DMA. 
Relative cell number of hMSC using PLDPBS alone or ‘PLDPBS extracts’ was 
both found to be relatively high, but no GFP transfection could be observed 
using these systems. Additionally, no hMSC could be observed on the PLDW, 
with no GFP transfection. However, GFP transfection of hMSC by the ‘PLDw 
extracts’ could be clearly observed, despite of reduced cell number. The 
effective transfection period in vitro, nevertheless, lasted for 1 day only 
although it is possible that this period could be longer in vivo as a result of 
potentially higher polymer degradation rates.  
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Abbreviations 
In alphabetical order 
CHX  chlorhexidine 
hMSC 
LA 
human mesenchymal stem cells 
lactide 
LD 
MCPM 
lipid-DNA complexes 
monocalcium phosphate monohydrate 
PGLA-DMA poly(propylene glycol -co- lactide) dimethacrylate 
PPG poly (propylene glycol) 
TCP tricalcium phosphate 
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6.1.  Summary  
The new materials investigated in this project consisted of fluid poly(propylene 
glycol-co-lactide) dimethacrylate (PGLA-DMA) filled with varying levels of β-
tricalcium phosphate (β-TCP) and monocalcium phosphate monohydrate 
(MCPM) powders. These composite materials were found to be injectable, 
rapid-setting, elastic, degradable, and capable of releasing ions active in bone 
re-mineralisation and therapeutic agents in a controllable manner. Such 
materials could therefore be considered to have potential clinical value as 
bone adhesives and drug delivery devices.  
 
Synthesis of PGLA-DMA with expected chemical structure, high 
methacrylation efficiency as well as high purity was achieved via adjusting the 
reaction conditions. The resultant PGLA-DMA was fluid and colourless.  
 
Incorporation of β-TCP and MCPM into PGLA-DMA did not appear to elicit 
any detrimental effect on material polymerisation, with composites fully 
polymerised within 200 s upon blue light exposure. Advantages of the 
incorporation of β-TCP and MCPM into PGLA-DMA were found to include 
elevated modulus with increased total filler content, closer to that of bone, 
particularly trabecular bone. In addition, the composite materials had 
accelerated degradation rate with increased MCPM content, resulting in faster 
phosphate and calcium release and higher buffering capacity of the acidic 
Chapter 6                                                                 Summary and future work 
 214 
polymer degradation products. The increase in release of phosphate and 
calcium ions could be of value in enhancing bone regeneration (Ripamonti et 
al. 1996), while the pH compensation ability of the fillers could potentially 
reduce the likelihood of pH-catalysed polymer bulk degradation and neutralise 
localised acid production (Sabir et al. 2009). Moreover, both polymers and 
composites appeared to exhibit a suitable level of biocompatibility as indicated 
by the spreading and increase in cell number on the material surfaces in vitro 
and close apposition of the implanted materials to the chick embryo femurs in 
vivo. Therefore, the formulation with highest filler and MCPM content were 
considerd to be the optimal for application as bone adhesives due to its high 
modulus, high phosphate and calcium release and buffering capacity. 
 
The set polymers and composites were found to be capable of releasing, 
locally and in a controllable manner, the antibacterial chlorhexidine (CHX; 
used as a model of small molecule drugs). Addition of 10 wt.% CHX did not 
affect the composite polymerisation and hydrolytic degradation. The release 
of CHX was found to be via diffusion, which increased with the total filler 
content and was associated with higher antibacterial activity.  
 
Large molecules such as freeze-dried powders of lipid-DNA complexes (LD) 
were incorporated into the unset PGLA-DMA, and preliminary studies 
demonstrated that the ‘extracts’ of the set polymer films containing LD (i.e. 
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components released from the polymer films) enabled non-localised gene 
expression over a short period, i.e., gene expression could be observed in 
human mesenchymal stem cells (hMSC) incubated in culture media 
containing DNA released from the set polymer films.  
 
6.2.  Future work 
In order to improve the potential value of the composite materials as 
candidates for bone adhesives and drug delivery devices, certain material 
properties could be improved by further investigation.  
 
6.2.1. Mechanical properties 
The elastic modulus of the composites obtained (10 ~ 30 MPa) was lower 
than that of human trabecular bone (20 ~ 500 MPa) (Agrawal and Athanasiou 
1997;Bergsma et al. 1995) and might not be able to provide sufficient 
functional support during bone regeneration. As no more filler can be added 
(since materials containing 70% filler have been found to be paste-like and 
would thereby reduce injectability), PGLA-DMA with shorter unit length of 
poly(propylene glycol) (PPG) could be produced as alternatives. This is 
because, as previously reported, PGLA-DMA consisting of shorter PPG unit 
length (e.g., PPG with molecular weight of 425 g/mol and unit length = 7) had 
a higher modulus after set than that with longer PPG unit length (e.g., in 
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present study, PPG with molecular weight of 1,000 g/mol and unit length = 17) 
due to its higher crosslinking density (Ho and Young 2006).  
 
In addition to the material elastic modulus, strength (e.g., tensile and 
compressive) of the materials should also be tested in future as this is an 
important parameter of engineering materials used in structures and 
mechanical devices (Yaszemski et al. 1996). 
 
6.2.2. Degradability 
Although in vitro degradation of the polymers and composites was 
investigated in this study, the in vivo degradation of these materials should be 
tested in future as this may differ due to the presence of enzymes in the body 
(Hou et al. 2004). If the in vivo degradation rate of these materials does not 
match the suggested optimal degradation rate (complete degradation in 12 
weeks (Ekholm et al. 1995), it would be possible to optimise the composite 
materials by adjusting the number of lactides (LA) per PGLA-DMA molecule 
(Ho and Young 2006) or by incorporation of β-TCP and MCPM at different 
levels (e.g. molar ratio of β-TCP to MCPM <1).  
  
6.2.3. Biocompatibility 
The present work examined bone cell proliferation on the material surfaces 
and bone tissue responses to the implanted materials using chick embryo 
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femurs. However, osteocompatibility and osteointegration of implanted 
materials in bone using other experimental models, e.g., sheep, need to be 
investigated to obtain information about the long-term in vivo biocompatibility. 
In addition, bonding strength between the implanted materials and the bone 
tissue after implantation could also be examined. 
 
6.2.4. Drug delivery 
In current study, it was found that the CHX release rate was reduced at later 
times, possibly due to the interaction between the basic CHX and the acidic 
polymer degradation products. Further study can include acidic drugs (e.g., 
ketoprofen, used for the treatment of arthritis) and neutral drugs (e.g., 
prednisolon, used in the treatment of rheumatic disease) to determine the 
effect of drug acid-base property on the drug release rate from the material 
(Young and Ho 2008). 
 
In addition, only one drug concentration and one sample dimension were 
used in this study. Further work would be required to assess how drug release 
would vary with drug concentration and sample dimension as these are 
important factors affecting the drug diffusion rate (Young and Ho 2008). 
 
6.2.5. DNA delivery 
It was found that gene expression could be observed only in hMSC incubated 
in culture media containing LD initially released from the set polymer films. 
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These LD were assumed to be released from the surface of the polymer films 
and the LD within the bulk of the polymer films would not be readily released 
prior to polymer degradation due to its large size. As previously reported, 
release rate of large particles from poly (ether-co-ester) networks usually 
depends on the rate of hydrolysis of the polymer crosslinks (Quick and Anseth 
2004). It would therefore be possible to increase the DNA release rates by 
increasing the polymer degradation rate, allowing more sustained gene 
transfection. Thus, a future work could examine a PGLA-DMA with higher LA 
content per molecule (this PGLA-DMA would be expected to degrade faster) 
(Ho and Young 2006). Thereafter, it would be of great benefit to use genes 
encoding osteogenic signaling molecules, such as bone morphogenetic 
proteins, in further study.  
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Appendix A. Raw materials and suppliers  
In alphabeic order 
Materials Suppliers Description 
α-modified Eagle’s 
medium 
Invitrogen, Paisley, UK  
β-TCP  Fluka, Gillingham, UK 95%  
acetone  Sigma-Aldrich, Gillingham, UK 99.9% 
alamarBlue
TM
 assay  AbD serotec, Düsseldorf, Germany  
brushite Sigma-Aldrich, Gillingham, UK 98% 
camphorquinone Sigma-Aldrich, Gillingham, UK 97% 
deionised water  Eppendorf, Hamburg, Germany molecular biology grade 
D,L- lactide Purac, Gorinchem, the Netherlands  molecular weight ~ 144 
g/mol 
dichloromethane Sigma-Aldrich, Gillingham, UK 99.8% 
Dulbecco’s modified 
Eagle’s medium  
Invitrogen, Paisley, UK  
fetal bovine serum  Invitrogen, Paisley, UK  
gWizTM GFP plasmids  Aldevron, Fargo, USA  
hMSC  Lonza, Basel, Switzerland passage 2-5 was used for 
experiment 
Hoechst 33258 dye Invitrogen, Paisley, UK  
hydroxyethyl methacrylate Invitrogen, Paisley, UK; 99% 
MetafecteneTM Pro  Biontex, Martinsried, Germany  
methacryloyl chloride Fluka, Gillingham, UK 97% 
MG-63 cells European Collection of Cell 
Cultures at the Health Protection 
Agency, Salisbury, UK 
human osteosarcoma cell 
line 
monetite  Sigma-Aldrich, Gillingham, UK 98% 
monocalcium phosphate 
monohydrate 
Sigma-Aldrich, Gillingham, UK 95% 
N,N-dimethyl-p-toluidine Sigma-Aldrich, Gillingham, UK 99% 
penicillin Invitrogen, Paisley, UK  
phosphate buffered saline  Invitrogen, Paisley, UK Ca2+/Mg2+ free 
poly (propylene glycol -co- 
lactide) dimethacrylate  
 synthesised by author (see 
Chapter 2, section 2.2.1 for 
details). 
propylene glycol Sigma-Aldrich, Gillingham, UK average molecular weight ~ 
1000 g/mol 
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toluidine blue Fluka, Gillingham, UK.  
triethylamine  Fluka, Gillingham, UK 98% 
trypsin-EDTA  Invitrogen, Paisley, UK  
stannous octoate Sigma-Aldrich, Gillingham, UK 95% 
streptomycin  Invitrogen, Paisley, UK  
All reagents were used as received unless otherwise specified. β-TCP were sieved 
(Laboratory test sieve, Endecotts Ltd, London, UK) to obtain particles of diameter less than 20 
μm. MCPM were ground using a ball mill (Retsch Mixer Mill MM 301, Haan, Germany) at 30 
Hz shaking frequency for 4 min and sieved (Laboratory test sieves of 20, 38, 75 and 106 μm, 
Endecotts Ltd, London, UK) in a vibratory shaker (Fritsch Analysette 3 Spartan, Obertein, 
Germany) for 30 min to obtain particles of diameters: 20~38 (denoted as 30), 38~75 (60) and 
75~106 (90) μm.  
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Appendix B. General techniques 
7.B.1. Raman spectroscopy 
Raman spectroscopy is based on inelastic scattering, or Raman Scattering, of a 
laser light. The laser light interacts with a sample, resulting in molecular 
vibrations or other excitation of the sample molecules and scattered laster light 
of a different wavelength. The difference in the wavelength between the 
scattered and the incedent light is a characteristic of the nature of the molecules 
present in the sample and can therefore be used to identify different functional 
groups (Ferraro et al. 2002a; Ferraro et al. 2002b).  
 
7.B.2. Dynamic mechanical analysis 
A typical dynamic mechanical analyser (DMA) has a force motor, a drive shaft, 
a linear variable displacement transformer positional sensor (LVDT) and two 
parallel plates. DMA can used to determine compressive modulus of a material. 
During the test, a compressive force (stress) is applied from the motor and 
transmitted through the drive shaft onto the sample. The deformation of the 
sample is measured by the LVDT and the strain is calculated. Compressive 
modulus is then determined from the slope of the stress-strain curve created by 
the DMA (Menard 2008a; Menard 2008b). 
 
7.B.3. Ion chromatography 
Ion chromatography is a form of liquid chromatography, separating and 
measuring ion concentrations of various species based on their affinity (ion 
interactions) with a resin of a chromatographic column (Fritz and Gjerde 2009). 
An ion chromatograph is a plot of intensity versus ion retention time. In the 
graph, each peak represents a separated ion and the ion concentration can be 
calculated using the area under the peak. 
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7.B.4. AlamarBlueTM assay 
AlamarBlueTM reagent is a buffered solution containing highly purified resazurin. 
Resazurin is dark blue in colour and has little intrinsic fluorescence. It can be 
reduced to pink and highly fluorescent resorufin when taken up by viable cells. 
The amount of resorufin produced is proportional to the number of viable cells. 
Cell viability can therefore be quantified by measuring resorufin fluorescence 
level (O'Brien et al. 2000; Oriowo et al. 2003).  
 
7.B.5. Chick embryo chorioallantoic membrane (CAM) assay 
The chick embryo chorioallantoic membrane (CAM) assay employs fertilised 
egg during the period of chick embryo development (Vargas et al. 2007). CAM 
itself is a transparent and highly vascularised extra-embryonic membrane. 
During the test, an implant or an implanted tissue is placed on the top of a CAM 
and incubated with the CAM for several days. This model allows investigation of 
CAM/tissue response to the implant. The CAM model generally exhibits similar 
tissue response with other mammalian models. Due to the advantages such as 
low cost and simplicity, this model is particularly attractive for rapid in vivo 
screening of biomaterials (Valdes et al. 2002).  
 
7.B.6. Flow cytometry (FCM) 
Flow cytometry (FCM) is base on light scattering which occurs when a particle 
(e.g., cell) deflects incident laser light. It can provide information regarding the 
size of the cells, their internal compleity and fluorescence level (if the cells 
examined have fluorophores inside or on their surface). Thus, FCM can be used 
to differentiate different cell types in a heterogeneous cell population and to 
quantify the number of cells with a specific property (e.g., with fluorescence at a 
specific wavelength) (Ormerod 2000;Carter and Ormerod 2000). 
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Appendix C. Factorial analysis 
Factorial experimental design (three variables, two level) was used in this 
project to investigate the effects of three variable on the measured outcome 
whilst minimising the number of samples for the experiments.  The following 
section explains the layout of a factorial experiment and its mathematical 
interpretation. 
 
7.C.1. Factorial design 
A typical three-variable, two level factorial design of  sample formulations is 
shown in Table 7.C.1.   
Table 7.C.1. Factorial design of sample formulations involving three 
variables (V) with two levels, high (H, indicated by +1) and low (L, 
indicated by -1). 
Sample number Sample formulations   V1 V2 V3 
1 SHHH +1 +1 +1 
2 SHHL +1 +1 -1 
3 SHLH +1 -1 +1 
4 SHLL +1 -1 -1 
5 SLHH -1 +1 +1 
6 SLHL -1 +1 -1 
7 SLLH -1 -1 +1 
8 SLLL -1 -1 -1 
Regarding sample formulations, for example, SHHH stands for the formulation with V1, V2 and 
V3 at their high levels and SHHL for the formulation with V1, V2 and V3 at their high, high and 
low levels respectively. 
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7.C.2. Mathematical interpretation 
Kinetic and equilibrium properties, P, are often related to variables by a power 
law. When there are three variables (V), the kinetic equation and its 
logarithmic form are: 
b3
3
b2
2
b1
1 VVkVP                                                                                            7.C.1 
where k is a constant, bi is the power of its corresponding variable.
 
332211 lnVblnVblnVblnklnP                                                               7.C.2  
3H32H21H1HHH
lnVblnVblnVblnklnP 
 
       A                                      
3L32H21H1LHH
lnVblnVblnVblnklnP 
 
       B 
3H32L21H1HHL
lnVblnVblnVblnklnP 
 
       C 
3L32L21H1LHL
lnVblnVblnVblnklnP 
 
       D 
3H32H21L1HLH
lnVblnVblnVblnklnP 
 
       E 
3L32H2L1LLH
lnVblnVblnVblnklnP  1  
       F 
H32L2L1LLH lnVblnVblnVblnklnP 31   
      G 
3L32L2L1LLL
lnVblnVblnVblnklnP  1  
       H 
 
where H and L represent the variable (V) at its high (H) and low (L) value 
respectively. 
 
A suitable factorial expression in this case could therefore be: 
1,2,33212,3321,3311,221332211 aFFFaFFaFFaFFaFaFaFlnPlnP   
7.C.3 
where <lnP> is the average value of ln P for all 8 possible formulation 
combinations (see Table 7.C.1), Fi = +/- 1 and Fi,j = FiFj (see Table 7.C.2 for 
the values of Fi and Fi,j), ai indicates the level of an effect that a factor has on 
a material property (P). 
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Table 7.C.2. Property combinations for a factorial experimental design 
involving three factors (F) with two levels, high (F=+1) and low (F=-1).  
Property of different sample 
formulation 
F1 F2 F3 F1,2 F1,3 F2,3 F1,2,3 
PHHH 1 1 1 1 1 1 1 
PHHL 1 1 -1 1 -1 -1 -1 
PHLH 1 -1 1 -1 1 -1 -1 
PHLL 1 -1 -1 -1 -1 1 1 
PLHH -1 1 1 -1 -1 1 -1 
PLHL -1 1 -1 -1 1 -1 1 
PLLH -1 -1 1 1 -1 -1 1 
PLLL -1 -1 -1 1 1 1 -1 
Fi standards for each individual factor whereas Fi,j for interaction factors (Fi,j =FiFj). 
Thus, Eq. 7.C.3. can also be expressed: 
1,2,32,31,31,2321 aaaaaaalnPlnP                                        7.C.4 
123231312321HHH aaaaaaalnPlnP   
      A’                                            
123231312321HHL aaaaaaalnPlnP   
      B’ 
123231312321HLH aaaaaaalnPlnP   
      C’ 
123231312321HLL aaaaaaalnPlnP   
      D’ 
123231312321LHH aaaaaaalnPlnP   
      E’ 
123231312321LHL aaaaaaalnPlnP   
      F’ 
123231312321LLH aaaaaaalnPlnP   
      G’ 
123231312321LLL aaaaaaalnPlnP   
      H’ 
 
From the definition of an arimetic mean 
)/8lnPlnPlnPlnPlnPlnPlnP(lnPlnP LLLLLHHLLHHHLLHLHHHH  LHLH
8
LLLLLHLHLHLHHLLHHLLHHHHH
)PPPPPPP(Pln
   
Since 
8
LLLLLHLHLHLHHLLHHLLHHHHHGM )PPPPPPP(PP   
therefore      
 lnPlnPGM  
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If A, B …H = A’, B’, …H’, respectively, 
3H32H21H1HHH
lnVblnVblnVblnklnP 
 
123231312321 aaaaaaalnP   
           A’’ 
3L32H21H1LHH
lnVblnVblnVblnklnP    
123231312321 aaaaaaalnP   
           B’’ 
3H32L21H1HHL
lnVblnVblnVblnklnP   
123231312321 aaaaaaalnP     
 
           C’’ 
3L32L21H1LHL
lnVblnVblnVblnklnP   
123231312321 aaaaaaalnP   
           D’’ 
3H32H21L1HLH
lnVblnVblnVblnklnP 
  
123231312321 aaaaaaalnP     
 
           E’’ 
3L32H21L1LLH
lnVblnVblnVblnklnP 
   
123231312321 aaaaaaalnP     
 
           F’’ 
H32L2L1LLH lnVblnVblnVblnklnP 31     
123231312321 aaaaaaalnP    
 
           G’’ 
3L32L2L1LLL
lnVblnVblnVblnklnP  1  
123231312321 aaaaaaalnP   
 
           H’’ 
 
Sum A’’,  B’’,  C’’,  D’’, E’’,  F’’, G’’, H’’,  
8 8 LLLLLHLHLHLHHLLHHLLHHHHH PPPPPPPP ln  
= 8 lnk + 4b1lnV1H + 4b1lnV1L + 4b2lnV2H + 4b2lnV2L + 4b3lnV3H + 4b3lnV3L  
= 8<lnP>
 
sum (A’’, B’’, C’’, D’’) – sum (E’’, F’’,G’’,H’’) 
1
1L
1H
1
4
LLLLLHLHLLHH
4
HLLHLHLHHHHH a
V
V
lnb
PPPP
PPPP
ln 2
 
sum (A’’, B’’,E’’, F’’) – sum (C’’, D’’,G’’,H’’) 
2
2L
2H
2
4
LLLLLHHLLHLH
4
LLHLHHLHHHHH a
V
V
lnb
PPPP
PPPP
ln 2
 
 
 
Chapter 7                                                                                          Appendices 
 228 
sum (A’’,C’’,E’’,G’’) – sum (B’’,D’’,F’’,H’’) 
 3
3L
3H
3
4
LLLLHLHLLHHL
LLHLHHHLHHHH
a
V
V
lnb
PPPP
PPPP
ln 2
4

 
sum (A’’,B’’,G’’,H’’) – sum (C’’,D’’,E’’,F’’) 
12
4
LHLLHHHLLHLH
LLLLLHHHLHHH
a0
PPPP
PPPP
ln 2
4

 
sum (A’’,C’’,F’’,H’’) – sum (B’’,D’’,E’’,G’’) 
13
4
LLHLHHHLLHHL
LLLLHLHLHLHH
a0
PPPP
PPPP
ln 2
4

 
sum (A’’,D’’,E’’,H’’) – sum (B’’,C’’,F’’,G’’)  
23
4
LLHLHLHLHHHL
LLLLHHHLLHHH
a0
PPPP
PPPP
ln 2
4

 
sum (A’’,D’’,F’’,G’’) – sum (B’’,C’’,E’’,H’’)  
123
4
LLLLHHHLHHHL
LLHLHLHLLHHH
a0
PPPP
PPPP
ln 2
4

 
 
Therefore 







L
H
i
P
P
ln2a                                                                                                 7.C.5 
where PH and PL are the geometric means of a property of all samples with 
the variable, at its high (H) and low (H) level, respectively.
  
 
Eq. 7.C.2 and 7.C.4 would be equivalent when the effect of interaction factors 
(an,m) is negligible. In this case, Eq. 7.C.4 can be simplified as 
321 aaalnPlnP   
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